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The c-Abl protein-tyrosine kinase regulates diverse cellular signaling pathways involved in cell 
growth, adhesion, and responses to genotoxic stress. Abl is well known in the context of Bcr-
Abl, the active fusion tyrosine kinase, which causes chronic myelogenous leukemia (CML) and 
other leukemias. The tyrosine kinase activity of Abl is tightly regulated by auto-inhibitory 
interactions involving its non-catalytic SH3 and SH2 domains. Mutations that perturb these 
intramolecular interactions result in kinase activation. This study examined the effect of 
activating mutations on the biochemistry and solution structure of Abl core proteins. In an active 
myristic acid-binding pocket mutant (A356N), the relative positions of the regulatory N-cap, 
SH3 and SH2 domains were virtually identical to those of the assembled wild-type core despite 
differences in catalytic activity and thermal stability. In contrast, a dramatic structural 
rearrangement in an active gatekeeper mutant (T315I) was observed with the positions of the 
SH2 and SH3 domains reversed relative to wild-type. These results show that Abl kinases can 
adopt multiple conformations in solution and kinase activation does not necessarily require 
destabilization of the assembled core structure. 
Small molecules that allosterically regulate Abl kinase activity through its non-catalytic 
domains may represent selective probes of Abl function. I developed a screening assay to 
identify chemical modulators of Abl kinase activity that either disrupt or stabilize the regulatory 
interaction of the SH3 domain with the SH2-kinase linker. This fluorescence polarization (FP) 
UNDERSTANDING ACTIVE ABL KINASE CONFORMATIONS: 
APPLICATION TO DISCOVERY OF SMALL MOLECULE  
ALLOSTERIC MODULATORS 
Prerna Grover, Ph.D. 
University of Pittsburgh, 2015
 
 v 
assay is based on a recombinant Abl protein containing the regulatory domains (Ncap-SH3-SH2-
linker, N32L) and a short fluorescein-labeled probe peptide that binds the SH3 domain. The 
probe peptide binds the recombinant Abl N32L protein in vitro producing a robust FP signal. 
Mutation of the SH3 binding site (W118A) or introduction of a high-affinity linker both resulted 
in loss of the FP signal. Pilot screens were performed with two chemical libraries (2800 
compounds total), and thirteen compounds were found to specifically inhibit the FP signal. 
Secondary assays showed that one of these hit compounds enhances Abl kinase activity in vitro. 
These results show that screening assays based on the regulatory domains of Abl can identify 
allosteric modulators of kinase function. 
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1.0  INTRODUCTION 
1.1 C-ABL KINASE OVERVIEW 
c-Abl was identified as the cellular homolog of the v-Abl oncogene in the Abelson murine 
leukemia virus (A-MuLV) that causes lymphosarcoma in mice [1–3]. Subsequently, it was found 
that the c-Abl gene is involved in human leukemias caused by chromosomal translocation t(9,22) 
that gives rise to the Philadelphia chromosome (discussed later in section 1.4), and encodes a 
non-receptor protein tyrosine kinase [4,5]. The mammalian c-Abl gene (or Abl 1), and its closest 
relative Arg (Abl related gene or Abl 2), are ubiquitously expressed. Both c-Abl and Arg are 
alternatively spliced in the first exon, and encode two splice variants of the protein – 1a and 1b 
that have distinct N-terminal sequences [6]. The 1b form of c-Abl is myristoylated at the N-
terminal glycine residue of the protein, while the 1a form is not myristoylated and is shorter by 
19 amino acids.  This thesis focuses on the 1b isoform of the c-Abl protein, and will be referred 
to hereafter as Abl . 
The domain organization of the c-Abl 1b protein is shown in Figure 1 [7,8]. The N-
terminal half of the protein contains a unique N-terminal region, followed by Src-homology 3 
(SH3) and Src-homology 2 (SH2) domains, an SH2-kinase linker, and the kinase domain. The 
kinase domain is followed by the C-terminal half of the protein that includes proline-rich  
 2 
 
Figure 1. The organization and regulation of Abl proteins. 
(A) Top: The modular domain organization of the c-Abl 1b protein is shown. It consists of a myristoylated N-cap, 
SH3 and SH2 domains, SH2-kinase linker, kinase domain, and a last exon region that includes proline rich regions, 
DNA and actin binding domains, nuclear localization and export signals. Bottom: The Abl core protein, which 
includes the N-terminal half of the protein as shown, was found to be sufficient for regulation of Abl kinase activity. 
(B) Left: The crystal structure of the assembled down-regulated conformation of the Abl core (PDB: 2FO0, [9]) is 
shown, with the disordered portion of the N-cap represented as a dotted line. The autoinhibited Abl core is stabilized 
by three critical intramolecular interactions. The linker forms a PP II helix and binds the Abl SH3 domain, while the 
SH2 domain interacts with back of the C-lobe of the kinase domain through extensive hydrogen bonding 
interactions. The myristoylated N-cap binds a hydrophobic pocket in the C-lobe of the kinase domain, and acts as a 
clamp packing the SH3 and SH2 domains against the back of the kinase domain. Right: In a maximally activated 
conformation of the Abl core, also called the ‘top-hat’ conformation, the SH2 domain is reoriented to the top of the 
kinase domain and stabilizes the active conformation of the kinase. The location of the SH3 domain and the linker 
could not be identified in this structure. 
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regions, nuclear localization and export signals, and DNA and actin binding domains. Through 
the SH2 and SH3 domains as well as the protein binding domains in the C-terminal region, Abl 
interacts with diverse classes of proteins such as transcription factors, actin, pro-apoptotic 
proteins, proteins in the DNA-damage repair pathway, and adaptor proteins. Consequently, Abl 
is involved in the regulation of several signaling pathways that regulate cell proliferation and 
survival, actin remodeling, cell adhesion and migration, and responses to DNA-damage and 
oxidative stress [7]. Moreover, the Abl protein is temporally localized to different sub-cellular 
compartments such as the nucleus, cytoplasm, and plasma membrane, depending on the cellular 
environment and activating stimuli. For example, while nuclear Abl is activated in response to 
DNA damage, and involved in cell cycle control and apoptotic promotion (discussed later in 
section 1.3), cytoplasmic Abl is activated at the cell periphery in response to integrin engagement 
and growth factor stimulation (discussed later in section 1.2.3.3) [7,10]. 
1.2 STRUCTURE AND REGULATION OF C-ABL 
As described above, Abl plays an important role in the regulation of multiple cellular processes 
in cells. Consequently, its kinase activity is tightly regulated by multiple mechanisms. Aberrant 
activation of Abl as a result of chromosomal translocations can lead to leukemias in humans, as 
discussed later in section 1.4. The following sections will discuss the key structural elements 
essential for the physiological regulation of Abl kinase activity. 
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1.2.1 Regulation by intramolecular interactions 
The kinase ‘core’ of the Abl protein consists of the N-terminal half of the protein, including the 
N-terminal cap, the SH3 and SH2 domains, the SH2-kinase linker, and a bi-lobed kinase domain 
(Figure 1) [11]. This Abl core protein was found to be necessary and sufficient for auto-inhibition 
of the Abl protein tyrosine kinase activity.  Subsequent X-ray crystal structures revealed three 
critical intramolecular interactions that are important for Abl auto-inhibition (Figure 1) [9,12,13]. 
Each of the elements involved in these intramolecular interactions are discussed below. 
1.2.1.1 N-terminal cap (N-cap) 
The N terminus of the Abl protein contains a unique 80 amino acid residue region called the N-
terminal cap (referred to as N-cap hereafter). Mutagenesis studies showed that deletion of this N-
cap region leads to kinase activation, thus suggesting that this region is important for inhibiting 
Abl kinase activity [13]. Further investigation into the mechanism of action revealed that the N-
cap is myristoylated at the N-terminal glycine residue and mutation of this glycine residue to 
alanine (G2A) leads to a loss of myristoylation and kinase activation, suggesting that 
myristoylation is important for Abl regulation [14]. Furthermore, deletion mutagenesis of the N-
cap revealed that residues 15-56 are not essential for the regulation of Abl kinase activity.  
The first crystal structure of the Abl core was solved in 2003 and revealed that the 
myristate moiety binds a deep hydrophobic pocket in the C-lobe of the kinase domain [12]. 
Mutations in the hydrophobic pocket in the kinase domain that disrupt myristate binding also 
lead to kinase activation [14]. Introducing polar residues in this hydrophobic pocket, including 
replacement of Ala356 with asparagine (A356N) or Val525 with aspartate (V525D), result in 
kinase activation, possibly through the loss of myristate binding. Interestingly, the crystal 
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structure showed that binding of the myristate moiety induces bending of the α-helix I in the C-
lobe of the kinase domain, and this conformational switch is important for auto-inhibitory 
interactions between the SH2 domain and the kinase domain (discussed later in section 1.2.1.3) 
[12]. 
In addition to the kinase domain, the N-cap also makes important contacts with the SH3 
and SH2 domains, and the SH3-SH2 connector that joins these domains. In the first crystal 
structure of Abl, the entire N-cap region, from the SH3 domain to the myristate moiety, was 
disordered [12]. Subsequently, a higher resolution crystal structure of the Abl core, with an 
internal deletion of residues 15-56, was solved where residues 65-82 were modeled into the 
electron density [9]. In this structure, amino acid residues 2-14 and 57-64 were still disordered 
and were predicted to form an inherently flexible structure that is shown as the dotted region in 
Figure 1. The crystal structure revealed that several residues in the N-cap, including Trp67, 
Leu73, and Leu74, interact with a patch of hydrophobic residues on the SH2 domain, while 
Lys70 interacts with several residues in the SH2 domain through hydrogen bonding. These 
interactions are important for kinase regulation since disruption of these interactions by 
individual mutations of Lys70 or Leu73 to alanine leads to kinase activation [9,13,14]. 
Interestingly, the crystal structure revealed that a serine residue at position 69 in the N-cap is 
phosphorylated. This phosphoserine residue forms hydrogen bonds with Ser145 and Trp146 in 
the SH3-SH2 connector. While mutation of the N-cap Ser69 to alanine (S69A) had a weak 
effect, mutation to glutamate (S69E) had a strong activating effect on Abl kinase activity. This 
suggests an important role for the Ser69 residue in kinase regulation, although the identity of the 
kinase responsible for this modification in vivo is not clear. In conclusion, the N-cap plays an 
important regulatory role in Abl auto-inhibition where the myristoylated N-terminal part of the 
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N-cap interacts with the C-lobe of the kinase domain, while the C-terminal portion interacts with 
the SH3-SH2 connector and the SH2 domain and acts as a clamp to stabilize the Abl SH3-SH2 
regulatory subunit against the back of the kinase domain. 
1.2.1.2 SH3 domain 
The SH3 domain is a small modular domain present in signaling proteins consisting of about 60 
amino acids [15]. The structures of many SH3 domains have been studied by X-ray 
crystallography and NMR spectroscopy, and a typical SH3 domain contains five anti-parallel β-
strands that form two perpendicular β-sheets [16,17]. In addition, there are two charged loops 
called the RT loop and the n-Src loop that vary across SH3 domains from different proteins.  
SH3 domains interact with other proteins through proline-rich regions that form poly-
proline type II helices (PP II). This principle was first discovered in a phage-display screen for 
binding partners of the Abl SH3 domain, and defined a consensus sequence for Abl SH3 binding 
as XPXXXPPPFXP, where X is any amino acid [18,19]. The ligand-binding site in the SH3 
domain consists of a cluster of conserved hydrophobic amino acids that form three shallow 
pockets, surrounded by the n-Src and n-RT loops that confer specificity and determine the 
orientation of ligand binding [17]. SH3 domains serve multiple functions, including scaffolding 
for signaling pathways, substrate recognition, and regulation of enzymatic activity. 
The Abl SH3 domain is important for regulation of Abl kinase activity, and deletion of 
the SH3 domain results in constitutive kinase activation [20–22]. The Abl SH3 domain regulates 
kinase activity by interacting with the SH2-kinase linker, which forms a PPII helix (Figure 2) 
[12]. Mutations in the ligand binding surface of the SH3 domain that are predicted to disrupt this 
SH3:linker interaction, such as P131L and W118A, lead to kinase activation [22,23]. Moreover,  
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Figure 2. Mutations that disrupt the Abl SH3:linker interaction cause kinase activation. 
A model of the interface between the SH3 domain and the SH2-kinase linker, derived from the down-regulated Abl 
core crystal structure (PDB: 2FO0 [9]), is shown. The positions of residues in the SH3 domain and linker, which are 
important for Abl regulation, are color-coded and presented as sticks. Green: Mutations of W118 and P131 in the 
SH3 domain and proline residues 242 and 249 in the linker cause disruption of the SH3:linker interaction, and 
consequent kinase activation. Cyan: Mutation of E117 in the SH3 domain disrupts the ionic interaction with K313 
(located in the N-lobe of the kinase domain) and results in kinase activation. Blue: Phosphorylation of tyrosine 
residues 89 and 134 in the SH3 domain, and Y245 in the linker are correlated with kinase activation. The 
phosphorylation of Y89 and Y134 interferes with SH3:linker interaction. 
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phosphorylation of tyrosine residues in the Abl SH3 domain, such as Tyr134 and Tyr89, are also 
predicted to disrupt the SH3:linker interaction and are associated with kinase activation [24,25]. 
In addition, SH3 domain Glu117 makes an ionic contact with kinase domain N-lobe Lys313. 
This interaction also contributes to kinase auto-inhibition since mutating these residues (E117K 
or K313E) disrupts this salt bridge and leads to kinase activation [23]. 
1.2.1.3 SH2 domain 
SH2 domains are small modular protein domains containing about 100 amino acids, and are 
present in most non-receptor protein tyrosine kinases and other signaling proteins [15]. SH2 
domains were first identified as homologous non-kinase domain sequences shared by the 
oncoproteins Src and Fps, and later found to be present in many other proteins [26]. Structurally, 
a typical SH2 domain contains a central hydrophobic anti-parallel β-sheet, which is flanked by 
two α-helices [15]. SH2 domains bind protein or peptide ligands containing a phosphotyrosine 
(pY) residue, followed by specific amino acids that define selectivity [27]. The ligand binding 
surface of the SH2 domain consists of two pockets – one contains a conserved arginine residue 
and binds the phosphotyrosine side chain, while the other interacts with hydrophobic residues C-
terminal to the phosphotyrosine. While the first phosphotyrosine binding pocket is highly 
conserved, the second recognition pocket is variable across different proteins and confers 
binding specificity. By virtue of their ability to recognize and bind unique phosphotyrosine 
containing motifs, SH2 domains play multiple roles in proteins and signaling pathways. They 
play an important role in the regulation of enzymatic activity by auto-inhibitory interactions, 
recognition of enzymatic substrates, and have scaffolding functions in signaling pathways. 
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The crystal structure of the Abl core revealed that the SH2 domain in Abl interacts with 
the back of the C-lobe of the kinase domain through extensive hydrogen bonding and 
hydrophobic interactions [12]. These interactions are dependent on the restructuring of the C-
terminal helix αI, which is induced by binding of the myristoylated Ncap to the C-lobe as 
described above [9,12,14]. Mutations in the SH2 domain or the C-lobe of the kinase domain that 
disrupt this interaction were found to lead to kinase activation [14]. In a maximally activated 
conformation of Abl that lacks all intramolecular interactions, the SH2 domain was found to 
reorient its position to the top of the N-lobe of the kinase domain [9]. The SH2 domain, in this 
“top-hat” conformation, interacts with specific residues in the N-lobe of the kinase domain and 
stabilizes this active conformation. A similar stabilization of the active conformation by SH2-N-
lobe interaction is also seen in the non-receptor tyrosine kinase, Fes. 
1.2.1.4 SH2-kinase linker 
The SH2-kinase linker forms a PPII helix and acts as an internal ligand for the Abl SH3 domain, 
thus contributing to the down-regulated conformation of the Abl kinase core [12]. Even though 
similar SH3:linker interactions  are also observed in the structures of downregulated Src-family 
kinases, there are important differences in the SH2-kinase linker sequences. In contrast to Hck, a 
member of the Src kinase family, the Abl SH2-kinase linker contains a tyrosine residue at the 
second proline position in the ‘PXXP’ motif, and this Tyr245 points away from the SH3 domain 
and packs in a hydrophobic crevice in the kinase domain [12]. Moreover, the Abl linker contains 
two additional residues near the N-lobe of the kinase domain, Trp254 and Glu255, which 
contribute towards the unique conformation exhibited by the Abl SH2-kinase linker. 
Furthermore, hydrogen exchange mass spectrometry studies have shown that the Abl SH2-kinase 
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linker binds the SH3 domain in the absence of the kinase domain [28], which is not the case for 
Hck.  
The SH3:linker interaction is important for the regulation of Abl kinase activity, as 
mutation of linker proline residues (P242E and P249E) disrupts SH3:linker interaction and leads 
to kinase activation (Figure 2) [23]. Moreover, phosphorylation of Tyr245 in the linker has also 
been associated with kinase activation, and mutation of this residue (Y245F) leads to a decrease 
in kinase activity [29]. In contrast, a recent study from our laboratory has shown that increasing 
the proline content of the linker enhances SH3:linker interaction (this engineered high affinity 
linker is referred to as HAL hereafter [30]) (Figure 3). Remarkably, introduction of this HAL 
sequence into the Abl core protein overcame the effects of certain activating mutations such as 
A356N. A356N is a mutation in the hydrophobic pocket of the C-lobe of the kinase domain that 
disrupts binding of the myristoylated N-cap resulting in kinase activation (discussed earlier in 
section 1.2.1.1) [14]. When the HAL sequence is combined with this A356N mutation, the kinase 
activity of the HAL-A356N Abl core is significantly reduced in comparison to the A356N Abl 
core with a wild-type linker [30].  This observation suggests that SH3-linker interaction has a 
dominant influence on the overall structure and activity of the kinase domain.  Furthermore, the 
SH3:linker interaction was also found to regulate inhibitor sensitivity of the oncogenic fusion 
protein, Bcr-Abl (discussed later in section 1.4.2). Remarkably, the introduction of this HAL 
sequence into Bcr-Abl sensitized Bcr-Abl transformed cells to apoptotic induction by both ATP-
competitive and allosteric inhibitors of the Abl kinase. 
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Figure 3. Increased proline content in the SH2-kinase linker enhances SH3:linker interaction. 
Left: A model of the wild-type SH3:linker interface derived from the down-regulated Abl core (PDB: 2FO0, [9]) is 
shown. The side chains of the linker residues that were modified in the high affinity linker (HAL) mutant are shown 
as sticks. Right: A model of the SH3:HAL interface shows the positions of the five proline substitutions [30]. The 
sequence of the wild-type and the high affinity linker are shown in the box at the bottom, with the modified residues 
highlighted in red.  These linker proline substitutions enhance intramolecular binding to the SH3 domain as shown 
by hydrogen exchange mass spectrometry and FP assay (see main text for details). 
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1.2.1.5 Kinase domain 
The catalytic or kinase domains of serine, threonine, and tyrosine kinases are evolutionarily 
conserved in both primary amino acid sequence as well as structure [31]. Like other kinases, the 
kinase domain of Abl is bi-lobed, consisting of a smaller N-terminal lobe (N-lobe) and a larger 
C-terminal lobe (C-lobe). The N-lobe of the kinase consists of a β-sheet composed of 5 strands, 
and a single α-helix known as the αC helix, while the C-terminal lobe (C-lobe) is primarily 
helical. The hinge region in between the two lobes is also conserved, and contributes to the 
catalytic function of the kinase. The N-lobe and the hinge region define the site where ATP 
binds, which includes the phosphate binding loop or P-loop. Both lobes contribute conserved 
residues that are important for the catalytic transfer of γ-phosphate from ATP to the tyrosine 
residue in the substrate. In addition, the C-lobe contains the peptide substrate binding site, and 
the activation loop. 
The relative positions of the two lobes of the kinase domain and conserved residues in 
these structural features play an important role in the catalytic reaction and the dynamic 
interchange between the inactive and active conformations of the kinase domain. Interestingly, 
while most kinases adopt similar active conformations, the inactive conformations of the kinase 
domains are remarkably diverse, thus providing opportunities for selective inhibitor discovery 
[32–35]. The crystal structures of the Abl kinase domain bound to ATP-competitive inhibitors 
dasatinib and imatinib (discussed later in sections 1.4.4 and 1.4.3, respectively) highlight the 
features of the active and inactive conformations adopted by the Abl kinase domain (Figure 4) 
[32,36]. In the active conformation shown in Figure 4A, a conserved glutamate residue (Glu286) 
in the αC helix forms an ionic interaction with Lys271 in the N-lobe. This interaction is  
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Figure 4. Active vs. inactive conformation of the Abl kinase active site. 
(A) The crystal structure of dasatinib (pink carbons) bound to the Abl kinase domain (PDB: 2GQG, [36]) highlights 
the features of the active kinase conformation. The conserved DFG motif is flipped in and Asp381 coordinates a 
magnesium ion important for catalysis. The ionic interaction between Lys271 and Glu286 is important for 
coordinating the phosphate group of ATP. The phosphorylated Tyr412 forms a hydrogen bond with Arg386, and 
contributes to stabilization of the active conformation. (B) The crystal structure of imatinib (pink carbons) bound to 
the Abl kinase domain (PDB: 1IEP, [32]) shows the features of the inactive conformation of the active site. The 
DFG motif is flipped out, while ionic interaction between K271 and E286 is maintained. The activation loop is 
folded into the active site, and Tyr412 forms a hydrogen bond with the conserved Asp363 (catalytic aspartate).  
Imatinib also forms a key hydrogen bond with the gatekeeper residue Thr315. 
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important for coordinating the phosphate group of ATP and is conserved in the active 
conformations of protein kinases. Interestingly, this ionic interaction is maintained in the 
imatinib bound inactive conformation as well (Figure 4B), in contrast to c-Src. However, in 
another crystal structure of the Abl kinase domain bound to an ATP-peptide conjugate, the 
kinase domain adopts a Src-like inactive conformation where the αC helix is switched out and 
this Glu-Lys salt bridge is disrupted [37]. The activation loop in the C-lobe contains a tyrosine 
residue (Tyr412) that undergoes autophosphorylation upon activation. Phosphorylation of 
Tyr412 stabilizes an ‘open’ conformation of the active site through an ionic interaction with a 
neighboring arginine residue, allowing access to the peptide substrate (Figure 4A). On the other 
hand, in the inactive ‘closed’ kinase conformation, the activation loop is folded back into the 
active site and Tyr412 forms a hydrogen bond with a conserved aspartate residue (Asp363) in the 
catalytic loop (Figure 4B). This conformation of the activation loop mimics substrate binding, 
and stabilizes the inactive conformation of the kinase. Furthermore, the position of a highly 
conserved aspartate-phenylalanine-glycine (DFG) motif also plays an important role in 
determining the active vs. inactive kinase conformation. In the active conformation, Asp381 is 
oriented towards the active site (also called the ‘DFG in’ conformation) and coordinates a 
magnesium ion important for catalysis (Figure 4A). In the inactive conformation, Asp381 is 
flipped away from the active site (also called ‘DFG out’) and Phe382 occludes the active site, 
thus preventing catalytic activity (Figure 4B). This DFG out conformation is also important for 
the specificity of imatinib binding to Abl (discussed later in section 1.4.3.1). 
The gatekeeper residue is a structurally conserved feature in the ATP binding site that 
regulates the binding of nucleotide and small molecule inhibitors to the ATP binding site [38–
41]. A majority of kinases contain threonine or a larger amino acid in this position, and the size 
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of the residue regulates access to a pre-existing cavity in the ATP-binding pocket. While 
mutations in this residue are commonly known to confer resistance to targeted inhibitors of 
multiple kinases, these mutations have sometimes been reported to be present before inhibitor 
treatment [42,43]. These mutations are thus predicted to independently influence kinase activity 
and correlate with kinase oncogenic potential. Consistent with this hypothesis, a threonine to 
methionine mutation at the gatekeeper position in the epidermal growth factor receptor (EGFR) 
is associated with lung cancer [42].  In an attempt to understand the mechanism of this activation, 
a recent study found that substitution of the gatekeeper position with bulky hydrophobic residues 
such as isoleucine or methionine stabilizes the ‘hydrophobic spine’ of the active kinase 
conformation, thus promoting kinase activity [44]. On the other hand, substitution with smaller 
residues such as glycine or alanine resulted in either no change or a modest increase in kinase 
activity, respectively. The threonine to isoleucine gatekeeper mutation in Bcr-Abl (T315I) is 
clinically relevant since it causes resistance to most Abl kinase inhibitors and will be further 
discussed in section 1.4.3.2. Similar to mutations in EGFR, platelet derived growth factor 
receptor (PDGFR), and Src, a threonine to isoleucine substitution in Abl results in an increase in 
kinase activity.  Remarkably, Abl with the T315I mutation is able to transform Ba/F3 cells to the 
same extent as Bcr-Abl [44]. An additional study found that the phosphorylation status of 
tyrosine residues in the P loop of the kinase domain is distinct for Bcr-Abl gatekeeper mutants 
and suggested altered substrate specificity for these kinases [45].  Furthermore, a recent study 
from our group investigated the conformational dynamics of the Abl T315I mutant and found 
that this mutation induces dynamic conformational changes not only at the site of the mutation, 
but also at interface of the SH3 domain and the linker [46]. To summarize, these studies 
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demonstrate that the gatekeeper position in the Abl kinase domain has significant influences on 
both kinase regulation and inhibitor sensitivity. 
1.2.1.6 C-terminal region 
In contrast to Src-family kinases, Abl has a large C-terminal region following the kinase domain 
[7,8]. This region, encoded by a single exon and known as the last exon region, contains several 
motifs important for diverse functions exhibited by Abl. These include proline-rich motifs that 
interact with the SH3 domains of signaling adaptors such as Crk, a DNA binding domain, three 
functional nuclear localization signals, a nuclear export signal, and F-actin and G-actin binding 
domains. These domains are important for mediating interactions with other signaling molecules, 
and for determining Abl subcellular localization as required for biological functions. 
1.2.2 Conformational dynamics of Abl proteins 
The X-ray crystal structures of the Abl core discussed above provides valuable insight into the 
intra-molecular interactions regulating Abl kinase activity [9,12]. However, X-ray 
crystallography only presents a singular static view of the protein structure, in its assembled, 
downregulated state. Protein kinases, like many other biomolecules, are not rigid entities and 
undergo dynamic changes between different conformations in solution. Thus, an analysis of 
conformational dynamics is essential to our understanding of the different activation states of the 
protein in solution. To this end, this section will discuss the different techniques that are used to 
evaluate conformational dynamics of proteins in solution, and their application to the study of 
Abl kinase dynamics. 
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1.2.2.1 Small Angle X-ray Scattering (SAXS) 
Small angle X-ray scattering is a valuable technique for the characterization of large protein 
structures that are not amenable to crystallization or NMR analysis [47–50]. It is especially 
useful to investigate the conformational states of large structures with multiple domains, and can 
provide a low resolution picture of the relative orientation of these domains, or the shape and 
size of molecular assemblies of these protein domains. The X-ray scattering patterns can be 
analyzed to predict the average ensemble of multiple conformational states. While the radius of 
gyration (Rg) of a molecule is useful in estimating the relative size of the molecule, ab initio 
calculation of low-resolution 3-dimensional molecular envelopes can aid in predicting the overall 
shape. This approach to determination of molecular envelopes is attractive because the shapes of 
the reconstructed molecular envelopes are independent of any specific, previously known atomic 
model.  
SAXS has been used to investigate the conformation of an active mutant Abl core 
protein, referred to as Ablactivated or ΔNcap-2PE, which lacks the N-cap and myristoylation site, 
and includes two mutations in the SH2-kinase linker (P242E, P249E) that disrupt the SH3:linker 
interaction [9]. The molecular envelope generated from SAXS analysis predicted a reorientation 
of the SH2 domain to the top of the N-lobe of the kinase domain, in an extended “top-hat” 
conformation, while the exact positions of the SH3 domain and the SH2-kinase linker could not 
be modeled. This study also used SAXS to analyze the Abl kinase domain and the 
downregulated Abl core and found that the predicted conformations from SAXS are consistent 
with the X-ray crystal structures. Additionally, this study examined another active mutant Abl 
core protein, AblSH2-mutant, which includes mutations in the SH2 and kinase domains (I164E, 
T291E, Y331A) that disrupt the SH2:kinase domain interface in the top-hat conformation, in 
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addition to the absence of N-cap and the SH3:linker interaction as described above for Ablactivated. 
This protein was predicted to sample multiple conformational states, and the molecular shape 
could not be reconstructed for structural interpretation. It is pertinent to note here that all the 
proteins in this study were purified in the presence of a small molecule ATP-site inhibitor 
(PD166326) to prevent protein aggregation, and the presence of this small molecule bound to the 
active site in the kinase domain could potentially influence the conformational state of the 
proteins in solution. 
A recent study utilized a combination of SAXS and nuclear magnetic resonance 
spectroscopy (NMR) to investigate the conformations adopted by a modified Abl core protein, 
Abl ΔN-cap, which lacks the N-cap including the myristoylation signal [51]. This study 
examined the effect of imatinib (an ATP-competitive tyrosine kinase inhibitor discussed in 
section 1.4.3) and GNF-5 (an allosteric inhibitor that acts through the myristic acid binding 
pocket and is discussed further in section 1.4.5) on the Abl ΔN-cap conformation in solution in 
comparison to the apo form of the kinase. The Abl ΔN-cap apo form adopts a ‘closed’ 
conformation similar to the down-regulated Abl core crystal structure, and the radius of gyration 
(Rg) for the Abl ΔN-cap apo (27Å) is similar to the Abl core (28Å) [9,51].  Despite this protein 
lacking two of the three intra-molecular interactions that are important for down-regulation 
(discussed earlier in section 1.2.1), namely the myristoylated N-cap and the SH2:kinase domain 
interactions, this protein adopts a closed conformation suggesting that the SH3:linker interaction 
may be sufficient to maintain Abl in a down-regulated conformation. Interestingly, the presence 
of imatinib leads to an ‘open’ conformation where the SH3 and SH2 regulatory domains appear 
to be displaced from the back of the kinase domain, and the radius of gyration is increased to 
31Å. However, this effect of imatinib leading to a displacement of the regulatory SH3-SH2 
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domains could possibly be due to the absence of the N-cap and the myristic acid moiety. In 
contrast to imatinib, addition of GNF-5 does not have any significant influence and the 
conformation is very similar to the Abl ΔN-cap apo form. Remarkably, addition of GNF-5 to the 
complex of Abl ΔN-cap and imatinib leads to a reversal to the ‘closed’ conformation similar to 
the Abl ΔN-cap apo form. This effect is consistent with GNF-5 acting through the myristic acid 
binding pocket and inducing stabilization of this complex. 
1.2.2.2 Hydrogen Exchange Mass Spectrometry (HXMS) 
Hydrogen exchange mass spectrometry is a valuable technique to analyze protein conformation 
and dynamics in solution [52]. This technique is not limited by protein size or solubility 
constraints that are seen for NMR spectroscopy and X-ray crystallography studies, requires 
relatively small quantities of proteins, and can provide information about protein dynamics on a 
wide time scale. HXMS uses heavy or deuterated water (D2O) and it measures the rate of 
exchange of the backbone amide hydrogen atoms with deuterium in solution. Solvent-exposed 
amide hydrogen atoms and ones that are involved in weak hydrogen bonds undergo a rapid 
exchange. In contrast, amide hydrogen atoms that are buried in the interior of the protein, or are 
involved in forming stronger hydrogen bonds exchange more slowly. The exchange reaction can 
be quenched at multiple time points, and the rate of exchange can be measured by mass 
spectrometry since deuterium has a larger mass than hydrogen. Several studies from our 
laboratory, in collaboration with Dr. John Engen’s research group at Northeastern University, 
have used HXMS to examine the conformational dynamics of Abl proteins and will be 
summarized here. 
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Initial HXMS studies with Abl proteins investigated the conformational dynamics of the 
Abl regulatory domains in the absence of the kinase domain. One of these studies found that the 
presence of the SH2-kinase linker, which binds to the SH3 domain in cis, slows down the rate of 
cooperative unfolding of the SH3 domain, thus providing the first evidence for interaction 
between the SH3 domain and the linker in the absence of the kinase domain [28]. Moreover, this 
study also tested different lengths of the linker, and identified the minimum number of residues 
required for SH3 domain engagement. Another HXMS study investigated the effect of the N-cap 
on deuterium uptake by the Abl regulatory domains (SH3 alone, SH3-SH2 or 32, SH3-SH2-
linker or 32L) [53]. The N-cap was found to have a stabilizing influence on the SH3 domain but 
only in the presence of the SH2 domain, and this effect was further enhanced in the presence of 
the linker.  This observation suggests that the N-cap stabilizes SH3:linker interaction, consistent 
with the overall structure of the downregulated Abl core. Moreover, a recent study examined the 
effect of increased proline content in the linker on SH3:linker interaction using the the high 
affinity linker (HAL) discussed earlier in section 1.2.1.4. This study showed that increased linker 
proline content resulted in enhanced SH3 engagement, measured as stabilization of the SH3 
domain to deuterium uptake [30]. 
Earlier work from our lab has shown that Src family kinases phosphorylate multiple 
tyrosine residues in the Abl regulatory domains, including the tyrosine residue at position 89 in 
the SH3 domain [25]. In the down-regulated Abl core crystal structure, this tyrosine residue is 
present at the SH3:linker interface, suggesting that phosphorylation of this residue could 
potentially disrupt SH3:linker interaction. In support of this idea, phosphorylation of this residue 
enhances Bcr-Abl kinase activity, and HXMS studies found that phosphorylation of this residue 
results in linker disengagement as measured by the rate of cooperative unfolding of the SH3 
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domain [24]. Moreover, phosphorylation of Tyr89 also disrupts binding of Abl binding protein, 
ABI1 to the Abl SH3 domain. 
Other studies have used HXMS to investigate the effect of mutations on the 
conformational dynamics in the Abl core proteins [30,46]. In agreement with the crystal structure 
of the down-regulated wild-type Abl core, HXMS analysis of this protein found that the N-cap, 
linker, activation loop, and portions of the SH3 and SH2 domains that are exposed on the surface 
and predicted to be solvent exposed, are fairly dynamic and undergo rapid deuterium exchange 
[46]. On the other hand, this analysis also revealed that a region including the C-lobe of the 
kinase domain and the SH2:kinase domain interface is protected from deuterium exchange, and 
hence represents a more stable or rigid part of the protein structure. Additionally, this study also 
examined the effect of the gatekeeper mutation, T315I (discussed in sections 1.2.1.5 and 1.4.3.2), 
and found an increase in deuterium uptake not only in the vicinity of the mutation site, but also 
in the RT-loop of the SH3 domain. Another HXMS study examined the effect of an activating 
mutation, A356N in the myristic acid binding pocket (discussed in section 1.2.1.1), and found an 
increase in deuterium uptake in the N-lobe of the kinase domain adjacent to the active site, in 
addition to changes at the site of mutation [30]. Moreover, this study also examined the effect of 
the high affinity linker (HAL), discussed in section 1.2.1.4 and above in the context of the Abl 
32L proteins, on the Abl core protein dynamics. The introduction of HAL into the wild-type Abl 
core resulted in a decrease in deuterium uptake in parts of the SH3 and SH2 domains as well as 
in parts of the N-lobe and C-lobe of the kinase domain close to the active site, thus suggesting a 
global stabilization of the inactive Abl core conformation. Remarkably, this study found that 
introduction of the HAL into the A356N Abl core mutant reverses the dynamic effects of this 
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mutation on Abl core conformation. Together, these studies provide evidence for allosteric 
communication between different parts of the Abl kinase core that are responsible for regulation. 
HXMS has also been useful in investigating the stabilizing influence of small molecule 
inhibitors on Abl core dynamics. For example, HXMS studies have examined the effect of GNF-
5 (an allosteric inhibitor acting through the myristic acid binding pocket, discussed later in 
section 1.4.5), alone and in combination with an ATP-competitive tyrosine kinase inhibitor, 
dasatinib (discussed later in section 1.4.4) [54,55]. The binding of GNF-5 to the Abl core protein 
was found to induce conformational changes not only in the drug-binding site but also at a 
distance in the ATP-binding site. Moreover, additional studies showed that binding of a 
combination of GNF-5 and dasatinib to the mutant Abl core T315I protein induces similar 
conformational changes as those when dasatinib was bound to the wild-type Abl core. Thus, 
these results suggest that binding of allosteric inhibitors to the myristic acid binding pocket in 
Abl core mutants helps to stabilize the inactive conformation or remodel the conformation of the 
Abl active site making it accessible to ATP-competitive inhibitors. 
1.2.2.3 Nuclear Magnetic Resonance Spectroscopy (NMR) 
NMR is a valuable technique to determine structures of proteins and other biomolecules in 
solution, and to study protein dynamics and folding [56,57]. Besides X-ray crystallography, this 
is the only other technique that provides atomic resolution for structure determination. While 
NMR is useful for proteins that are not amenable to crystallization, it is constrained by 
requirements of a large amount of protein at high concentration, and magnetic field strength 
places an upper limit on the size of proteins for which structures can be resolved (typically 
around 40 kDa). 
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The first few NMR studies with Abl proteins focused on the regulatory domains since 
they could be easily expressed with heavy isotope labeling in bacterial expression systems. The 
solution structures of the Abl SH2 and SH3 domains were first solved by NMR [58,59]. 
Additionally, the NMR solution structure of the regulatory SH3-SH2 unit in the absence of the 
kinase domain revealed that the domains are flexible relative to each other [58,60]. There is very 
little structural information available about the protein domains present in the C-terminal half of 
the protein that is encoded by the last exon region of Abl, except the actin binding domain whose 
solution structure was solved using NMR [61]. Moreover, NMR has also been useful to study 
inter-molecular domain interactions in proteins, and was used to identify the proline-rich motif in 
the Crk SH2 domain that binds to the Abl SH3 domain, and validate the multi-domain interaction 
between Crk II and Abl [62]. 
In 2005, a method to isotopically label proteins expressed in Sf9 insect cells was 
optimized and used to express the Abl kinase domain for NMR studies [63]. This was followed 
by an elegant study to determine the solution structure of the Abl kinase domain in complex with 
four different ATP-competitive inhibitors – imatinib, nilotinib, and dasatinib, and PD180970 
[64]. These solution structures found that imatinib and nilotinib bind Abl in the DFG-out 
conformation (also discussed in sections 1.2.1.5, 1.4.3, and 1.4.4), while dasatinib predominantly 
binds Abl in the DFG-in active conformation (also discussed in sections 1.2.1.5 and 1.4.4), thus 
providing solution validation for the X-ray crystal structures. Furthermore, a combination of 
solution NMR, X-ray crystallography, and HXMS was utilized to demonstrate that GNF-2, an 
allosteric inhibitor of Abl (discussed later in section 1.4.5), binds the myristic acid binding 
pocket in the C-lobe of the kinase domain [55]. Recently, solution NMR and X-ray 
crystallography was also used to confirm that the Ile164 residue in the Abl SH2 domain is 
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involved in the binding interface with the monobody 7c12 (discussed later in section 1.4.5), and 
the monobody acts by destabilizing one of the active conformations of the Abl kinase [65]. 
Finally, a recent study utilized a combination of SAXS and NMR to investigate the 
conformations adopted by the largest Abl protein to be studied by NMR so far [51]. This study 
examined the effect of imatinib (an ATP-competitive tyrosine kinase inhibitor discussed in 
section 1.4.3) and GNF-5 (an allosteric inhibitor that acts through the myristic acid binding 
pocket and is discussed further in section 1.4.5) on a modified Abl core protein, Abl ΔN-cap, that 
lacks the N-cap including the myristoylation signal. As discussed in detail above in section 
1.2.2.1, the Abl ΔN-cap apo form adopts a ‘closed’ conformation similar to the down-regulated 
Abl core crystal structure, while the presence of imatinib leads to an ‘open’ conformation where 
the SH3 and SH2 regulatory domains appear to be displaced from the back of the kinase domain. 
Remarkably, addition of GNF-5 to the complex of Abl ΔN-cap and imatinib leads to a reversal to 
the ‘closed’ conformation similar to the Abl ΔN-cap apo form. This effect is consistent with 
GNF-5 acting through the myristic acid binding pocket and inducing stabilization of this 
complex through reassembly of the downregulated state. 
1.2.3 Physiological regulation of Abl kinase function 
As discussed in section 1.1, Abl is ubiquitously expressed and involved in regulating multiple 
cellular functions. Consequently, the kinase activity of Abl is tightly regulated in vivo by 
multiple mechanisms. While section 1.2.1 discusses the auto-inhibitory interactions that are 
important for Abl regulation, this section will discuss the cellular stimuli that result in Abl 
activation. 
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1.2.3.1 Phosphorylation 
The kinase activity of Abl is regulated by phosphorylation and dephosphorylation of critical 
tyrosine residues in the activation loop and regulatory domains. In the absence of activating 
stimuli, neither endogenous nor overexpressed Abl is phosphorylated [20,21,23,29]. However, 
when Abl is activated in response to intracellular or extracellular signals, there is a 
corresponding increase in tyrosine phosphorylation.  
In the inactive Abl kinase, the activation loop folds into the active site and Tyr412 (also 
discussed earlier in section 1.2.1.5) forms a hydrogen bond with the conserved Asp363 to 
stabilize the inactive conformation and prevent substrate and ATP binding [31,33]. Activation 
loop Tyr412 can undergo autophosphorylation as well as be phosphorylated by other tyrosine 
kinases including members of the Src family [66,67]. Phosphorylation of Tyr412 stabilizes the 
active kinase conformation, while replacement with phenylalanine impairs kinase activation [29]. 
In addition to Tyr412, phosphorylation of Tyr245 in the SH2-kinase linker is also required for 
maximal Abl kinase activity, and mutation of this residue has been shown to inhibit kinase 
activation in vitro [29]. However, this phosphorylation-induced activation is not mediated by 
disruption of SH3:linker interaction as observed by HXMS studies [24]. Phosphorylation of 
several other tyrosine residues is implicated in the regulation of Abl kinase activity. Tyr134 in 
the SH3 domain is directly involved in binding the PXXP motif, and phosphorylation of this 
residue is predicted to disrupt SH3:linker interaction [22,25]. Similarly, phosphorylation of SH3 
domain Tyr89 has been shown to interfere with SH3:linker interaction and cause kinase 
activation [24,25]. Additionally, phosphorylation of Tyr283 in the N-lobe of the kinase domain 
or Ser94 in the SH3 domain are predicted to disturb the closed packing of the SH3 domain 
against the N-lobe of the kinase domain and disturb the inhibitory intra-molecular interactions 
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[22]. In contrast to the activating effect of phosphorylation of residues discussed above, 
phosphorylation of Ser69 in the N-cap plays a role in stabilizing the down-regulated 
conformation of the Abl kinase core (also discussed earlier in section 1.2.1.1) [9]. The sites of 
phosphorylation are modeled on the structure of the down-regulated Abl core and presented in 
Figure 5. 
In addition to autophosphorylation and phosphorylation by other tyrosine kinases, Abl is 
also regulated by the action of tyrosine phosphatases such as protein tyrosine phosphatase non-
receptor type 6 (PTPN6), type 12 (PTPN12), and type 18 (PTPN18) [8]. 
1.2.3.2 Interaction with binding partners 
Multiple protein partners interact with Abl, and may play a role in regulating its kinase activity 
[8]. Some of these binding partners are also substrates of Abl, and may play a role in complex 
regulatory networks. On one hand, some proteins interact with the Abl SH3 and SH2 domains, 
through their polyproline motifs or phosphotyrosine sites, respectively. On the other hand, other 
proteins interact with the Abl proline-rich or phosphotyrosine sites through their SH3 or SH2 
domains, respectively. Additionally, interactions may also occur through other binding domains 
in the C-terminal region of the Abl protein. Sometimes, a single protein uses multiple 
mechanisms to interact with Abl. One such example is the adaptor protein Crk II, which contains 
a single SH2 and two SH3 domains. Crk II interacts with the proline-rich motifs in the C-
terminal region of Abl through the Crk II SH3 domain, and is phosphorylated by Abl kinase at a 
specific tyrosine residue (Tyr 221). These events cause a conformational change, exposing a 
PXXP motif in the SH2 domain of Crk which binds the Abl SH3 domain causing kinase 
activation [62,68]. Abl interacting proteins – 1 and 2 (ABI1 and ABI2) were the first identified  
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Figure 5. Regulatory phosphorylation sites in the Abl core. 
The location of the tyrosine and serine residues that are important for Abl regulation are modeled on the down-
regulated structure of the Abl core (PDB: 2FO0, [9]). Phosphorylation of these residues (except Ser69) is correlated 
with an increase in kinase activity. Ser94, Tyr89, and Tyr134 are located in the SH3 domain (red), Tyr245 is located 
in the SH2-kinase linker (orange), and Tyr283 and Tyr412 are located in the kinase domain (gray). The 
phosphorylation of Ser69, located in the N-cap (black), is important to stabilize the downregulated conformation of 
the kinase. 
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binding protein partners of the SH3 domain of Abl, and their effect on the kinase activity of Abl 
is not clear [69,70]. They interact with the Abl SH3 domain through their PXXP binding motifs, 
as well as bind the proline rich motifs in the C-terminal region of Abl through their SH3 
domains. On one hand, ABI 1 binding has been shown to be associated with Abl oligomerization 
and enhanced phosphorylation of Abl substrates, thus suggesting that it plays a role in Abl 
activation. On the other hand, ABI1 can also inhibit the transforming activity of v-Abl and 
phosphopeptides derived from ABI1 have been found to have an inhibitory effect on Abl activity 
[70,71]. Another binding partner of Abl is the RAS effector protein RIN1 that binds both the 
SH3 and SH2 domains in Abl through its PXXP motif and a phosphotyrosine site respectively, 
leading to Abl kinase activation [72].  Some proteins have also been implicated in the negative 
regulation of kinase activity, such as Tusc2 (or Fus1) and Prdx1 (or PAG) [73,74]. Interestingly, 
Prdx1 was shown to bind the Abl SH3 domain as well as the kinase domain and inhibit Abl 
kinase activity [73].  These studies have important implications for the discovery of small 
molecules that allosterically regulate Abl function, because interaction with the SH3 domain or 
other regulatory motifs may result in either Abl activation or inhibition. 
1.2.3.3 Growth factor induced activation 
Abl is activated by stimulation of cells with PDGF and EGF, and is involved in mediating the 
mitotic and chemotactic responses to these factors [66,75]. 
When cells are treated with PDGF, Abl kinases are recruited to the cytoplasmic domain 
of PDGFR within minutes, and the subsequent Abl activation requires Src and phospholipase C-
γ1 (PLC-γ1) activities [66,75–77]. Src is known to phosphorylate Abl at multiple tyrosine 
residues including the activation loop Tyr412, and other tyrosine residues in the regulatory 
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domains and cause kinase activation [76]. Moreover, PLC- γ1 is also important for Abl activation 
since PLC- γ1 activation leads to depletion of phosphatidylinositol 4,5-bis-phosphate (PIP2), 
which is a substrate of PLC- γ1 as well as an inhibitor of Abl [77]. Furthermore, Abl-deficient 
mouse embryonic fibroblasts are unable to reorganize the actin cytoskeleton and exhibit delayed 
S-phase entry on PDGF stimulation [66,78]. 
Abl is also activated upon stimulation with EGF, though the exact mechanism of 
activation is uncertain [66,79]. Interestingly, a high affinity binding site for the SH2 domain of 
Abl is present in all four members of EGFR family, and Abl has been found to be associated 
with EGFR in several cell lines [79,80]. These studies suggest that Abl may directly associate 
with EGFR, and this interaction is predicted to stabilize Abl in an open and active conformation. 
Furthermore, a recent study found that active Abl phosphorylates EGFR and subsequently 
inhibits its endocytosis from the cell surface, thus suggesting that activated Abl promotes 
increased cell-surface expression of EGFR [81]. 
1.3 C-ABL IN DNA DAMAGE 
Abl is known to be activated in response to several genotoxic stresses such as ionizing radiation 
and exposure to DNA damaging agents such as cisplatin, methylmethane sulfonate (MMS), 
mitomycin C (MMC), and doxorubicin [82–84]. In response to genotoxic stress, nuclear Abl is 
activated by several kinases involved in the DNA damage repair (DDR) pathways such as ataxia 
telangiectasia-mutated (ATM), and DNA-dependent protein kinase (DNA-PK) [85–87]. ATM, a 
serine/threonine kinase related to phosphinositide 3-kinases (PI3K), interacts with Abl through 
its SH3 domain and phosphorylates Abl on Ser465 in response to ionizing radiation [85,86]. This 
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phosphorylation event is required for Abl activation since a S465A mutation abrogates this IR-
induced activation, and Abl activation is not seen in ATM deficient cells [85,86]. Interestingly, 
Abl is known to interact with and phosphorylate modulators of both DNA-damage induced 
apoptosis and DNA-damage repair pathways. In addition, activation of Abl has been shown to 
promote the DDR pathway in some studies, while it has been shown to inhibit this process in 
others. The sections below will examine the role of Abl in promoting cell survival or cell death 
in response to DNA-damage. 
1.3.1 Role of Abl in the DNA damage repair pathway 
Multiple proteins involved in the DNA-damage repair pathway have been found to interact with 
Abl, and many of them are Abl kinase substrates [8]. Many initial studies found that Abl 
phosphorylation of these proteins leads to inhibition of the DNA-damage repair process. Rad51, 
an important protein involved in the homologous recombination (HR) pathway to repair double-
stranded breaks (DSBs) in DNA, interacts with the Abl SH3 domain through two PXXP motifs, 
and Abl phosphorylates Tyr54 and Tyr315 on Rad51 [88]. The phosphorylation of Tyr54 inhibits 
the ability of Rad51 to bind single stranded DNA, and its function in mediating DNA-strand 
exchange [88]. On the other hand, phosphorylation of Tyr315 has been shown to stabilize the 
association between Rad51 and chromatin, suggesting a positive influence on Rad51 activity 
[89]. Thus, the exact effect of the Abl kinase on Rad51 activity in DNA damage repair is not 
clear. In addition to Rad51, Abl phosphorylates DNA-PK, an important mediator of the non-
homologous end joining (NHEJ) DNA repair process, and disrupts its ability to form a complex 
with DNA, thus leading to reduced NHEJ repair [90]. Moreover, Abl phosphorylates WRN, a 
RecQ helicase that is involved in DNA metabolism, and inhibits its exonuclease and helicase 
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activities, thus inhibiting NHEJ DNA repair process [91]. Abl also interacts with BRCA1, a 
protein associated with DSB repair, and this interaction is disrupted in response to IR [92]. To 
summarize, most of these studies suggest that Abl has an inhibitory effect on the DNA damage 
repair processes. 
DNA damage repair is predicted to happen in two phases – a short phase of fast rejoining 
kinetics which repairs the majority of lesions and lasts about 2 hours, followed by a longer phase 
of slow rejoining kinetics. Interestingly, a recent study examined the effect of Abl on the DNA-
damage response over time [93]. Pre-treatment with imatinib, a selective inhibitor of Abl kinase 
activity discussed later in section 1.4.3, led to a higher rate of DSB repair and clonogenic 
survival in response to ionizing radiation as compared to control cells. Moreover, a pronounced 
effect was seen at later time points suggesting that Abl inhibits the second phase of slower DNA 
repair. In contrast, a recent study with primary non-immortalized mouse embryonic fibroblasts 
(MEFs) presented evidence supporting a role for Abl positively regulating the DNA-damage 
repair process [94]. Lack of Abl expression in these primary MEFs was found to result in 
reduced ATM and ATR kinase activity, nuclear foci formation, and DNA repair. These 
observations suggest that Abl activation, in response to DNA damage, plays a secondary role in 
the activation of ATM and ATR kinases. To summarize, while several studies suggest that Abl 
has an inhibitory effect on DNA-damage repair, a few studies provide evidence for a positive 
regulatory effect on these processes. Moreover, a kinetic analysis of Abl activation and its 
influence on the DNA-damage repair pathways may aid in a better understanding of the function 
of Abl in this process.  Discovery of selective small-molecule activators of Abl kinase activity 
may enable such studies. 
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1.3.2 Abl signals inducing apoptosis 
In response to genotoxic stress, Abl has been shown to interact with several proteins that mediate 
apoptotic cell death. Interestingly, Abl-deficient cells or cells expressing a kinase-dead mutant of 
Abl are resistant to IR-induced apoptosis [95]. While there is no clear evidence for a direct 
association of Abl with p53, Abl is known to induce apoptosis in response to DNA damage by 
both p53-dependent and p53-independent mechanisms [96–99]. Moreover, Abl also 
phosphorylates Mdm2 and neutralizes its inhibitory effect on p53, thus leading to p53 
stabilization and accumulation [100,101]. Additionally, another member of the p53 family of 
tumor-suppressors, transcription factor p73, interacts with the Abl SH3 domain through its 
PXXP motif [102–105]. Upon treatment with ionizing radiation, Abl phosphorylates p73, leading 
to accumulation of p73 and apoptotic induction. Furthermore, in response to DNA damage, Abl 
also phosphorylates and stabilizes YAP1, a transcriptional co-activator that works with p73 to 
induce expression of pro-apoptotic genes [106].  These findings suggest that Abl is required for 
induction of apoptosis in response to DNA damage, and that multiple proteins may contribute to 
this effect. Interestingly, a recent study found that inhibition of Abl kinase activity using imatinib 
leads to an increase in the clonogenic survival of irradiated cells, suggesting that Abl inhibition 
confers resistance to radiation treatment [93]. 
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1.4 BCR-ABL AND CHRONIC MYELOGENOUS LEUKEMIA 
1.4.1 Disease overview 
Chronic Myelogenous Leukemia (CML) is a clonal hematopoietic stem cell disorder that arises 
from a single transformed myeloid progenitor cell. The estimated number of new cases in the 
United States in 2015 is about 6,660 (12.3% of all leukemias) and the number of estimated 
deaths is around 1140 (4.7% of all leukemias) [107]. CML usually affects older adults with the 
average age at diagnosis being 64 years. Owing to the discovery of targeted drugs such as 
imatinib (discussed in detail in sections 1.4.3 and 1.4.4), the 5-year survival rate for CML 
patients has significantly improved from about 31% in the early 1990s to about 60% for patients 
diagnosed between 2004-2010 [107].  
Clinically, chronic myelogenous leukemia is classified into three diseases phases, on the 
basis of the number of immature white blood cells, also called ‘blasts’, in the blood or bone 
marrow [108–110]. Most patients are diagnosed in the chronic phase of the disease, which is 
characterized by the expansion of mature myeloid cells, especially granulocytes, and is usually 
asymptomatic. This stage is diagnosed by a high number of mature granulocytes in the peripheral 
blood, weight loss, and splenomegaly. Patients in the chronic phase typically have less than 15% 
blasts in the blood or bone marrow, and usually respond well to imatinib treatment. If left 
untreated, the chronic phase usually last for about 2 to 5 years, and the disease progresses to the 
accelerated and blast crisis phases. Both the accelerated and blast phases of the disease are 
characterized by a decrease in hematopoietic cell differentiation, and accumulation of immature 
blasts in the bone marrow and peripheral blood (>15%). The accelerated phase lasts about 6 to 
18 months, while the blast phase only lasts about 3 to 6 months. The transition to accelerated and 
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blast phases is accompanied by accumulation of genetic aberrations. Patients in blast crisis are 
characterized by poor appetite, splenomegaly, and proliferation of blast cells to other organs. In 
the advanced stages of disease, patients usually don’t respond well to treatment. 
1.4.2 Bcr-Abl: origin and mechanism of activation 
The Philadelphia chromosome is the cytogenetic hallmark of chronic myelogenous leukemia, 
and was the first cytogenetic change to be associated with cancer [111]. The Philadelphia 
chromosome is formed by a reciprocal translocation between chromosomes 9 and 22 [112,113]. 
This translocation, described as t(9;22)(q34;q11), juxtaposes the Bcr and Abl genes, leading to 
the expression of a fusion oncogenic tyrosine kinase, Bcr-Abl [4,5,111,114]. The Philadelphia 
chromosomal translocation is known to occur at three different breakpoint regions in Bcr 
[minor(m), major (M), micro (µ)], thus giving rise to three variants of the Bcr-Abl fusion protein 
– p185, p210, or p230 respectively [114]. These different types of Bcr-Abl include varying 
lengths of the Bcr gene fused to the Abl sequence, and consequently varying domains from the 
Bcr protein, and are associated with different disease pathologies [115]. The p185 Bcr-Abl 
includes the coiled-coil oligomerization domain, the SH2 domain binding site, and the 
serine/threonine kinase domain, and is associated with about 10% cases of acute lymphocytic 
leukemia (ALL). The p210 form of Bcr-Abl includes a Bcr-derived pleckstrin homology domain 
and a Dbl/Cdc24 guanine exchange factor homology domain, in addition to the coiled coil, SH2 
domain binding site, and serine/threonine kinase domain, and is associated with about 95% of 
CML and about 20% of ALL cases (Figure 6). The p230 form of Bcr-Abl includes the Rac GAP 
domain of Bcr, in addition to the above described domains, and is associated with chronic  
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Figure 6. The modular domain organization of the Bcr-Abl p210 protein. 
Bcr-Abl, an oncogenic protein tyrosine kinase, is the result of a chromosomal translocation that causes the fusion of 
Bcr and Abl proteins. The p210 variant of Bcr-Abl, responsible for CML, consists of multiple Bcr-encoded domains 
as shown – a coiled-coil domain (CC), a serine/threonine (S/T) kinase domain, a Dbl/Cdc24 guanine nucleotide 
exchange factor homology (DH) domain, and a pleckstrin homology (PH) domain. These Bcr domains are followed 
by Abl-encoded domains – partial N-cap, SH3 and SH2 domains, a SH2-kinase linker, kinase domain, and the last 
exon region containing proline rich regions, nuclear localization and export signals, and DNA and actin binding 
domains. The domain organization of the c-Abl 1b protein is shown at the bottom for reference. 
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neutrophilic leukemia (CNL). The discussion below is limited to the p210 form of Bcr-Abl 
responsible for CML. 
The N-terminal fusion of Bcr to Abl results in the partial deletion of the N-cap region, 
leading to a loss of myristoylation that serves an important function in inhibiting Abl kinase 
activity (discussed earlier in section 1.2.1.1). Bcr-Abl does include the SH3 and SH2 domains, 
kinase domain, and the C-terminal region of Abl. Moreover, the addition of Bcr domains 
upstream of the Abl tyrosine kinase plays an important role in kinase activation and is required 
for Bcr-Abl oncogenicity [116,117]. An important example is the coiled-coil domain at the N-
terminus of the Bcr protein [118,119]. This domain causes oligomerization of kinase molecules, 
leading to auto-phosphorylation, and kinase activation. Remarkably, disruption of Bcr-Abl 
oligomerization by deletion or mutation of the coiled-coil domain leads to a decrease in Bcr-Abl 
kinase and transforming activities. 
Although Bcr-Abl exhibits constitutive tyrosine kinase activity, several studies suggest 
that some of the regulatory intra-molecular interactions seen in Abl may persist in Bcr-Abl. X-
ray crystallization studies of imatinib bound to Abl have shown that it selectively binds the 
inactive conformation of the kinase domain (discussed in section 1.4.3.1), suggesting that it must 
trap Bcr-Abl in the same inactive conformation [32,33]. Moreover, mutations in the regulatory 
domains of Abl that disrupt the down-regulated conformation of Abl kinase core have been 
shown to cause resistance to imatinib [120]. Furthermore, enhanced SH3:linker intra-molecular 
interaction sensitizes Bcr-Abl-transformed cells to apoptosis by both ATP-competitive and 
allosteric inhibitors [30]. These studies suggest that Bcr-Abl may sample a dynamic range of 
conformations in solution, with the equilibrium being controlled by the same mechanisms that 
regulate Abl auto-inhibition (e.g. SH3-linker interaction). 
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Bcr-Abl expression is sufficient to induce factor-independent growth and survival in 
mouse fibroblasts, human myeloid progenitor cells, and primary bone marrow cells [108,121–
123]. Moreover, transplantation of Bcr-Abl-transduced bone marrow cells in mice gives rise to 
CML-like myeloproliferative disease (MPD) [124]. Furthermore, the tyrosine kinase activity of 
Bcr-Abl is critical for leukemogenesis, since kinase-dead Bcr-Abl-transduced cells do not induce 
MPD in mice [108]. Bcr-Abl acts as the oncogenic driver by interacting with signaling proteins 
and activating multiple signaling pathways involved in mitogenic signaling, altered cell adhesion 
and motility, disruption of DNA-damage repair processes, inhibition of apoptosis, and increases 
degradation of negative regulators of kinase activity [125]. Examples of some of these pathways 
include Ras and mitogen-activated protein kinase (MAPK), Janus kinase (JAK) – signal 
transducer and activator of transcription (STAT), phosphoinositide 3-kinase (PI3K), and Src-
family kinases, which are normally under strict physiological control by hematopoietic cytokines 
and growth factors. 
1.4.3 Imatinib: targeted Bcr-Abl kinase inhibitor 
One of the first examples of the selective inhibition of tyrosine kinase activity using small 
molecules was provided by the discovery of a class of compounds called tyrphostins that 
selectively inhibited EGFR kinase activity [126].  Subsequent studies reported a 2-
phenylaminopyrimidine compound as an inhibitor of the PDGFR [127]. Imatinib (Gleevec, STI-
571; Novartis) was developed as a derivative of 2-phenylaminopyrimidine to be a more potent 
inhibitor of PDGFR, and was subsequently found to inhibit the kinase activity of Abl tyrosine 
kinases and the stem cell factor receptor kinase (c-Kit) [128]. In a seminal study published in 
1996, Brian Druker and colleagues reported that imatinib selectively inhibited the growth of Bcr-
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Abl-positive cells and the growth of Bcr-Abl positive tumors in vivo [129]. Remarkably, it had 
no effect on the growth of non-transformed parental cells, or Bcr-Abl-negative transformed cells. 
Moreover, imatinib was found to inhibit hematopoietic colony formation by Bcr-Abl-positive 
cells obtained from patient samples. The success of these pre-clinical studies led to the first 
clinical trial with imatinib in 1998 [130]. In the initial phase I clinical trial, imatinib was 
remarkably successful with 53 out of 54 (98%) patients in chronic phase achieving complete 
hematologic response (CHR) after 4 weeks of treatment. This initial response was maintained in 
96% of the patients for over a year. Moreover, 21 out of 38 (55%) patients in the accelerated or 
blast crisis phases achieved partial hematologic response as well. In a phase II clinical trial, 91% 
patients in chronic phase showed CHR, and 89% of these showed no disease progression. 
However, patients in the accelerated phase and blast crisis achieved only 69% and 21% 
hematologic responses, respectively. The phase III clinical trial compared the efficacy of 
imatinib with the standard treatment at the time (interferon-α plus cytarabine), and found that 
patients treated with imatinib showed a significantly higher complete cytogenetic response rate 
(CCyR) with 96.7% of patients in chronic phase showing no disease progression after 18 months. 
Based on the overall efficacy and survival rate, imatinib was approved for treatment of CML by 
the FDA in 2001 [131]. The success of imatinib was followed by the development of several 
second and third generation ATP-competitive tyrosine kinase inhibitors of Abl kinases that will 
be discussed in section 1.4.4. 
1.4.3.1 Imatinib: mechanism of action 
Crystal structures of the Abl kinase domain in complex with imatinib were solved to elucidate 
the mechanism of imatinib binding and specificity [32,33]. These studies revealed that imatinib 
binds between the N- and C-lobes of the kinase domain close to the activation loop and the helix 
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αC. Moreover, the drug specifically binds to a unique conformation of the kinase domain where 
the activation loop is pointed inward and the DFG motif is flipped outward (discussed earlier in 
section 1.2.1.5). The DFG-out conformation prevents ligation of a critical magnesium ion that is 
required for catalysis. Moreover, imatinib forms a hydrogen bond with Asp381 of the DFG 
motif, which helps stabilize its binding to Abl. Furthermore, imatinib binding is stabilized by 
other hydrogen bonding interactions with Met318, Thr315 (gatekeeper residue), Glu286, His361, 
and Ile360, and several van der Waals interactions. A comparison of the inactive and active 
conformation of kinases has been helpful in understanding specificity exhibited by imatinib 
towards Abl [32,35]. While protein tyrosine kinases from different kinase families in the active 
state exhibit quite similar conformations, they adopt distinct conformations in the inactive state. 
Thus, imatinib achieves selective binding by stabilizing this distinct and relatively unique 
inactive conformation of Abl. 
1.4.3.2 Mechanisms of resistance to imatinib 
While the high rates of hematologic and cytogenetic responses to imatinib have been very 
promising, resistance to imatinib treatment has been a major concern. About 20-30% of CML 
patients are predicted to develop resistance to imatinib over the course of their treatment 
[132,133]. The mechanisms of resistance to imatinib can be divided into two types – Bcr-Abl-
dependent, and Bcr-Abl-independent mechanisms. 
Imatinib resistance: Bcr-Abl-dependent mechanisms 
One possible mechanism of Bcr-Abl dependent resistance to imatinib is through Bcr-Abl gene 
amplification, that results in over-expression of the Bcr-Abl protein. In the first set of 11 patients 
reported to show resistance to imatinib, 3 patient samples showed gene amplification as tested 
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using fluorescent in situ hybridization (FISH) [134]. In a larger set of 66 patient samples tested 
for Bcr-Abl amplification, only 2 patient samples showed amplification [135], suggesting that 
this mechanism is relatively uncommon. 
A second mechanism that is commonly seen is the emergence of mutations in Bcr-Abl 
that render the kinase refractory to imatinib. In the first report on patients who developed 
resistance to imatinib, 6 out of 11 patients were found to have a single nucleotide change in Bcr-
Abl, resulting in a mutation where the gatekeeper threonine residue at position 315 was mutated 
to isoleucine [134]. Based on the crystal structure of imatinib bound to the Abl kinase domain, 
this mutation not only prevents formation of a critical hydrogen bond between the tyrosine 
residue and imatinib, but the side chain of the isoleucine residue also introduces a steric clash 
that prevents imatinib binding [32]. T315I has turned out to be the most recalcitrant imatinib-
resistance mutation, and is responsive to only one of the clinically available ATP-competitive 
drugs which was designed to specifically inhibit this mutant kinase (ponatinib; discussed below 
in section 1.4.4). Furthermore, this T315I mutation has also been shown to enhance the kinase 
activity of the Abl and Bcr-Abl proteins as discussed earlier in section 1.2.1.5. Since this initial 
study, numerous other mutations in the kinase domain have been reported to cause resistance to 
imatinib treatment. These include mutations that either directly disrupt imatinib binding (e.g. 
T315I), or alter the kinase conformation such that it is incompatible for imatinib binding. 
Mutations belonging to the latter category are predominantly found in specific regions in the 
kinase domain such as the P-loop (e.g. Glu255, Tyr253), activation loop (e.g. His396), or at the 
SH2-kinase interface (e.g. Met351), but a few have also been reported in the regulatory domains 
(e.g. Ser154, Thr212) [132,136,137]. The most commonly mutated residues, representing 60-
70% of all mutations in clinical samples, are found in the kinase domain and include Gly250, 
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Tyr253, Glu255, Thr315, Met351, and Phe359 [132]. Interestingly, some of these mutations have 
been shown to enhance Bcr-Abl’s transforming potential [45,138].  
A comprehensive experimental study examining the effect of random mutagenesis of 
Bcr-Abl on the sensitivity of Bcr-Abl-transformed cells towards imatinib revealed many novel 
mutations that confer resistance to imatinib [120]. A majority of the mutations reported in the 
clinic were identified in this screen as well. Interestingly, this study found mutations not only in 
the drug binding site, but also in the regulatory domains of the Abl core. The positions of these 
mutated residues are distributed across all domains in the Abl kinase core and are presented in 
Figure 7. These mutations are predicted to cause resistance through an allosteric mechanism that 
promotes kinase activation. This is consistent with the inability of imatinib to bind the active 
(DFG-in, discussed earlier in section 1.2.1.5) conformation of the kinase domain [32,33]. 
Imatinib resistance: Bcr-Abl-independent mechanisms 
Bcr-Abl-independent resistance accounts for about 50% of imatinib-resistant cases of CML and 
can be attributed to a multitude of different mechanisms [132,139]. One possible mechanism is 
the reduction in intracellular drug levels due to a decrease in drug influx in the presence of α-1 
acid glycoprotein in the membrane, increase in drug efflux through P-glycoprotein mediated 
active transport levels, or changes in drug metabolism by cytochrome P450 isoenzymes. Other 
mechanisms of resistance include activation of other tyrosine or serine/threonine kinases 
downstream of Bcr-Abl signaling, leukemic stem cells refractoriness, and minimal residual 
disease in leukemic stem cells. 
Some patients exhibit resistance to imatinib despite inhibition of Bcr-Abl kinase activity, 
and this could be due to activated downstream signaling pathways [135]. Several studies have 
implicated Lyn, Fyn, and Hck, members of the Src kinase family, in imatinib resistance in CML.  
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Figure 7. Point mutations in the Abl kinase core induce resistance to imatinib. 
The location of residues, which render Bcr-Abl transformed cells resistant to imatinib upon mutation, are mapped 
onto the down-regulated structure of the Abl core (PDB: 2FO0). These mutations were identified in an unbiased in 
vitro screen [120]. Note that many of these mutations are located in the regulatory domains of the Abl core, 
indicating an allosteric mechanism of resistance through the drug binding site.  The position of imatinib (carbons in 
magenta) in the active site was mapped by aligning the kinase domain of this structure with that of an imatinib-
bound kinase domain crystal structure (PDB: 1IEP). 
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In an early study, K562 CML cells were cultured in increasing concentrations of imatinib to 
develop drug resistance. These resistant cells, in comparison to imatinib-sensitive cells, were 
found to have higher Lyn activity, and inhibition of Lyn kinase expression resulted in reduced 
proliferation and survival of these cells [140,141]. Moreover, imatinib resistance has been 
associated with upregulation of Hck, Lyn, or Fyn expression and/or activity levels in clinical 
samples from patients with accelerated or blast phase CML disease [140,142–144]. Additionally, 
a recent study found that Fyn potentially contributes to Bcr-Abl-induced genomic instability, 
leading to CML progression into blast phase of the disease [145]. In addition to these studies, 
work from our laboratory has shown that Fyn, Lyn, and Hck phosphorylate multiple tyrosine 
residues in the activation loop as well as regulatory domains of Abl [25]. The phosphorylation of 
some of these residues is predicted to disrupt regulatory intra-molecular interactions in the Abl 
core leading to kinase activation [24,25]. Moreover, recent studies from our lab have shown that 
overexpression of Hck in K562 CML cells leads to resistance to imatinib treatment and is 
correlated with increase in tyrosine phosphorylation in the Bcr-Abl SH3 domain (Tyr89) and 
activation loop (Tyr412). Furthermore, selective inhibition of Hck results in reversal of these 
phosphorylation events and restores imatinib sensitivity [146,147]. To summarize, these studies 
suggest an important role for Src-family kinase-mediated imatinib resistance in CML in the 
absence of mutations in the Bcr-Abl kinase domain. The success of dasatinib, a dual Bcr-Abl and 
Src-family kinase inhibitor (discussed below in section 1.4.4), in CML treatment suggests that 
inhibition of Src-family kinase activity can contribute towards reducing the incidence of drug 
resistance to tyrosine kinase inhibitors. In addition to SFKs, other signaling pathways such as 
MAPK, PI3K, and JAK-STAT, have also been implicated in resistance to imatinib [148]. 
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The vast majority of chronic phase CML patients achieve complete cytogenetic response 
(CCyR) following imatinib treatment, but relapses are commonly observed after imatinib 
cessation, due to the persistence of a ‘residual’ population of CML stem and progenitor cells 
[148]. In patients who have achieved MMR or CMR with imatinib treatment, 0.09% to 1.61% 
Bcr-Abl positive leukemic stem cells are found to persist as observed in engraftment studies in 
immunodeficient mice [149]. Multiple studies have shown that tyrosine kinase inhibitors are able 
to inhibit Bcr-Abl kinase activity in leukemic stem cells [150,151]. However, in contrast to 
differentiated cells, these cells do not undergo apoptosis following drug treatment [151]. This 
suggests that these cells may not be totally dependent on Bcr-Abl for growth, and hence cannot 
be eliminated by tyrosine kinase inhibitor treatment and contribute to the minimal residual 
disease.  Thus bone marrow transplantation remains as the only true cure for CML. 
1.4.4 Second and third generation ATP-competitive inhibitors of Bcr-Abl 
Although chronic use of imatinib leads to drug resistance in a large number of patients as 
discussed above, it has served as an important prototype for selective targeting of tyrosine 
kinases. Moreover, the X-ray crystal structure of imatinib bound to Abl has provided valuable 
insight into imatinib’s mechanism of action, and has been used to develop second- and third-
generation tyrosine kinase inhibitors (TKIs). 
Nilotinib (Tasigna, AMN107; Novartis) is one such second generation ATP-competitive 
TKI that is a structural analog of imatinib and selectively binds the inactive (DFG-out) 
conformation of the kinase. Nilotinib is about 50 times more potent than imatinib for Bcr-Abl 
inhibition in vitro, and like imatinib, inhibits c-Kit and PDGFR as well [152]. Nilotinib is able to 
inhibit a majority of the imatinib-resistant Bcr-Abl mutants. However, the gatekeeper mutant 
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(T315I) is completely resistant to nilotinib, and a few other kinase domain mutants including 
Y253H, E255K/V, and F359C/V are less sensitive to nilotinib [109,153,154]. Nilotinib was 
approved for second-line treatment of chronic and accelerated phase CML patients who are 
resistant to imatinib in 2007, and for front-line chronic phase CML therapy in 2010.  
Dasatinib (Sprycel, BMS-354825; Bristol-Meyers Squibb), another second-generation 
ATP-competitive TKI, is a dual Abl and Src family kinase inhibitor. In contrast to imatinib and 
nilotinib, dasatinib binds the active (DFG in) conformation of the kinase domain, and is about 
300 fold more potent than imatinib against cells expressing Bcr-Abl [36,155]. Dasatinib is also 
able to bind and inhibit a majority of imatinib-resistant Bcr-Abl mutants, with the exceptions of 
the gatekeeper mutant T315I which is completely resistant, and V299L and F317L mutants that 
are not as sensitive [109,156]. Dasatinib was approved for second-line treatment of all CML 
patients who are resistant to imatinib in 2006, and for front-line chronic phase CML therapy in 
2010. 
Bosutinib (Bosulif, SKI-606; Pfizer), is another second generation ATP-competitive TKI 
that can inhibit Abl as well as Src family kinases. Unlike the other three inhibitors described 
above, bosutinib does not inhibit c-Kit and PDGFR [157,158]. Bosutinib also inhibits a majority 
of imatinib-resistant mutants, but the gatekeeper T315I mutant is recalcitrant to this drug as well. 
In 2012, bosutinib was approved for second-line treatment of CML patients who are resistant or 
intolerant to the other TKIs. 
Ponatinib (Iclusig, AP24534; Ariad) is a third generation ATP-competitive TKI and the 
first approved inhibitor with activity against the Bcr-Abl T315I mutant [159]. Ponatinib, similar 
to imatinib, binds the inactive conformation of the Abl kinase domain through extensive 
hydrogen bonding and hydrophobic interactions, though drug binding does not require the 
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formation of a hydrogen bond with the Thr315 residue. Moreover, in contrast to imatinib, 
ponatinib interacts with the sidechain of the mutant T315I residue through a hydrophobic 
interaction and is thus able to bind and inhibit the Bcr-Abl T315I mutant. Ponatinib is about 500-
fold more potent than imatinib for Bcr-Abl inhibition, and showed an impressive response in the 
phase I and II clinical trials with patients who had been pre-treated with the other TKIs and those 
harboring the T315I mutation [160,161]. Ponatinib was approved for second-line treatment for 
patients in all disease phases of CML who were resistant or intolerant to other TKIs in 2012. 
However, long-term exposure to ponatinib was found to result in an increased incidence of 
arterial thrombotic events in patients from the phase II study [160,161]. As a result, a large 
randomized phase III clinical trial comparing imatinib and ponatinib was suspended until more 
information is available about drug efficacy and safety. Currently, ponatinib is approved with 
restrictions and additional safety guidelines for patients harboring the Bcr-Abl T315I mutant, or 
those that are resistant to all other TKI therapies. 
Another class of inhibitors, known as switch pocket inhibitors (DCC-2036; Deciphera 
Pharmaceuticals), bind the residues Arg386/Glu282 in the switch region and prevent Abl from 
adopting an active conformation [162]. DCC-2036 is able to inhibit a majority of the imatinib-
resistant mutants, including the gatekeeper T315I mutant. A phase I clinical trial was initiated 
with CML patients harboring the T315I mutation to assess the safety and tolerability of 
prolonged drug exposure, and the results of the study are awaited. 
1.4.5 Allosteric inhibitors of Bcr-Abl 
In addition to the tremendous efforts invested in the development of tyrosine kinase inhibitors 
targeting the active site of the kinase, a few studies have identified small molecules that act at 
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allosteric sites that are distant from the active site. Allosteric inhibitors are predicted to target 
regulatory mechanisms and sites that are relatively unique to individual kinases, and thus may 
exhibit reduced off-target effects, improve selectivity, and hence be better tolerated and have 
fewer side effects. 
The first allosteric inhibitor of Bcr-Abl, GNF-2, was discovered by Nathanael Gray and 
co-workers using a high-throughput cytotoxicity assay and Bcr-Abl-transformed cells in 2006 
[163]. Subsequent biochemical and structural studies showed that GNF-2 binds to the myristic 
acid binding pocket of Abl and stabilizes the inactive conformation of the kinase [55]. 
Surprisingly, GNF-2 was unable to inhibit several imatinib-resistant mutants of Bcr-Abl, 
including the T315I mutation. However, a combination of GNF-2 with nilotinib was effective in 
inhibiting the Bcr-Abl T315I mutant, as well as many other imatinib resistant mutants. 
Moreover, a combination of GNF-5 (a GNF-2 analog with improved pharmacokinetics) and 
nilotinib was able to effectively reduce splenomegaly, white blood cell counts, and STAT5 
phosphorylation in a murine bone marrow transplantation model of CML. Furthermore, this 
combination also resulted in an overall increased survival of animals in this study. Structural 
characterization of GNF-5 revealed conformational changes in the ATP binding site on 
compound binding, supporting allosteric communication between the myristic acid binding 
pocket and the ATP binding site (as discussed earlier in section 1.2.2.2) [54]. 
Besides identification of small molecules, a few research groups have developed peptides 
or monobodies to further understand and manipulate the allosteric regulation of Bcr-Abl. In one 
study, disruption of the N-terminal coiled-coil region of Bcr-Abl using a peptide was shown to 
inhibit the oligomerization of Bcr-Abl resulting in decreased kinase activity, and increased 
sensitivity to both imatinib and GNF-2 [164]. In another study, the interface between the SH2 
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domain and N-lobe of the kinase domain in the maximally activated ‘top-hat’ conformation of 
Bcr-Abl was disrupted using a monobody, HA4-7c12, resulting in inhibition of Bcr-Abl kinase 
activity and decreased survival of CML cell lines [65]. While intra-cellular delivery of these 
reagents restricts their clinical applicability, they are useful tools to understand the importance of 
allosteric interactions in Bcr-Abl activity regulation. 
1.5 ROLE OF C-ABL IN SOLID TUMORS 
In contrast to the role of Bcr-Abl in CML and other leukemias, the exact role of Abl in solid 
tumors is not as clear. There are a few reports about amplification, over-expression, and 
activation of Abl and/or Arg kinases in solid tumors [165]. Abl kinases are usually activated 
downstream of hyperactive receptor tyrosine kinases such as the PDGFR, EGFR, ERBB2 (or 
HER2), or insulin-like growth factor 1 receptor (IGF1R) [80,166–169]. Since Abl is involved in 
the regulation of diverse cellular processes, it is not surprising that it also plays a role in multiple 
facets of tumor growth and metastasis. In recent years, many research groups have been 
investigating the role of Abl kinases in diverse aspects of tumor pathology such as proliferation 
and survival, response to cellular stresses such as DNA damage, epithelial-to-mesenchymal 
transition (EMT), tumor invasion, and tumor metastasis. While the role of Abl in response to 
DNA damage is discussed earlier in section 1.3, this section will focus on the role of Abl in 
promoting or suppressing tumor growth and survival. 
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1.5.1 Abl as a promoter of tumor growth 
The activation of Abl kinases has been associated with changes in cell growth and survival. 
Depletion of Abl expression in breast cancer cells using siRNA showed that Abl is required for 
anchorage independent growth in breast cancer cells [169]. Moreover, Abl was also found to be 
required for anchorage independent growth of gastric and hepatocellular carcinoma cells [170]. 
While the exact mechanisms of Abl-induced cell proliferation are still being investigated, some 
signaling pathways that have been shown to be involved include RAC, p38, and ERK5 [171]. 
1.5.2 Abl as a suppressor of tumor growth 
In contrast to the role of Abl in promoting the growth of tumor cells, a few studies have shown a 
role for Abl in suppressing the growth of breast cancer cells. In a breast cancer xenograft mouse 
model, stimulation of EpHB4 receptor tyrosine kinase with ephrin B2 resulted in Abl activation, 
and a decrease in tumor growth through an Abl-Crk pathway [172]. Imatinib treatment blocked 
this effect, and Abl-dependent Crk phosphorylation was shown to be required for the effect of 
ephrin B2 on the growth arrest and apoptotic induction seen in breast cancer cells. Interestingly, 
another study reported that expression of a constitutively active form of Abl in a murine breast 
cancer cell line enhanced TGFβ induced growth arrest in 3D cell cultures, and inhibited the 
growth of tumor xenografts [173]. Moreover, active Abl kinase also suppressed TGFβ induced 
secretion of matrix metalloproteinase enzymes and inhibited cell migration in 3D cell culture. 
The discrepancy in the role of Abl in promoting vs. suppressing growth or invasiveness 
of solid tumors can be explained by the heterogeneity of solid tumors in terms of diverse 
activated signaling pathways, cell type, and tumor microenvironment. The function of Abl in 
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solid tumors could potentially depend on a combination of these factors and requires more 
investigation with selective modulators of Abl kinase activity. 
1.6 HYPOTHESIS AND SPECIFIC AIMS 
The kinase activity of Abl is tightly regulated by multiple intra-molecular interactions, and 
disruption of these interactions leads to kinase activation. Although Bcr-Abl exhibits constitutive 
tyrosine kinase activity, several studies strongly suggest that some of the regulatory intra-
molecular interactions seen in Abl may persist in Bcr-Abl. The positions of the regulatory SH3 
and SH2 domain have been established in either the down-regulated Abl core conformation or 
the maximally activated mutant kinase. However, the reorientation of the regulatory domains and 
their positions as a consequence of kinase activation under different cellular circumstances are 
not known. Conformation dynamic studies using HXMS have shown that effects of mutations in 
the Abl core are allosterically communicated to other sites in the kinase core. Furthermore, 
recent NMR analysis has shown that when the ATP-site inhibitor imatinib is bound to the Abl 
kinase domain, the structure becomes more dynamic with respect to the SH2 and SH3 domains. 
Based on these studies, I propose the hypothesis that Abl kinase activation does not require 
complete disruption of all intra-molecular interactions and reorientation of regulatory domains.  
Interaction between the SH3 domain and the SH2-kinase linker of Abl has been shown to 
be critical for regulation of Abl kinase activity. On one hand, disruption of the SH3:linker 
interaction by mutations or phosphorylation of tyrosine residues has been shown to activate Abl 
kinase, and induce resistance towards imatinib in Bcr-Abl transformed cells. On the other hand, 
enhanced SH3:linker interaction (as seen in our engineered HAL forms of Abl) overcomes the 
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effects of activating mutations in Abl, and sensitize Bcr-Abl transformed cells to both ATP-
competitive (e.g. imatinib) and allosteric (GNF-2) inhibitors. Thus, I propose the hypothesis that 
a small molecule that acts through the regulatory domains of Abl and influences SH3:linker 
interaction can be a potential agonist or antagonist of Abl kinase activity.  Such compounds will 
represent valuable new probes to better understand the role of Abl signaling in complex cellular 
environments (e.g., DNA damage response; breast cancer metastasis) and may represent new 
drug leads for Abl-related cancers. 
 
My thesis project tested these hypotheses with the following specific aims: 
 
Specific Aim 1: 
To investigate the effect of activating and stabilizing mutations on Abl core kinase activity, 
enzyme kinetics, thermal stability, and conformation in solution. 
 
Specific Aim 2: 
To develop a fluorescence-polarization assay to screen chemical libraries to identify allosteric 
modulators of Abl kinase activity that act through the regulatory domains. 
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2.0  THE C-ABL KINASE ADOPTS MULTIPLE ACTIVE CONFORMATIONAL 
STATES IN SOLUTION* 
2.1 SUMMARY 
Protein-tyrosine kinases of the Abl family have diverse roles in normal cellular regulation and 
drive several forms of leukemia as oncogenic fusion proteins.  In the crystal structure of the c-
Abl kinase core, the SH2 and SH3 domains dock onto the back of the kinase domain, resulting in 
a compact, fully assembled state. This inactive conformation is stabilized by the interaction of 
the myristoylated N-cap with a pocket in the C-lobe of the kinase domain. Mutations that perturb 
these intramolecular interactions result in kinase activation.  Here we present X-ray scattering 
solution structures of multi-domain Abl kinase core proteins modeling diverse active states.  
Surprisingly, the relative positions of the regulatory Ncap, SH3 and SH2 domains in an active 
myristic acid binding pocket mutant (A356N) were virtually identical to those of the assembled 
wild-type kinase core, indicating that Abl kinase activation does not require dramatic 
reorganization of the downregulated core structure.  In contrast, the positions of the SH2 and 
SH3 domains in the clinically relevant imatinib-resistant gatekeeper mutant T315I appear to be 
switched relative to their positions in the wild-type protein.  Thus Abl kinase activation can 
occur with (T315I) or without (A356N) global allosteric changes, revealing the potential for 
previously unrecognized signaling diversity. 
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*SAXS data were collected by Lee Makowski, Department of Chemistry and Chemical Biology, 
Northeastern University and analyzed by John Badger, DeltaG Technologies, San Diego, CA. 
2.2 INTRODUCTION 
The c-Abl tyrosine kinase is a modular signaling protein with multiple physiological roles 
ranging from regulation of the actin cytoskeleton to integration of DNA damage responses in the 
nucleus [8,174].  Abl is well known in the context of Bcr-Abl, the oncogenic tyrosine kinase 
responsible for chronic myelogenous leukemia (CML) and some cases of acute lymphocytic 
leukemia [175].  In CML, the normally tight regulation of c-Abl is lost as a result of fusion to Bcr 
sequences, and this uncontrolled kinase activity drives myeloid progenitor cell transformation 
and disease progression. Clinical management of CML has been revolutionized by the 
development of ATP-competitive inhibitors for the Abl kinase domain, of which imatinib 
(Gleevec) is the prototype [131].  The selectivity of imatinib for Bcr-Abl stems in part from its 
ability to trap a unique inactive conformation of the kinase active site [33].  Nevertheless, the 
evolution of drug-resistant mutants that affect imatinib binding has required the ongoing 
development of newer classes of Abl inhibitors. The so-called ‘gatekeeper’ mutant of Bcr-Abl, in 
which kinase domain position Thr315 in the imatinib binding site is replaced by isoleucine 
(T315I mutant), has been particularly difficult to target with small molecule inhibitors [134]. 
Other work has shown that the T315I mutation enhances both c-Abl and Bcr-Abl kinase activity, 
although the effect of this mutation on the overall structure and dynamics of c-Abl is less clear 
[46,138].   
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Crystallographic work on the Abl kinase ‘core’, which consists of an N-terminal cap 
region (N-cap), regulatory SH2 and SH3 domains as well as the kinase domain, has identified a 
compact, inactive conformation regulated by multiple interdomain contacts [9,12].  In this 
downregulated state, the SH2 and SH3 domains are docked onto the back of the kinase domain. 
Regulatory domain interactions are stabilized by addition of a myristic acid group to the N-cap, 
which inserts into a deep C-terminal lobe cavity unique to the Abl kinase domain. Mutations that 
perturb any of these intramolecular interactions lead to kinase domain activation, providing 
important validation of the crystal structure [14].  A model of the assembled, downregulated Abl 
core structure is presented in Figure 8A. 
While X-ray crystallography has provided tremendous insight regarding the relative 
positions of the regulatory and catalytic domains in the downregulated state of the Abl core, the 
fate of these domains as a function of kinase activation is less clear.  A single crystal structure of 
the Abl core that was activated by removal of all regulatory constraints revealed dramatic 
repositioning of the SH2 domain to the top of the kinase domain N-lobe (PDB ID: 1OPL, 
molecule B [12]), a result supported by other solution-based biophysical measurements [46]. 
Another attractive approach to investigate Abl structure is X-ray solution scattering, 
which enables structural characterization of protein forms that are not amenable to crystallization 
[47–50]. In particular, flexible conformations of large structures with multiple domains can be 
readily analyzed with this technique.  Ensembles containing multiple conformational states may 
be identified from X-ray scattering patterns.  In addition to well-known structural measures such 
as the radius of gyration (Rg) of the molecules in a sample, methodology for the ab initio 
calculation of low-resolution 3-dimensional molecular envelopes from intensity data has become  
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Figure 8. Abl core proteins. 
A) Crystal structure of the assembled, downregulated Abl kinase core (PDB:2F0O [9]).  The Abl core is composed 
of a myristoylated (Myr) N-cap, followed by the SH3, SH2, and kinase domains.  The unstructured part of the N-cap 
that extends to the C-lobe of the kinase domain is represented as a dotted line.  The SH2-kinase linker forms a 
polyproline type II helix which engages the SH3 domain.  B) Positions of activating mutations of the Abl core used 
in this study.  These include isoleucine substitution of the Thr315 gatekeeper position in the kinase domain (T315I), 
asparagine substitution of Ala356 (A356N) in the kinase domain C-lobe pocket that engages the myristoylated N-
cap, and glutamic acid replacement of two prolines in the SH2-kinase linker (P242, P249) which were combined 
with deletion of N-cap residues 1-82 in the mutant ΔNcap-2PE. C) Enlarged views of boxed portions from the Abl 
core structure in panel B are shown to highlight the exact position of the Thr315 (left, brown box) and Ala356 (right, 
blue box) residues. 
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well-established [50]. This approach to determination of molecular envelopes is attractive 
because the shapes of the reconstructed molecular envelopes are independent of any specific, 
previously known atomic model.  
Using the same hyperactive c-Abl protein (PDB ID: 1OPL, molecule B [12]) where SH2 
was observed to be positioned on the top on the kinase domain N-lobe by X-ray crystallography, 
a molecular envelope was obtained by X-ray solution scattering. The conformation of Abl from 
those measurements yielded a fully extended conformation with the kinase, SH2, and SH3 
domains in a linear arrangement, although the precise location of SH3 was not resolved [9].  
Between the inactive assembled state and this fully disassembled state, X-ray solution scattering 
data from an SH2 mutant of the hyperactive construct identified an intermediate state (or set of 
states) that has resisted a specific structural interpretation [9].  In complementary studies, recent 
NMR analysis showed that when the ATP-site inhibitor imatinib is bound to the Abl kinase 
domain, the structure becomes more dynamic with respect to the SH2 and SH3 domains [51]. 
Taken together, these studies demonstrate remarkable dynamic interplay between the Abl 
regulatory and catalytic domains which raises the important question of the ensemble of possible 
active states attainable.  Despite intense research efforts, our understanding of the structural 
transitions between the active and inactive states of Abl and the mechanisms that determine the 
equilibrium between them remains incomplete. 
To characterize the range of active conformational states attainable by the Abl kinase, we 
created four recombinant Abl core proteins that model a graded range of active states. This 
approach allowed us to sample the core conformation at various points along the activation 
coordinate, in contrast to previous approaches that reference only a highly mutagenized active 
form that adopts a single extended conformation.  X-ray scattering was used to determine the 
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solution structures of these proteins, which included: 1) the wild-type (WT) myristoylated Abl 
kinase core protein, identical in amino acid sequence and post-translational modifications to the 
one for which the crystal structure was solved by Nagar, et al. [9,12];  2) an alanine to asparagine 
point mutant in the myristic acid-binding pocket of the kinase domain N-lobe (A356N), which 
interferes with insertion of the myristate group of the N-cap necessary for kinase downregulation 
(Figure 8C) [14]; 3) an imatinib-resistant mutant in which the gatekeeper threonine is substituted 
with isoleucine (T315I) Figure 8C [134]; and 4) a double mutant lacking a portion of the N-cap 
(amino acids 1-82) including the myristoylation site plus dual proline to glutamate substitutions 
in the SH2-kinase linker (prolines 242 and 249) which disrupt intramolecular docking of the SH3 
domain (ΔNcap-2PE) [9,12].  The positions of these mutations are modeled on the crystal 
structure of the downregulated Abl core in Figure 8B, while Figure 8C shows enlarged views of 
the sites of mutation.  These kinase proteins span a broad range of intrinsic catalytic activities, 
with the following rank order:  wild-type < A356N < T315I < ΔNcap-2PE.  Our X-ray scattering 
results demonstrate that activation of the Abl kinase domain does not necessarily require 
regulatory domain displacement or destabilization of the assembled core structure associated 
with downregulation. However, the clinically important imatinib-resistant mutation T315I causes 
an unexpected and dramatic rearrangement of the overall core structure, providing new insight 
into its heightened catalytic and signaling capabilities. 
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2.3 MATERIALS AND METHODS 
2.3.1 Recombinant protein expression and purification 
Construction of baculovirus vectors for insect cell expression of the Abl core proteins used in 
this study has been described elsewhere [9,30].  For protein production, Sf9 cells were co-
infected with Abl core and YopH phosphatase baculoviruses to allow purification in the 
dephosphorylated state [30].  Abl proteins were purified from infected cell lysates using a 
combination of ion exchange and affinity chromatography and dialyzed against 20 mM Tris-HCl 
(pH 8.3) containing 100 mM NaCl and 3 mM DTT.  Purity and mass of each purified protein 
was verified by SDS-PAGE and mass spectrometry.   
2.3.2 Protein kinase activity measurements 
Tyrosine kinase activity of recombinant Abl core proteins was assessed using the FRET-based 
Z’Lyte kinase assay system and Tyr-2 peptide substrate as described elsewhere [46]. The Tyr2 
peptide substrate is labeled with fluorescein and coumarin at the N-terminal and C-terminal ends, 
and the emission ratio (ER) of the coumarin to fluorescein (FRET) fluorescence serves as the 
readout. Briefly, recombinant Abl kinase was incubated with ATP (50 µM) and Tyr2 peptide 
substrate (1 µM) for one hour. Assays were performed in quadruplicate in black 384 well plates 
(Corning #3676) in reaction volumes of 10 µL/well. Development reagent containing a selective 
protease was then added and the reaction was allowed to incubate for an additional hour. The 
development protease can selectively cleave the unphosphorylated peptide, resulting in 
disruption of FRET, and a high ER. On the other hand, phosphorylated peptide is not cleaved 
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and high FRET fluorescence results in a low ER. The assay includes a 0% phosphorylation 
control with unphophorylated peptide and no kinase, and a 100% phosphorylation control with a 
stoichiometrically phosphorylated Tyr2 peptide. The coumarin and fluorescein fluorescence is 
measured at the end of the assay, and the emission ratio for each well is normalized to the 0% 
and 100% phosphorylation controls.  
2.3.3 Transient expression of Abl proteins in HEK 293T cells 
The activity of Abl proteins expressed in HEK 293T cells was assessed as described previously 
[30]. Briefly, 106 HEK 293T cells were plated overnight in 6 cm dishes and then transfected with 
2.5 µg plasmid DNA and X-tremeGENE9 DNA transfection reagent (Roche Applied Science). 
Twenty-four hours post-transfection, cells were lysed and protein concentrations were 
determined using the Bradford assay reagent (Pierce). Equal amounts of cell lysates from each 
condition were separated by SDS-PAGE and immunoblotting was performed to detect overall 
phosphotyrosine levels (pY99; Santa Cruz Biotechnology) and Abl expression levels (Abl 
polyclonal sc-131, Santa Cruz). 
2.3.4 Kinetic protein kinase assay 
The ADP Quest assay (DiscoverRx) [176], which fluorimetrically measures kinase activity as the 
production of ADP, was used to determine Abl kinase reaction velocities.  Assays were 
performed in quadruplicate in black 384 well plates (Corning #3571) in reaction volumes of 10 
µL/well. The Tyr2 substrate peptide (EAIYAAPFAKKK) was dissolved in the ADP Quest assay 
buffer (15 mM HEPES, pH 7.4, 20 mM NaCl, 1 mM EGTA, 0.02% Tween-20, 10 mM MgCl2, 
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0.1 mg/ml bovine γ-globulins), while ATP stocks were prepared in 10 mM Tris-HCl (pH 7.0). 
The kinase reaction was initiated by the addition of ATP and read at 5 min intervals for 3 h in a 
SpectraMax M5 Microplate reader (Molecular Devices). To determine the substrate Km, the ATP 
concentration was fixed at 50 μM and the substrate peptide was serially diluted from 0.2-200 
μM. For ATP Km determination, the substrate concentration was fixed at the respective substrate 
Km for each of the kinases, and the ATP concentration was titrated over the range of 0.2-200 μM. 
The resulting progress curves were analyzed according to the method of Moroco et al. [177]. 
Briefly, raw fluorescence data were corrected for non-enzymatic ADP production (no kinase or 
substrate control) and kinase auto-phosphorylation (rate observed in the absence of substrate), 
and converted to pmol ADP produced using a conversion factor determined from an ADP 
standard curve generated under the same reaction conditions. The resulting values were plotted 
against time, and the linear portion of each progress curve was fit by regression analysis to 
determine the reaction velocity. Substrate and ATP Km values were determined by non-linear 
regression analysis using the Michaelis-Menten equation (GraphPad Prism 6). 
2.3.5 Differential Scanning Fluorimetry (DSF) 
DSF measurements were performed using a StepOnePlus real-time quantitative PCR instrument 
(Applied Biosystems) and software (version 2.3).  DSF assays (20 µl) were run in duplicate in 
sealed MicroAmp Fast 96-well qPCR plates (Applied Biosystems).  DSF profiles were acquired 
with recombinant Abl core proteins (2 μM) in bicine buffer (10 mM bicine, 150 mM NaCl, pH 
8.0) and SYPRO Orange (Sigma) diluted to a 5X working concentration. Parallel reactions 
without proteins were run in parallel to correct for background fluorescence. DSF reactions were 
allowed to equilibrate to 25 oC for 2 min, followed by an increase to 99 oC at a 1% temperature 
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ramp rate (1.6 oC/min) with continuous data collection. Background fluorescence was subtracted 
and mean fluorescence intensities were then plotted as a function of temperature.  Melt curves 
were fit using the Boltzmann sigmoid function of GraphPad Prism 6, and Tm values were 
calculated as the midpoint of the thermal transition between the minimal and maximum 
fluorescence intensities. 
 Small molecules (20 μM) were pre-incubated with the Abl core proteins (1 μM) 
for 30 minutes in bicine assay buffer (10 mM bicine, 150 mM NaCl, pH 8.0). SYPRO Orange 
(Sigma) was added at 5X final concentration and fluorimetry profiles were acquired as described 
above. Control reactions without proteins were included to correct for background fluorescence.  
2.3.6 X-ray solution scattering data collection 
SAXS data were collected using the undulator-based beam line X9 at the National Synchrotron 
Light Source (NSLS) at Brookhaven National Laboratory configured with two detectors [178] in 
order to collect both SAXS and WAXS data simultaneously, over the range of 0.006 < q < 2.0 Å–
1, where q is the momentum transfer (q = 4π sin(θ)/λ), 2θ is the scattering angle and λ is the 
wavelength of incident X-rays.  Data were collected at an X-ray wavelength of 0.9184 Å.  A 
Photonic Science CCD detector operated as the WAXS detector and a Mar 165 CCD as the 
SAXS detector. The SAXS detector was located 3.4 m from the sample.  Samples were loaded 
into a 96-well plate and aspirated into the 1.5-mm diameter, thin-walled sample tube using an 
automated system previously described [178].  Preliminary data processing was carried out using 
the X9 software package to produce circularly averaged intensity profiles combining data from 
the two detectors and extending over the entire range of q values. 
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2.3.7 Reconstruction of molecular envelopes 
Reconstructions of molecular envelopes from X-ray solution scattering data were performed 
using programs from the ATSAS software suite [179]. The particle distance distribution function, 
P(r), was calculated using GNOM [180] with data resolution limits and the maximum allowed 
inter-atomic distance, rmax, selected empirically so as to optimize the fit to the intensity data. In 
addition to scoring trials for P(r) using the output from GNOM, the shape of P(r) and the 
reciprocal space fit of P(r) to the observed data were also checked by visual inspection.  
Three-dimensional models of connected beads were generated to fit the data using 
GASBOR [50] with the number of beads set approximately equal to the number of amino acids 
in the Abl constructs. Between 10 and 40 independent modeling runs were performed on each 
data set, depending on the consistency of solutions and, for key selected examples, to assess the 
reproducibility of features in the molecular envelopes by comparing sub-averages from 
replicated reconstruction runs. Grid objects and molecular surfaces corresponding to Abl 
molecular envelopes were obtained by aligning replicate reconstructions with the DAMSEL and 
SUPCOMB [181] programs. A locally developed program was used to convert these aligned 
reconstructions to contiguous grid objects in which the volumes filled by the molecular envelope 
are represented by a set of pseudo-atoms set on a cubic grid with a 4 Å interval.  For the seven 
reconstructions carried out on the initial data collection run (run 1) the grid objects were 
generated by counting the number of aligned beads within 8 Å of each grid point and 
thresholding these number densities to give objects with approximately the same partial specific 
volume as calculated from the Abl sequence. The reconstructions for the four data sets collected 
in the second run (run 2) showed somewhat more scatter so the larger range of 16 Å was used to 
calculate bead number densities to obtain an appropriately smooth molecular envelope. Except 
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for the highly extended ΔNcap-2PE construct, analysis focused on the most extended set of 
examples collected under a single set of experimental conditions (run 1). 
2.4 RESULTS 
2.4.1 Biochemical characterization of the kinase activity of Abl kinase proteins 
Recombinant Abl core proteins were expressed in Sf-9 insect cells, purified to homogeneity, and 
their masses and post-translational modifications (myristoylation; phosphorylation) were 
confirmed by mass spectrometry. Additional constructs incorporating a high affinity linker 
sequence (‘HAL9’) [30] that stabilizes intramolecular binding to the SH3 domain were expressed 
as controls.  Using an in vitro kinase assay [46], we determined the concentration of each Abl 
kinase required for 50% maximal substrate phosphorylation (EC50) as a relative measure of 
intrinsic protein kinase activity.  As shown in Figure 9A, the kinases spanned a wide range of 
activities, with the WT (least active) and ΔNcap-2PE (most active) differing by nearly 60-fold.  
The A356N and T315I mutants exhibited intermediate activities, with the T315I mutant nearly 8-
fold more active than the A356N mutant. Earlier studies have reported the activity of the A356N 
and T315I mutants in cell-based assays, but the activity of the ΔNcap-2PE Abl mutant has not 
been tested in cells [30]. We therefore expressed these mutant Abl proteins in HEK 293T cells, 
and examined Abl kinase activity by immunoblotting for the total phosphotyrosine content in the 
whole cell lysates. As shown in Figure 9B, we found that cells expressing mutant Abl proteins 
have higher phosphotyrosine content, correlating with an increase in kinase activity. 
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Figure 9. Kinase activity measurements for Abl proteins. 
A) In vitro kinase assays of recombinant purified Abl proteins. Kinase activity was determined at ambient 
temperature using a FRET-based tyrosine kinase assay with a peptide substrate and increasing amounts of each 
recombinant Abl protein. Each condition was repeated in quadruplicate, and the extent of phosphorylation is 
expressed as mean percentage phosphorylation relative to a control phosphopeptide ± SD. Each kinase activation 
curve was best-fit by non-linear regression analysis, and the resulting EC50 values for half-maximal kinase activity 
are shown. (Note: The S.D. values are smaller than the diameter of the symbols, and therefore cannot be seen.) B) 
Kinase activity of Abl proteins in cells. Each Abl protein was expressed in 293T cells, and the overall protein 
tyrosine phosphorylation was assessed in the cell lysates by immunoblotting with an anti-phosphotyrosine antibody, 
with Abl blots performed as a control. The rank order of activity was the same in two independent experiments, and 
a representative blot is shown. 
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Cells expressing the wild-type Abl core protein, on the other hand, showed no increase in 
phosphotyrosine content in comparison to the vector-transfected (V) cells, indicating that the 
core is effectively downregulated in this system.  The relative activities of the wild-type and 
mutant Abl core proteins are consistent with their intrinsic catalytic activities observed in the in 
vitro kinase assay (Figure 9A). To test whether the increased phosphotyrosine content seen with 
the ΔNcap-2PE Abl mutant is a consequence of enhanced Abl kinase activity, we introduced a 
mutation in a catalytic aspartate residue (D382N) that is predicted to render the kinase 
catalytically inactive [9]. As shown in Figure 9B, we observe a complete loss of phosphotyrosine 
content in cells expressing this ΔNcap-2PE D382N mutant protein, thus confirming that Abl 
kinase activity is directly responsible for the observed increase in phosphotyrosine content in 
HEK 293T cells. 
We then proceeded to characterize the enzyme kinetics of the recombinant Abl core 
proteins using a fluorimetric kinetic kinase assay (ADP Quest, DiscoverRx) [176]. In contrast to 
the end-point kinase assay described above, the ADP Quest assay can be used to determine the 
enzymatic rate of reaction by measuring the accumulation of ADP, which results from 
phosphorylation of a peptide substrate, as a function of time. In addition to the wild-type, 
A356N, and T315I Abl core proteins, we also determined kinetic constants for the HAL9 Abl 
core and an Abl kinase domain protein that lacks the SH2 and SH3 regulatory domains [30]. To 
determine a protein concentration that gives a basal rate of reaction of about 9 pmol ADP 
produced per minute, we first conducted a kinase titration experiment. Figure 10A shows a 
representative experiment for the wild-type Abl core kinase at multiple protein concentrations, 
and the rate of reaction was found to increase with increasing concentrations of the kinase. We  
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Figure 10. Characterization of wild-type Abl core enzyme kinetics. 
A) Left: The time-course of ADP production for seven concentrations of Abl core wild-type was determined at 
ambient temperature using the ADP Quest kinetic kinase assay as described in the Materials and Methods. A 
representative experiment is shown. Right: The linear portion of each curve was analyzed by linear regression to 
determine the slope, which is equivalent to the rate of reaction in pmol APD produced/min. B) The rates of reaction 
for Abl core wild-type were determined at the indicated substrate peptide (left) and ATP (right) concentrations as 
described in the Materials and Methods. These rates were plotted as a function of concentration of the peptide 
substrate (left) and ATP (right) and exhibit saturation kinetics. The Km values were determined by fitting these 
curves to the Michelis-Menten equation using non-linear regression analysis (red lines). The kinetic constants for the 
mutant Abl core proteins were determined similarly and are presented in Table 1. 
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observed similar trends for the other Abl proteins as well, and fixed the kinase concentrations to 
yield a basal rate of 9 pmol ADP produced per minute. We then determined the Km values for the 
substrate peptide, EAIYAAPFAKKK, and ATP for each of the Abl kinase proteins. Figure 10B 
shows a representative experiment for Km determination for the wild-type Abl core protein for 
the substrate peptide (left) and ATP (right), and both curves obey Michelis-Menten kinetics. 
Similar trends were observed for the other Abl kinase proteins as well, and the Km values for 
each protein are summarized in Table 1. For the Tyr2 substrate peptide, the Km values for the 
active Abl core mutants, A356N and T315I, are about three-fold lower than the wild-type Abl 
core, suggesting that these mutants have a higher affinity for this peptide substrate. The substrate 
Km for the Abl kinase domain protein is about seven-fold lower than the wild-type Abl core, 
suggesting that the lack of regulatory constraints may make the active site more open to peptide 
binding. In contrast to these active proteins, the substrate Km for the HAL9 Abl core protein is 
similar to the wild-type Abl core. The ATP Km values are in similar range for the four Abl core 
proteins, while the Abl kinase domain protein has a four-fold higher Km than the wild-type Abl 
core protein. The significance of this higher ATP Km is also likely to reflect conformational 
differences in the ATP-binding site result from removal of the regulatory region.  
2.4.2 Thermal stability of Abl proteins 
We then compared the thermal stability of each recombinant Abl protein using a differential 
scanning fluorimetry (DSF) assay [182]. Each purified Abl protein was gradually heated in a 
quantitative PCR instrument in the presence of the reporter dye, SYPRO orange. As the 
temperature rises and the protein unfolds, the reporter dye gains access to the hydrophobic 
interior of the protein, resulting in an increase in dye fluorescence.  The resulting rise in  
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Table 1. Kinetic constants for recombinant Abl core proteins. 
The Km values for the Tyr2 peptide substrate and ATP were determined for each Abl core protein using the ADP 
Quest assay as described under Materials and Methods. All experiments were performed twice, except for the wild-
type Abl core, for which peptide substrate experiments were performed four times, and ATP experiments were 
performed three times. The table shows the mean Km values + S.E. 
 
 
Abl Protein 
Substrate Peptide 
Km (μM) 
ATP Km (μM) 
WT 144.6 + 1.6 9.8 + 0.1 
A356N 49.1 + 1.7 19.4 + 0.3 
T315I 42.2 + 3.0 11.0 + 1.4 
HAL9 150.2 + 5.4 21.2 + 1.6 
Kinase 20.9 + 0.4 36.0 + 3.5 
 
 
 
fluorescence as a function of temperature eventually reaches a maximum, and the resulting 
protein ‘melt curve’ is fit by non-linear regression analysis to obtain a Tm value (temperature at 
which half-maximal thermal denaturation is observed). Figure 11A shows representative curves 
from a DSF experiment for the wild-type Abl core as well as the ΔNcap-2PE (least stable) and 
HAL9 Abl core (most stable) proteins. Interestingly, we observed a difference in the baseline 
fluorescence at 25 °C for the three proteins. The Abl ΔNcap-2PE protein exhibits higher baseline 
fluorescence in comparison to the wild-type, suggesting that the hydrophobic regions in the Abl 
ΔNcap-2PE protein are more accessible and it potentially adopts an open conformation. On the  
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Figure 11. Thermal stability measurements for recombinant Abl proteins. 
A) Differential scanning fluorimetry (DSF) assay.  DSF was performed on the seven recombinant Abl kinase core 
proteins as described in Materials and Methods. Background-corrected fluorescence intensities for the wild-type Abl 
core, HAL9 Abl core, and the ΔNcap-2PE protein are plotted as a function of temperature for a representative assay. 
Thermal melt temperatures, or temperatures at which half-maximal fluorescence (Tm) was observed, were 
determined and are presented in Table 2.  B) The changes in average melt temperature (ΔTm) for each Abl protein, 
with respect to the wild-type Abl core as a reference, are presented here and in Table 2. 
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other hand, the lower baseline fluorescence observed with the Abl core HAL protein suggests 
that the hydrophobic regions in this protein are less accessible and it potentially adopts a 
relatively compact conformation. The thermal melt temperatures (Tm) for each protein were 
determined, and are summarized in Table 2. Additionally, we calculated the change in thermal 
melt temperature (ΔTm) for each of these proteins with the wild-type Abl core protein as a 
reference. As shown in Figure 11B and Table 2, the Tm values for the wild-type (assembled) core 
and the fully disrupted ΔNcap-2PE mutant varied by more than 13 °C.  This large decrease in the 
Tm of the ΔNcap-2PE mutant relative to WT is consistent with the loss of regulatory constraints 
and a resulting increase in dynamic behavior.  The myristate binding pocket mutant (A356N), on 
the other hand, showed only a 5 °C reduction in thermal stability relative to wild-type, consistent 
with the more modest enhancement of kinase activity compared to ΔNcap-2PE. Remarkably, the 
T315I gatekeeper mutant showed a reduction in Tm of less than 2 °C relative to wild-type, 
suggesting that this mutant adopts a thermally stable albeit more active conformation.  X-ray 
scattering data presented in the next section support this idea. 
As shown in Figures 11A and 11B, the Tm value for the HAL9 Abl core protein is higher 
by almost 3 °C as compared to the wild-type Abl core. This is consistent with the stabilizing 
effect of the enhanced SH3:linker interaction on the wild-type Abl core protein, as observed 
earlier in HXMS studies [30]. In addition to the Abl proteins discussed above, we also tested the 
thermal stability of proteins that include the high affinity linker in the context of the A356N and 
T315I mutations, HAL9-AN and HAL9-TI respectively [30]. We observed that the combination 
of the high affinity linker with the active mutant Abl proteins results in an increase in Tm, 
suggesting that enhanced SH3:linker interaction leads to stabilization of these mutant proteins. 
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Table 2. Thermal melt temperatures (Tm) for recombinant Abl core proteins. 
The Tm values were determined, for each Abl protein, using the DSF assay as described in the Materials and 
Methods. The Tm values are presented as mean + S.E.M. [n=6 for Abl core WT; n=5 for Abl core HAL9; n=4 for 
Abl core A356N, T315I and HAL9-AN; and n=2 for Abl core HAL9-TI and ΔNcap-2PE]. The change in the 
average melt temperature (ΔTm) was also calculated for each protein with the wild-type Abl core as a reference. 
 
 
Abl Protein 
Melt Temperature 
Tm (°C) 
ΔTm (°C) 
WT 53.9 + 0.2 0 
HAL9 56.8 + 0.2 2.8 
A356N 48.8 + 0.2 -5.2 
HAL9-AN 51.7 + 0.1 -2.2 
T315I 52.4 + 0.4 -1.5 
HAL9-TI 55.0 + 0.0 1.1 
ΔNcap-2PE 40.4 + 0.3 -13.5 
 
 
 
These results are consistent with the earlier study where enhanced SH3:linker interaction was 
found to be dominant over these activating mutations and led to a reduction in their kinase 
activity in cell culture [30]. X-ray scattering data presented in the next section support these 
ideas. 
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2.4.3 X-ray scattering analysis 
We next collected small and wide angle X-ray solution scattering data under a consistent set of 
conditions from each of the Abl core constructs.  Calculations of the radii of gyration, Rg, show 
that the average solution structures of the WT and A356N proteins are the nearest to that 
expected for a spherical protein, while the Rg from T315I and ΔNcap-2PE correspond to shapes 
that are significantly more elongated (Table 3).  The rank order of Rg for these samples is WT ≈ 
A356N < T315I << ΔNcap-2PE, which correlates closely with their intrinsic protein tyrosine 
kinase activity ranking (Figure 9).  The smallest values for Rg were obtained for the three 
constructs that included the high-affinity linker (HAL9) sequence [30], consistent with the role of 
SH3:linker interaction in stabilizing the assembled structure of the downregulated kinase (Figure 
11). 
The values of Rg obtained from our experiments also compare favorably with previously 
published results (using the GNOM program) of Rg = 27.2 Å for the compact, inactive WT form 
and Rg = 31.7 Å for a structurally undetermined active form that may contain multiple active 
conformational states [9].  However, our data for the fully extended ΔNcap-2PE construct 
yielded an Rg = 39.4 Å, which is larger than the Rg value of 34.5 Å obtained for this construct in 
the previous study. This conformational form consists of a linear array of structural domains and 
some flexing between domains, perhaps in response to different experimental conditions or the 
presence of the stabilizing ligand used in this earlier work (and absent here), may account for this 
difference in Rg.  
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Table 3. Radii of gyration (Rg) for recombinant Abl core proteins. 
Radii of gyration, Rg, were calculated from X-ray scattering curves as reported by the OLIGOMER program [183] 
and by the GNOM program [180] from the fitting of P(r).  Systematic discrepancies were reduced by making 
comparisons between data sets collected under the same experimental conditions, with the exception of the data set 
for the ΔNcap-2PE control. The rank order for the Rg obtained with OLIGOMER is consistent with that obtained 
from GNOM with just one minor inversion that is within the estimated errors of the Rg determinations. 
 
 
Abl Protein Rg (Å; OLIGOMER) Rg (Å; GNOM) 
A356N 29.7 27.7 
WT 29.7 28.1 
T315I 31.5 28.7 
ΔNcap-2PE 42.6 39.4 
HAL9 26.9 26.8 
HAL9 + A356N 27.3 27.1 
HAL9 + T315I 28.5 27.1 
 
 
 
2.4.4 Shape reconstructions from X-ray solution scattering data 
Reconstructions of the molecular envelopes of each Abl structure from solution X-ray scattering 
were performed using standard methods in order to identify distinct conformational states and to 
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compare these states with the available Abl crystal structures. Conclusions regarding the relative 
similarities of the reconstructed molecular envelopes to each other were checked by calculation 
of overlaps with the SUPCOMB program [181]. Insights regarding the solution structure of each 
Abl core protein resulting from these reconstructions are summarized below. 
Wild-type and A356N myristic acid binding pocket mutant.  Reconstructions of the 
protein shapes from the WT Abl core protein and the A356N myristic acid binding pocket 
mutant differ only slightly from one another, and also agree quite well with the crystal structure 
of the inactive conformation (PDB: 2F0O; Figure 12A).  Previously reported solution scattering 
data collected from a WT Abl sample containing a stabilizing ligand also resulted in a shape 
consistent with this crystal structure [9].  Although the A356N mutation enhances the intrinsic 
kinase activity of Abl both in vitro and in cells (Figure 9) [30], the shape of this reconstruction 
suggests that this mutation induces an active conformation without movement of the SH2 to the 
so-called ‘top-hat’ position, where it engages the kinase domain N-lobe and stabilizes an active 
conformation of the kinase domain [184].  This conclusion is supported by previous results from 
hydrogen exchange mass spectrometry, which revealed that an identical A356N Abl core protein 
shows very little difference in deuterium uptake relative to the wild-type form [30].  These results 
imply that activation of Abl by displacement of the myristate group from the N-lobe may result 
in an active state in which the core retains the assembled configuration. 
T315I imatinib-resistant gatekeeper mutant.  Unlike the A356N mutant, the shape of the 
T315I reconstruction is markedly different from that of the WT Abl core (Figure 12B). In this 
case, the reconstructed molecular envelope tends towards a 'squashed pear' form that is poorly fit 
by the crystal structure of the inactive conformation.  Instead, the T315I envelope is better fit by 
the crystal structure of the disassembled Abl structure (PDB: 1OPL, molecule B [12]), in which 
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Figure 12. X-ray solution scattering reconstructions of molecular envelopes for Abl constructs and fits by 
atomic models.  
For all models, the purple dots indicate the reconstruction volumes.  The backbone chain traces for the kinase, SH2 
and SH3 domains are displayed as blue, green and red tubes, respectively. The best overlap between model and 
reconstruction in all images was obtained using SUPCOMB [21] and the images were rendered with MIFit.  (A) 
Reconstructions for wild-type and A356N mutant Abl core proteins superimposed on the main chain trace from the 
crystal structure of Abl in the inactive form (PDB ID: 2FO0 [9]).  (B) Left: Reconstruction of the T315I gatekeeper 
mutant superimposed on the crystal structure of the assembled Abl core (PDB: 2FO0, [9]). Note that the T315I 
scattering envelope is fit poorly by the 2FO0 structure, leaving the position of the SH3 domain and N-cap 
unaccounted for (dotted line and arrow).  Right: The T315I envelope is superimposed on the extended conformation 
of an active Abl structure (PDB: 1OPL, molecule B [10]).  The SH3 domain was then manually fit in the remaining 
void adjacent to the kinase domain.  (C) Reconstruction for the ΔNcap-2PE construct showing the fit of kinase and 
SH2 domains from the disassembled crystal structure (PDB ID: 1OPL, molecule B), with the SH3 domain fitted to 
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the unfilled volume.  (D) Scattering envelopes for the high affinity SH2-kinase linker variant of the Abl core protein 
(HAL9) as well as variants that combine HAL9 with A356N (HAL9 + A356N) and T315I (HAL9 + T315I) Abl 
core constructs superimposed on the downregulated Abl structure (PDB: 2FO0 [9]). SAXS data and analysis 
courtesy of John Badger, DeltaG Technologies, and Lee Makowski, Department of Chemistry and Chemical 
Biology, Northeastern University. 
 
 
 
the SH2 domain is juxtaposed to the kinase domain N-lobe.  The SH3 domain was not visualized 
in this crystal structure but if the SH2-kinase linker is refolded, the remaining unfilled space in 
the envelope can be fit by the SH3 domain.  This model strongly suggests that this single drug 
resistance mutation in the kinase domain has profound allosteric effects on the overall shape of 
the Abl core.  This previously unobserved active state of Abl may contribute to the unique 
kinetic properties and altered substrate selection profile of the T315I mutation in the context of 
Bcr-Abl [138].  The model is also consistent with previous hydrogen exchange studies, which 
revealed subtle increases in SH3 domain deuterium uptake in the T315I mutant compared to WT 
Abl [46]. 
Hyperactive ΔNcap-2PE mutant.  Analysis of scattering data from the ΔNcap-2PE 
construct revealed a molecular envelope with a highly elongated appearance, as expected from 
earlier work [9] (Figure 12C).  The prior study modeled the ΔNcap-2PE protein using an Abl 
conformation based on PDB entry 1OPL (molecule B) for the kinase and SH2 domains, with the 
SH2 domain in the ‘top-hat’ configuration next to the kinase domain N-lobe as described above. 
The SH3 domain was fitted so as to occupy the remaining empty space adjoining the SH2 
domain and extending to the full 115 Å length of the molecular envelope.  The surface of our 
reconstruction more clearly defines the separate domains of this extended structural arrangement, 
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with a narrowing of the protein envelope at the boundaries of the kinase, SH2 and SH3 domains.  
These results provide an important control for the novel active structures observed with the 
A356N and T315I Abl cores. 
2.4.5 Enhanced SH3-linker interaction reverses the structural changes induced by the 
T315I mutation 
Recent work from our laboratory has shown that the strength of intramolecular SH3 domain 
interaction with the SH2-kinase linker has a dominant effect on Abl kinase activity and Bcr-Abl 
kinase inhibitor sensitivity [30].  This study reported a series of Abl and Bcr-Abl proteins with 
modified linkers containing extra proline residues to enhance internal SH3 docking. The HAL9 
linker, described in the previous section, has five linker proline substitutions that reverse the 
activating effects of both the A356N and T315I mutations in cell based assays [30].  These 
observations predicted that X-ray scattering studies of the HAL9 forms of our active Abl mutants 
would show a return to the assembled inactive state associated with the crystal structure of the 
wild-type Abl core.  To test this idea, we expressed and purified HAL9 versions of the Abl core 
protein on the WT, A356N and T315I backgrounds. X-ray scattering data were then collected on 
each of these proteins, and compared to results with the complementary constructs with wild-
type linkers. 
The shape of the reconstruction from the HAL9 construct that is otherwise wild-type 
(Figure 12D, left) is completely consistent with the crystal structure of the WT Abl core in the 
assembled inactive conformation (PDB ID: 2FO0; [9]).  This result indicates that the introduction 
of five additional linker prolines enhances SH3 engagement without distorting the overall shape 
of the downregulated molecule.  The shape of the reconstruction from the WT sample (Figure 
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12A) lies somewhere in between the shapes of the HAL9 (Figure 12D, left) and T315I (Figure 
12B) structures, suggesting that in solution the WT form is poised between inactive and active 
conformational states. Intensity data and the resulting reconstruction of the HAL9 variant of the 
A356N protein (Figure 12D, middle) are also indistinguishable from those obtained for the 
HAL9 construct with a wild-type kinase domain.  This observation is fully consistent with 
previous hydrogen exchange data showing that subtle dynamic changes resulting from the 
A356N mutation are abolished by incorporation of this high affinity linker sequence [30].  
Remarkably, the intensity data and molecular reconstruction from the HAL9 protein 
incorporating the T315I mutation (Figure 12D, right) are also very similar to those obtained from 
the control HAL9 construct (Figure 12D, left). This result suggests that enhanced SH3-linker 
interaction reverses the dramatic structural rearrangement triggered by the T315I mutation 
(Figure 12B).  Similarly, the compact shape of the HAL9 variant of the T315I protein is 
consistent with the observation that the enhanced activity of the T315I mutant is suppressed in 
cells when coupled to the HAL9 sequence [30].  The shape reconstructions for the three HAL 
proteins are also consistent with the radii of gyration, which are all smaller than the value 
observed for WT Abl (Table 3).    
2.4.6 Effect of small molecules on thermal stability of Abl kinase proteins 
Ponatinib is an ATP-competitive inhibitor of Abl that was rationally designed to bind to the Abl 
T315I mutant and inhibit its kinase activity [159]. Ponatinib, like imatinib, also selectively binds 
the inactive kinase conformation (DFG-out) of the protein. In order to investigate the effect of 
ponatinib on Abl core protein dynamics, we tested the effect of this drug on the thermal stability 
of the Abl core proteins. In addition to ponatinib, we tested the effect of two additional small 
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molecules – imatinib (the first generation ATP-competitive inhibitor) and DPH (a small 
molecule that activates Abl through the myristic acid binding pocket) on the thermal stability of 
these proteins [185]. Figure 13A shows representative thermal melt curves of the wild-type Abl 
core incubated with each of these three small molecules. The presence of imatinib and ponatinib 
results in a shift of the melt curve to the right, suggesting an increase in the thermal melt 
temperature (Tm) that correlates with increased protein stability. Moreover, we observed a more 
robust stabilization with ponatinib, which is consistent with its higher potency in inhibiting the 
wild-type Abl core. In contrast to the inhibitors, we observed a decrease in the Abl core Tm in the 
presence of DPH, suggesting that this compound destabilizes Abl as a function of activation. In 
addition to the wild-type Abl core, we also tested the effects of these small molecules on the 
mutant Abl core proteins, A356N and T315I, and calculated the change in Tm for each small 
molecule-protein complex with DMSO as a reference. As shown in Figure 13B, imatinib results 
in stabilization of both the wild-type and A356N Abl core proteins, but not the Abl T315I 
protein. This is consistent with the inability of imatinib to bind the T315I Abl mutant because of 
steric clash and loss of hydrogen bonding [32,33,134]. Moreover, we observe that DPH 
destabilizes the wild-type and T315I Abl core proteins, but not the A356N protein. Since the 
Ala356 residue is in the myristic acid binding pocket, this suggests that the mutation to 
asparagine at this site interferes with DPH binding. Ponatinib binding to Abl core induces a 
robust increase in protein stability for the three Abl core proteins tested in this study. These 
results provide important information about the effect of small molecules on Abl core protein 
stability and present a foundation for future analysis of Abl protein dynamics in the presence of 
these small molecules. 
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Figure 13. Effects of the Abl kinase inhibitors (imatinib and ponatinib) and activator (DPH) on thermal 
stability of recombinant Abl proteins. 
A) Differential scanning fluorimetry (DSF) assay.  DSF was performed on the wild-type Abl core protein in the 
presence of the indicated compounds as described in Materials and Methods. Background-corrected fluorescence 
intensities for each inhibitor-treated protein are plotted as a function of temperature in this representative assay.  B) 
The change in melt temperature  (ΔTm) was calculated for the three Abl core proteins in the presence of the indicated 
compounds, with DMSO as a reference. The changes in melt temperature (ΔTm) are presented as average values ± 
SE. 
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2.5 DISCUSSION 
SAXS analyses of the diverse Abl core constructs presented here reveal a set of closely similar 
structures that differ in subtle yet important ways.  Determination of Rg and the shapes of the 
molecular envelopes show an increase from compact to more elongated forms (Table 3 and 
Figure 12).  The relatively smooth variation of these parameters among the WT, A356N and 
HAL9 proteins suggests that the differences in observed data correspond not to distinct 
conformations, but rather to differences in conformational equilibria in which two or more 
conformations are present in different proportions.  As the proportion of the larger component 
increases, the value of Rg estimated from the X-ray scattering data will increase. Reconstructions 
of molecular envelopes from ensembles are difficult to anticipate, but can be estimated from data 
simulations if models of the dominant components are available [186]. 
Reconstructions of the most compact forms (Figure 12), obtained from constructs 
incorporating the HAL9 sequence, are all well fit by a crystal structure of the inactive form (PDB 
ID: 2FO0; [9]). The role of the additional prolines engineered into the linker is to provide 
additional stability for this structural form compared to WT. We surmise that the set of structural 
states corresponding to Abl samples containing the HAL9 sequence is highly dominated by this 
inactive conformation, even when combined with activating mutations at other sites (A356N and 
T315I).  This observation suggests that enhancement of natural SH3:linker interaction with small 
molecules or antibodies may effectively inhibit these and other mutant forms of c-Abl and Bcr-
Abl. 
Data from the T315I and ΔNcap-2PE proteins are not consistent with a gradual change in 
conformational equilibria.  Data collected from the T315I mutant shows that it exhibits a large 
and unanticipated departure from the inactive conformation.  When calculated with GNOM, the 
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value of Rg obtained from the T315I data is slightly lower than the published value obtained 
from an SH2 mutant of a hyperactive form with 'molecular envelopes that resemble Ablactivated 
(viz. ΔNcap-2PE) although more compact' [9].  We interpret this conformational change as due 
to a rearrangement of the SH2 and SH3 domains. When interpreted on the basis of the alternative 
Abl conformation identified from protein crystallography (PDB: 1OPL, molecule B), the kinase 
and SH2 domains fit well into the reconstruction but leave a large unfilled volume adjacent to the 
kinase domain. The volume of this region is approximately the same as that of the SH3 domain 
(not visible in the crystal), and we suggest that it identifies the positioning of the SH3 domain 
within this structure (Figure 12). This model appears feasible relative to the crystal data since, 
when modeled in this position, the SH3 domain fits in a volume that is not occupied by other 
domains in the 1OPL crystal cell as suggested previously by Nagar et al. [9]. 
An extended arrangement of kinase, SH2 and SH3 domains has also been reported for a 
crystal structure of the c-Src kinase that models a possible active state [187].  This c-Src structure 
is almost the same length as our Abl-T315I reconstruction but fits the contours of the molecular 
envelope less well than the model based on 1OPL molecule B (data not shown). Nevertheless, 
the possibility of some conformational flexibility between domains or the mixing of active and 
inactive populations of T315I might account for this level of misfit so this interpretation cannot 
be ruled out by the solution scattering data. 
The structure of the highly active protein, ΔNcap-2PE, is most divergent from the other 
structures. The elongated reconstruction derived from the ΔNcap-2PE scattering data is 
consistent with previous results that associated a highly elongated appearance with this active 
form of the protein [9], but very different from that of T315I despite the high intrinsic kinase 
activities of both proteins (Figure 9).  Altogether, our results show that the multi-domain Abl 
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proteins studied here can take on at least three distinct conformations (or families of closely 
related conformations): a compact conformation (WT, A356N, HAL); a highly elongated, active 
conformation (ΔNcap-2PE); and a novel, intermediate conformation exhibiting a previously 
unobserved arrangement of regulatory domains (T315I).  Clearly Abl kinases, and by extension 
other multi-domain kinases including members of the Src and Tec families, likely adopt a wide 
range of active states in solution. This observation supports a previously unrecognized level of 
signaling diversity that may be exploitable for therapeutic gain. 
Our results show that the small molecule ATP-competitive inhibitors, imatinib and 
ponatinib, stabilize the Abl core proteins by DSF assay. This is in contrast to a recent study 
where imatinib binding to Abl ΔNcap protein resulted in a more open and dynamic conformation 
with respect to the regulatory SH2 and SH3 domains [51]. This discrepancy could be explained 
by the difference in the proteins used for the two studies. While our study examined the effect of 
compounds on Abl core proteins that include the myristoylated N-cap, the study by Skora et al. 
[51] examined effect of imatinib on an Abl protein that lacks the N-cap and myristoylation 
signal. Based on our results in the thermal melt assay, it would be interesting to examine the 
solution structure of the myristoylated Abl core proteins in the presence of these small molecules 
using SAXS. X-ray scattering analysis of a complex of Abl core T315I and ponatinib could 
provide valuable insight into the relative orientation of the regulatory domains, and help 
understand the effect of ponatinib on Abl core conformational dynamics. In particular, it would 
be very interesting to determine whether the addition of panatinib is sufficient to restore the 
positions of the Ncap, SH3 and SH2 domains to those observed in the assembled, downregulated 
state. 
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3.0  FLUORESCENCE POLARIZATION SCREENING ASSAYS FOR SMALL 
MOLECULE ALLOSTERIC MODULATORS OF C-ABL KINASE FUNCTION* 
3.1 SUMMARY 
The c-Abl protein-tyrosine kinase regulates intracellular signaling pathways controlling diverse 
cellular processes and contributes to several forms of cancer. The kinase activity of Abl is 
repressed by intramolecular interactions involving its regulatory Ncap, SH3 and SH2 domains. 
Small molecules that allosterically regulate Abl kinase activity through its non-catalytic domains 
may represent selective probes of Abl function. Here we report a screening assay for chemical 
modulators of Abl kinase activity that either disrupt or stabilize the regulatory interaction of the 
SH3 domain with the SH2-kinase linker. This fluorescence polarization (FP) assay is based on a 
purified recombinant Abl protein consisting of the N-cap, SH3 and SH2 domains plus the SH2-
kinase linker (N32L protein) and a short fluorescein-labeled probe peptide that binds to the SH3 
domain. In assay development experiments, we found that the probe peptide binds to the 
recombinant Abl N32L protein in vitro, producing a robust FP signal that can be competed with 
an excess of unlabeled peptide. The FP signal is not observed with control N32L proteins bearing 
either an inactivating mutation of a conserved tryptophan residue in the SH3 domain or enhanced 
SH3:linker interaction.  Pilot screens were performed with an FDA-approved compound library 
and the NCI Diversity Set III, and twenty-three compounds were identified that significantly 
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reduced the FP signal in comparison to the untreated controls. Secondary assays showed that one 
of these hit compounds, the antithrombotic drug dipyridamole, enhances Abl kinase activity in 
vitro to a greater extent than the previously described Abl agonist, DPH.  Docking studies 
predicted that this compound binds to a pocket formed at the interface of the SH3 domain and 
the linker, suggesting that it activates Abl by disrupting this regulatory interaction.  These results 
show that screening assays based on the non-catalytic domains of Abl can identify allosteric 
small molecule regulators of kinase function, providing a new approach to selective drug 
discovery for this important kinase system. 
 
 
*Mass Spectrometric analysis was performed by Roxana Iacob and John Engen, Department of 
Chemistry and Chemical Biology, Northeastern University. Surface plasmon resonance data 
were collected and analyzed by Haibin Shi, Department of Microbiology and Molecular 
Genetics, University of Pittsburgh. Molecular dynamic simulation and docking studies were 
performed by Matthew Baumgartner and Carlos Camacho, Department of Computational and 
Systems Biology, University of Pittsburgh. 
3.2 INTRODUCTION 
The c-Abl protein-tyrosine kinase plays diverse roles in the regulation of cell proliferation, 
survival, adhesion, migration and the genotoxic stress response [7,8,188]. Abl kinase activity is 
perhaps best known in the context of Bcr-Abl, the translocation gene product responsible for 
chronic myelogenous leukemia (CML) and some forms of acute lymphocytic leukemia 
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[174,175]. The clinical management of CML has been revolutionized by selective ATP-
competitive inhibitors of Bcr-Abl, of which imatinib is the prototype [131].  However, chronic 
use of kinase inhibitors often leads to drug resistance due to selection for mutations that disrupt 
drug binding or allosterically influence the conformation of the drug binding pocket [120].     
The growing problem of imatininb resistance in Bcr-Abl has fueled efforts to identify 
compounds that work outside of the kinase active site. Such compounds offer advantages in 
terms of enhanced specificity, because they have the potential to exploit non-conserved 
regulatory features unique to c-Abl that persist in Bcr-Abl as well [30].  The kinase activity of 
Abl is tightly regulated in vivo by an auto-inhibitory mechanism. The Abl ‘core’ region, which 
includes a myristoylated N-terminal ‘cap’ (N-cap), SH3 and SH2 domains, an SH2-kinase linker 
and the kinase domain, is both necessary and sufficient for Abl auto-inhibition [13]. Subsequent 
X-ray crystal structures of the Abl core revealed three critical intramolecular interactions that 
regulate kinase activity [9,12,14] (Figure 14A and B). First, the SH2-kinase linker forms a 
polyproline type II helix that binds to the SH3 domain, forming an interface between the SH3 
domain and the N-lobe of the kinase domain.  Second, the SH2 domain interacts with the back of 
the kinase domain C-lobe through an extensive network of hydrogen bonds.  Aromatic 
interactions between the side chains of SH2 Tyr158 and kinase domain Tyr361 also help to 
stabilize this interaction (see Panjarian et al. for an explanation of the Abl amino acid numbering 
scheme [189]). Finally, the myristoylated N-cap binds a deep hydrophobic pocket in the C-lobe 
of the kinase domain, clamping the SH3 and SH2 domains against the back of the kinase domain.  
Small molecules that occupy the myristic acid binding site in the C-lobe of the kinase domain 
have proven to be effective allosteric inhibitors of Bcr-Abl function [55,163].   
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Figure 14. FP assay for small molecule modulators of Abl kinase function. 
A) Crystal structure of the auto-inhibited Abl core (PDB: 2FO0, [9]).  Key features include the N-cap, SH3 and SH2 
domains, the SH2-kinase linker, and the kinase domain. The disordered portion of the N-cap is indicated by the 
dotted line. The N-terminal portion of the N-cap is myristoylated and engages a deep pocket in the kinase domain.  
B) Cartoon depiction of the intramolecular interactions regulating assembly of the downregulated Abl core.  Note 
that the linker forms a polyproline helix that binds in cis to the SH3 domain.  C) Fluorescence polarization (FP) 
assay. The FP assay combines a recombinant Abl Ncap-SH3-SH2-linker (N32L) protein and an SH3-binding 
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peptide probe labeled with a fluorescent moiety (F). The probe peptide binds the SH3 domain in the Abl N32L 
protein, resulting in an FP signal. Small molecules (S) may bind to the SH3 domain and block probe peptide binding 
directly; such molecules would be expected to disrupt SH3:linker interaction (case 1). Alternatively, small 
molecules may stabilize SH3:linker interaction, making the SH3 domain inaccessible to the probe peptide (case 2).  
In either case, small molecule binding is predicted to result in a loss of the FP signal. 
 
 
 
Mutational analysis demonstrates that intramolecular SH3:linker interaction plays a central role 
in Abl auto-inhibition.  Substitution of linker proline residues at positions 242 and 249 with 
glutamate disrupts SH3:linker interaction, resulting in Abl kinase activation [23].  In contrast, 
increasing the proline content of the linker enhances internal SH3 binding and overcomes the 
activating effects of mutations in the myristic acid binding pocket as well as the kinase domain 
gatekeeper residue (Thr315) [30]. Remarkably, enhanced SH3:linker interaction also 
dramatically sensitizes Bcr-Abl-transformed cells to inhibition by both imatinib and the allosteric 
inhibitor, GNF-2, which binds to the myristic acid binding pocket [30]. These findings suggest 
that small molecules enhancing or disrupting this natural regulatory mechanism may represent 
selective allosteric modulators of Abl kinase activity. 
In contrast to the tremendous research efforts invested in discovering inhibitors for Abl 
kinase activity, few studies have explored the discovery of small molecules that activate Abl.  
Selective agonists may represent useful probes to examine the role of Abl kinase activity in 
normal cellular functions, such as DNA-damage repair pathways.  Abl is activated in response to 
multiple forms of genotoxic stress and interacts with modulators of both DNA-damage induced 
apoptosis (e.g. p73) and DNA repair (e.g. Rad51), resulting in cell death or survival depending 
on the cellular environment [188]. Pharmacological activation of Abl may enhance the efficacy 
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of radiation therapy or genotoxic drugs by enhancing tumor cell death. Moreover, recent studies 
have shown that Abl inhibits the growth of breast cancer xenografts and promotes the phenotypic 
reversion of invasive breast cancer cells, suggesting that Abl agonists may have utility in 
combating cancer spread [165,173].  Clearly, selective and potent agonists are required to test the 
viability of Abl as a therapeutic target. 
In this study, we report the development and validation of a high-throughput screening 
assay for the identification of small molecules that interact directly with the non-catalytic region 
of the Abl core.  Our assay is based on the interaction of a fluorescent probe peptide with the 
SH3 domain in the context of a recombinant protein encompassing the regulatory region of the 
Abl core (Ncap-SH3-SH2-linker; referred to hereafter as the Abl ‘N32L’ protein).  Interaction of 
the probe peptide with the Abl N32L protein results in fluorescence polarization, providing a 
convenient assay for SH3 occupancy in a format compatible with high-throughput chemical 
library screening.  In theory, small molecules that bind to the SH3 domain and disrupt probe 
binding may also disrupt SH3:linker interaction in the context of Abl, resulting in kinase 
activation.  On the other hand, compounds that enhance internal SH3 binding to the natural 
linker may represent allosteric inhibitors. Using this FP approach, we screened two small 
libraries – an FDA-approved compound library of 1200 compounds and a diversity set of 1600 
compounds. One hit compound specifically inhibited the FP signal from the complex of the Abl 
N32L protein with the probe peptide, suggesting that it may interfere with SH3:linker 
interaction. This compound, a substituted pyrimido-pyrimidine known as dipyridamole, was 
confirmed to bind directly to the Abl N32L protein using both differential scanning fluorimetry 
and surface plasmon resonance. Dipyridamole was found to enhance the activity of a 
recombinant downregulated Abl core protein, but had no effect on an Abl core with engineered 
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high-affinity SH3:linker interaction. These observations suggest that dipyridamole binds to the 
Abl SH3 domain, resulting in linker displacement and kinase activation.  This conclusion is 
supported by computational docking and molecular dynamics simulations, which predict a 
binding site for the compound at the SH3:linker interface and subsequent displacement of the 
linker.  Our findings provide an important proof-of-concept that small molecules perturbing c-
Abl SH3:linker interaction may allosterically influence Abl kinase activity, and provide a simple 
yet powerful assay method for their discovery. 
3.3 MATERIALS AND METHODS 
3.3.1 Expression and purification of recombinant Abl proteins 
The coding sequence for the Abl Ncap-SH3-SH2-linker region (N32L; corresponding to residues 
2-255 with an internal deletion of residues 15-56; numbering based on the crystal structure of the 
human c-Abl core; PDB: 2FO0 [9]) was amplified by PCR and subcloned into the bacterial 
expression vector, pET21a (EMD Millipore). A similar construct was prepared using the 
sequence of Abl with a high-affinity linker (‘HAL9’) substitution as described previously [30]. 
One glycine and six histidine residues (GHHHHHH) were introduced at the N-terminus of the 
coding sequence of these proteins during sub-cloning. An inactivating mutation of the SH3 
domain (W118A) was introduced by site-directed mutagenesis using the QuikChange II method 
(Stratagene) and the pET21a-Abl N32L WT plasmid as a template. The Abl N32L proteins were 
expressed in E.coli strain Rosetta2(DE3)pLysS (EMD Millipore) and purified using immobilized 
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metal affinity chromatography. The purified proteins were then dialyzed against 20 mM Tris-
HCl (pH 8.3) containing 200 mM NaCl and 1 mM DTT. 
The wild-type and high-affinity linker (‘HAL9’) Abl core proteins (residues 1-531 with 
an internal deletion of residues 15-56) were expressed in Sf9 insect cells as previously described 
[30]. The Abl core proteins were purified using a combination of ion-exchange and affinity 
chromatography and dialyzed against 20 mM Tris-HCl (pH 8.3) containing 100 mM NaCl and 3 
mM DTT.  
The coding sequence for the Abl kinase domain (corresponding to residues 252-530; 
numbering according to the crystal structure of the human c-Abl core; PDB: 2FO0 [9]) was PCR 
amplified and subcloned into the bacterial expression vector pET21a (EMD Millipore). One 
glycine and six histidine residues (GHHHHHH) were introduced at the N-terminus of the protein 
during sub-cloning. The Abl kinase protein was expressed in E.coli Rosetta 2(DE3)pLysS (EMD 
Millipore) and purified as previously described by Seeliger et al [190]. The molecular weight and 
purity of all recombinant Abl proteins was confirmed by SDS-PAGE. 
3.3.2 Peptide synthesis 
Abl SH3 domain-binding peptides p41, p40, p8, and 3BP-1 [191,192] were synthesized by the 
University of Pittsburgh Genomics and Proteomics Core Laboratories.  For the FP assay, the 
peptides were labeled with 6-carboxyfluorescein at their N-termini. Molecular weight and purity 
of all peptides were verified by mass spectrometry.  Stock solutions (10 mM) were prepared in a 
1:1 mixture of DMSO and FP assay buffer (20 mM Tris-HCl, pH 8.3) for labeled peptides and 
neat FP assay buffer for unlabeled peptides. Peptide stock solutions were stored at -20°C. 
 92 
3.3.3 Fluorescence polarization assay 
Fluorescence Polarization (FP) experiments were performed in quadruplicate in low volume 
black 384 well plates with a non-binding surface (Corning; catalog # 3676). Peptides and 
proteins were added to each well in FP assay buffer (20 mM Tris-HCl, pH 8.3) for a final assay 
volume of 20 μL and mixed by shaking for 5 min at ambient temperature. The FP signal in 
millipolarization (mP) units was measured at an excitation wavelength of 485 nM and emission 
wavelength of 515 nM in a SpectraMax M5 microplate reader (Molecular Devices) using the 
Softmax Pro software (version 5.4.1). Each plate was read three times and the values were 
averaged prior to analysis. Raw fluorescence intensity was also read at the same wavelengths for 
each assay.  
3.3.4 Chemical library screening 
Pilot screens with the FP assay were performed with two small molecule libraries. A library of 
1200 FDA-approved small molecules was purchased from Prestwick Chemical, Inc. The 
Diversity Set III, a collection of 1597 compounds with chemically diverse scaffolds, was 
obtained from the Developmental Therapeutics Program, National Cancer Institute, National 
Institute of Health. Each library compound was screened at 10 μM and a final DMSO 
concentration of 1%. Compounds were added to 384-well assay plates first, followed by a pre-
mixed complex of the Abl N32L protein (25 μg) and the p41 probe peptide (50 nM).  Each plate 
also contained twenty-eight wells of the wild-type N32L protein plus p41 probe and DMSO as 
positive controls as well as twenty-eight wells of mutant Abl N32L-W118A protein plus p41 
probe peptide and DMSO as negative controls. Each plate was mixed on the shaker for 5 min, 
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read three consecutive times, and the average FP signal for each well was calculated. To identify 
potential hit compounds, three measures were used: (i) average FP signal; (ii) control normalized 
percent inhibition, in which the FP signal with each compound was normalized to the mean FP 
signal of the positive and negative plate controls according to the formula: [(sample FP – mean 
FPWT) / (mean FPW118A – mean FPWT) x 100] [193,194]; (iii) Z score, a statistical measure of 
variation of the mean sample FP signal that is independent of plate controls, calculated according 
to the formula: [(sample FP – mean FPsamples) / standard deviationsamples] [193,194]. The 
compounds were then ranked in order of increasing FP signal, decreasing control normalized 
percent inhibition, and increasing Z score. Potential hit compounds were then retested in 
quadruplicate using the FP assay under screening assay conditions. 
3.3.5 Differential Scanning Fluorimetry (DSF) 
Hit compounds (100 μM) were pre-incubated with the Abl N32L WT protein (1 μM) for 30 
minutes in bicine assay buffer (10 mM bicine, 150 mM NaCl, pH 8.0). SYPRO Orange (Sigma) 
was added at 5X final concentration and fluorimetry profiles were acquired with a StepOnePlus 
real-time quantitative PCR instrument (Applied Biosystems) and software (version 2.3). Assays 
were performed in duplicate in sealed MicroAmp Fast 96-well qPCR plates (Applied 
Biosystems), and control reactions without proteins were included to correct for background 
fluorescence. Assays were equilibrated at 25 °C for 2 minutes, followed by an increase in 
temperature at the rate of 1% (1.6 °C/min) to 99 °C, with continuous data collection. Mean 
fluorescence intensities, after subtracting background fluorescence, were plotted against 
temperature. Non-linear regression analysis using the Boltzmann sigmoid function in GraphPad 
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Prism 6 was used to determine the Tm values, the midpoint of the melt curve between the 
minimum and maximum fluorescence intensities. 
3.3.6 Surface Plasmon Resonance (SPR) 
SPR analysis was performed on a BIAcore T100 instrument (GE Healthcare) using four-channel 
CM5 biosensor chips at 25 ºC.  Recombinant purified Abl proteins were covalently attached to 
the CM5 chip via standard amine coupling chemistry [195,196]. Compounds 142 (dipyridamole; 
Prestwick Chemical) and 4B7 (NSC 288387; Fisher BioServices) were prepared in 20 mM Tris-
HCl, pH 8.3, 150 mM NaCl and 0.1% DMSO and flowed past the immobilized Abl protein 
channel and a reference channel on the biosensor at a flow rate of 50 µL/min for 3 min over a 
range of concentrations.  The initial binding reaction was followed by dissociation for 5 min, and 
the chip surface was regenerated using 20 mM Tris-HCl, pH 8.3, 150 mM NaCl, 0.1% DMSO, 
0.05% Tween 20 and 1 mM DTT at a flow rate of 50 µL/min for 10 min. Sensorgrams were 
recorded in triplicate, corrected for buffer effects, and fitted with the 1:1 Langmuir binding 
model using the BIAevaluation software suite version 2.0.4 (GE Healthcare). 
3.3.7 Protein kinase assays 
The ADP Quest assay (DiscoverRx) [176], which fluorimetrically measures kinase activity as the 
production of ADP, was used to determine Abl kinase reaction velocities.  Assays were 
performed in quadruplicate in black 384 well plates (Corning #3571) in reaction volumes of 10 
µL/well. Recombinant kinase protein concentrations were fixed at 40 ng/well for the wild-type 
Abl core, 9 ng/well for the high affinity linker core, and 1.4 ng/well for the Abl kinase domain. 
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The Tyr2 substrate peptide (EAIYAAPFAKKK) was dissolved in the ADP Quest assay buffer 
(15 mM HEPES, pH 7.4, 20 mM NaCl, 1 mM EGTA, 0.02% Tween-20, 10 mM MgCl2, 0.1 
mg/ml bovine γ-globulins), while ATP stocks were prepared in 10 mM Tris-HCl (pH 7.0). The 
kinase reaction was initiated by the addition of ATP and read at 5 min intervals for 3 h in a 
SpectraMax M5 Microplate reader (Molecular Devices). To determine the substrate Km, the ATP 
concentration was fixed at 50 μM and the substrate peptide was serially diluted from 0.2-200 
μM. For ATP Km determination, the substrate concentration was fixed at the respective substrate 
Km for each of the kinases, and the ATP concentration was titrated over the range of 0.2 - 200 
μM. The resulting progress curves were analyzed according to the method of Moroco et al. [177]. 
Briefly, raw fluorescence data were corrected for non-enzymatic ADP production (no kinase or 
substrate control) and kinase auto-phosphorylation (rate observed in the absence of substrate), 
and converted to pmol ADP produced using an ADP standard curve generated under the same 
reaction conditions. The linear portion of each progress curve was fit by regression analysis to 
determine the reaction velocity. Substrate and ATP Km values were determined by non-linear 
regression analysis using the Michaelis-Menten equation (GraphPad Prism 6). 
Each kinase protein was pre-incubated with the compounds 142 (10 μM), DPH (10 μM), 
4B7 (10 μM) or imatinib (1 μM) for 30 min at ambient temperature. This was followed by the 
kinase assay with the substrate and ATP concentrations fixed at their respective Km values. The 
pmol ADP produced were normalized to the amount of kinase present in each reaction, and 
plotted against time. The linear portion of each progress curve was then fit by regression analysis 
to determine the reaction velocity. 
Half-maximal effective concentrations (EC50) and activation constants (Kact) were 
determined for the Abl kinase core by both dipyridamole and the known Abl activator, DPH (5-
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(1,3-diaryl-1H-pyrazol-4-yl)hydantoin; Sigma-Aldrich) [185].  The kinase was pre-incubated 
with each compound (10 nM to 100 μM) for 30 min at ambient temperature, followed by kinase 
assay with the substrate and ATP concentrations fixed at their respective Km values. The rate of 
each reaction was plotted against compound concentration, and analyzed by non-linear 
regression analysis (GraphPad Prism 6) to determine the EC50 value. To determine the activation 
constant Kact, the basal rate of kinase activity was subtracted from the rates of reaction in the 
presence of each compound concentration, and plotted as a function of compound concentration. 
The resulting curves obeyed saturation kinetics and were best-fit by the following equation [177]: 
 
    Va = Vact [L] / (Kact + [L]) 
 
where Va is the reaction velocity in the presence of each activator concentration, Vact is 
the maximal reaction velocity, L is the activator concentration, and Kact is the activator 
concentration that yields half-maximal reaction velocity. 
3.3.8 Molecular dynamics 
To understand the dynamics of the recombinant N32L protein, for which there is no X-ray 
crystal structure, we ran unconstrained molecular dynamics (MD) simulations of residues 65-254 
of the assembled, downregulated Abl core structure (PDB 2FO0).  We disrupted the interaction 
between linker Pro249 and the SH3 domain by rotating the backbone bonds of linker Gly246.  
This glycine residue was chosen as a pivot point as it is more flexible and is located between 
Pro249 and the next strongly interacting residue (Val244) based on the predicted interaction 
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energy with the SH3 domain [197].  We also ran MD simulations of the (unmodified) isolated 
SH3 domain (residues 80-145) using the same parameters described below. 
MD simulations were conducted with the pmemd.cuda [198] module of AMBER14 [199], 
using the force fields AMBER ff14SB and gaff (general amber force fields) [200].  An octahedral 
TIP3P water box was constructed with 12 Å from the edge of the box to the solute and the total 
system charge was neutralized by adding chloride ions. The non-bonded cutoff was specified at 
10 Å.   In the first energy minimization run, the solute was held fixed and the solvent was 
relaxed through 500 cycles of steepest descent followed by 500 cycles of conjugate gradient 
minimization. Subsequently, the system was minimized again with no constraints through 2,000 
cycles of steepest descent followed by 3,000 cycles of conjugate gradient minimization. 
Following the energy minimization, a 50,000 step MD simulation was used to raise the system 
temperature to 300 K while holding the solute fixed with weak (10.0 kcal/mol) restraints on the 
solute atoms. The bonds involving hydrogens were held at a fixed length and an integration step 
of 2 fs was used.  This simulation was followed by a second equilibration simulation at constant 
pressure for 50,000 steps.  The final MD simulation of this equilibrated structure was run with no 
constraints for 100 ns. 
3.3.9 Computational docking 
The binding mode of hit compound 142 (dipyrimadole) was modeled to snapshots of the N32L 
and SH3 simulations by molecular docking using the program smina [201] with default docking 
parameters.  The box was defined by the coordinates of linker residues 247-251 plus an outer 
shell of 8 Å after alignment to the SH3 domain of the crystal structure (PDB 2FO0). 
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3.4 RESULTS AND DISCUSSION 
3.4.1 Abl fluorescence polarization (FP) assay design 
In this study, we developed a screening assay for small molecule allosteric modulators of Abl 
kinase function. Our goal was to enable discovery of chemical scaffolds that interact with the 
regulatory region of the Abl kinase core, as opposed to the kinase domain, thereby providing a 
path to enhanced selectivity and allosteric control of kinase function. In addition, we wanted a 
flexible assay with the potential to identify both inhibitors and activators of Abl function. To 
accomplish these goals, we developed a fluorescence polarization (FP) assay based on the N-
terminal region of Abl consisting of the Ncap, SH3 and SH2 domains, and the SH2-kinase linker 
(Abl N32L protein).  Binding of a fluorescently labeled probe peptide to the SH3 domain 
(displacing the linker) should result in an increased FP signal due to the slowed rotation of the 
N32L target protein-peptide complex (Figure 14C).  A small molecule that binds to the Abl 
N32L protein and enhances SH3 interaction with the linker in cis is predicted to prevent probe 
peptide binding, resulting in a decrease in the FP signal. Molecules in this class are predicted to 
act as allosteric inhibitors of Abl kinase activity, because they may enhance the natural negative 
regulatory interaction between the SH3 domain and the linker. Alternatively, compounds that 
interact with the SH3 domain and block probe peptide binding are also predicted to cause a 
decrease in the FP signal.  By displacing SH3:linker interaction in the context of downregulated 
Abl, compounds of this type may act as allosteric activators of kinase activity.  This assay design 
therefore has the potential to identify both types of Abl-binding compounds in a single chemical 
library screen. Their impact on Abl function can be easily distinguished in secondary assays for 
direct binding to the Abl domains, as well as functional assays. 
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3.4.2 Recombinant Abl regulatory proteins for FP assay development 
The target protein for the Abl FP assay consists of the first 255 residues of c-Abl (isoform 1b), 
and encompasses the Ncap, the SH3 and SH2 domains, as well as the SH2-kinase linker as 
described above.  This Abl N32L protein was expressed in bacteria in soluble form, purified to 
homogeneity, and its purity and identity were confirmed by SDS-polyacrylamide gel 
electrophoresis and mass spectrometry, respectively (Figure 15). Previous studies have 
established that regulatory SH3:linker interaction is maintained in this construct, despite the 
absence of the kinase domain [30,53].  In addition to the wild-type protein, two mutant forms of 
N32L were produced for use as controls. The first of these has an alanine substitution for a 
conserved tryptophan on the SH3 domain binding surface (W118A mutant; see Figure 16 for 
SH3 domain structure), which renders it unable to bind to the probe peptide and thus serves as a 
negative control.  In the second mutant, five linker residues were replaced with prolines to 
enhance interaction with the SH3 domain [30]. This high-affinity linker (HAL) substitution 
suppresses the activating effects of kinase domain mutations and influences the conformation of 
the kinase domain, enhancing both imatinib and allosteric inhibitor action (discussed earlier in 
section 1.2.1.4). The HAL protein therefore represents a second negative control for probe 
peptide binding to the SH3 domain.  Both the W118A and HAL forms of the Abl N32L protein 
were also expressed and purified from bacteria, and yielded soluble purified proteins of the 
expected mass (Figure 15). 
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Figure 15. Recombinant Abl Ncap-SH3-SH2-linker (N32L) proteins. 
Wild-type Abl-N32L protein and the corresponding high-affinity linker (HAL) and W118A mutants were expressed 
in E. coli BL21 Rosetta cells using the pET system and purified by immobilized metal affinity chromatography. 
Protein purity and mass were verified by SDS polyacrylamide gel electrophoresis (A) and mass spectrometry (B). 
Mass spectrometry analysis was performed by Roxana Iacob and John Engen, Department of Chemistry and 
Chemical Biology, Northeastern University. 
 101 
3.4.3 Structural basis for high affinity probe peptide binding to the Abl SH3 domain 
A suitable probe for the Abl N32L FP assay required a short, proline-rich peptide with sequence 
specificity for the Abl SH3 domain.  In addition, the probe peptide needed to bind to the SH3 
domain with sufficient affinity to compete for cis-interaction of the SH3 domain with the natural 
linker (Figure 14).  A survey of the literature identified four Abl SH3-binding peptides with the 
potential to serve as probes [191,192].  These peptides, designated p41, p40, p8, and 3BP-1, have 
KD values for the Abl SH3 domain in the 0.4 to 34 µM range. The Abl SH3-binding peptide 
sequences are presented in Figure 16A, and are aligned with those of the wild-type and high-
affinity SH2-kinase linkers of Abl. 
To explore the potential of known Abl SH3 peptide ligands to compete for natural 
SH3:linker interaction, we first compared the structure of the Abl SH3:linker interface from the 
downregulated Abl core (PDB: 2FO0) [9] with the crystal structure of the p41 peptide in 
complex with the Abl SH3 domain (PDB: 1BBZ) [192]. The C-terminal half of the p41 peptide is 
comprised exclusively of proline, which facilitates both PPII helix formation as well as tight 
interaction with the hydrophobic SH3 binding surface (Figure 16B).  In contrast, this region of 
the SH2-kinase linker is comprised of the less favorable SH3-binding sequence, KPTVY (Figure 
16C).  Specifically, p41 proline residues 9 and 10 fill the hydrophobic groove formed by the 
aromatic side chains of SH3 tyrosines 89 and 134; the linker is substituted with lysine in this 
position (Lys241).  The main chain carbonyl of p41 Pro8 forms a stabilizing hydrogen bond with 
Tyr134.  This position is substituted with threonine (Thr243) in the linker, which swings away 
from the SH3 surface.  The N-terminal sequence of the p41 peptide forms a network of polar 
contacts involving SH3 residues Ser94, Asp96, and Trp118.  None of these contacts are present  
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Figure 16. Peptide and linker interactions with the Abl SH3 domain. 
A) Sequences of the Abl SH3 binding peptides, p41, p40, p8, and 3BP-1, and their published binding affinities for 
the Abl SH3 domain [191]. Sequences of the wild-type (WT) and high-affinity (HAL) SH2-kinase linker sequences 
are also shown at the bottom. The peptide sequences are presented in the C- to N-terminal orientation to align with 
those of the linkers.  B) Crystal structure of the p41 peptide (cyan) bound to the Abl SH3 domain (PDB: 1BBZ) 
[202]. The SH3 surface is shown as a space filling model (red) and side chains of residues that interact with the p41 
peptide are shown as sticks. C) Crystal structure of the SH2-kinase linker (orange) bound to the Abl SH3 domain 
(red) from the Abl core (PDB: 2FO0, [9]).  Side chains of SH3 domain residues that interact with the p41 peptide as 
per panel B are shown as sticks. Note the lack of hydrophobic interactions and hydrogen bonds between the SH3 
domain and the linker in comparison to the p41 peptide. 
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in the SH3:linker interface, and the side chain of SH3 Asp96 is rotated away from the linker. 
Taken together, these structural features strongly suggested that p41, or one of the closely related 
peptides (p40, p8, and 3BP-1), may interact with the Abl N32L target protein with sufficient 
affinity to displace the wild-type linker and provide a stable FP signal. 
3.4.4 Selection of a probe peptide for the Abl N32L FP assay  
To evaluate the suitability of the four Abl SH3 peptide ligands (p41, p40, p8, 3BP-1; Figure 
16A) as FP probes, each peptide was synthesized and labeled with 6-carboxyfluorescein on its 
N-terminus. We first examined the baseline FP signal as well as the fluorescence intensity 
exhibited by each labeled peptide over a broad concentration range (1 - 1,000 nM) in the absence 
of the Abl N32L target protein.  As shown in Figure 17A, probe peptide concentrations greater 
than 50 nM exhibited stable baseline FP readings with minimal well-to-well variation. 
To test for Abl N32L protein interaction with each peptide in the FP assay, we held each 
probe peptide concentration at 50 nM and added the wild-type N32L protein over a range of 
concentrations. As shown in Figure 17B, both the p40 and p41 probe peptides produced a strong, 
saturable FP signal as a function of the N32L protein concentration. The p8 peptide also 
produced an FP response, albeit somewhat lower than that observed with p40 and p41, while the 
3BP-1 peptide was inactive. These FP results correspond to the rank order of binding affinities 
previously reported for these peptides with the isolated SH3 domain [191,192].  Since the 
structure of the Abl SH3 domain in complex with p41 is known (Figure 16B), we chose the p41 
peptide for FP assay optimization. 
  
 104 
 
Figure 17. Identification of p41 as optimal probe peptide for the Abl N32L FP assay. 
A) To characterize the baseline FP signal, the 6-carboxy-fluorescein labeled probe peptides p41 (red), p40 (green), 
p8 (blue), and 3BP-1 (black) were serially diluted over the concentration range of 1-1000 nM.  The FP signals (solid 
lines, left Y axis) and corresponding fluorescence intensities (dashed lines, right Y axis) were measured at ambient 
temperature and plotted as a function of peptide concentration. Average values are shown ± SE from four 
measurements per condition. B) To test for probe peptide interaction with Abl N32L by FP, each peptide (50 nM) 
was incubated with the Abl N32L protein over the range of 0.08-25 μg/well.  The resulting FP signals were 
measured at ambient temperature, corrected for baseline FP signal recorded in the absence of the N32L protein, and 
plotted against the N32L protein concentration. Average FP values are shown ± SE from four measurements per 
condition; error bars are smaller than the diameter of the data points. 
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3.4.5 Abl N32L FP assay development and optimization 
We next investigated whether the FP signal obtained with the p41 probe peptide was due to 
interaction with SH3 domain of the recombinant Abl N32L target protein. For these experiments, 
we compared the FP signal produced from the wild-type Abl N32L protein with the SH3 domain 
mutant (W118A) as well as the high-affinity linker (HAL) protein. As shown in Figure 18A, the 
wild-type Abl N32L protein produced a concentration-dependent increase in the FP signal as 
observed previously.  In contrast, the N32L W118A mutant failed to produce an FP signal with 
the p41 peptide over the same concentration range, indicating that the peptide requires this 
conserved SH3 domain tryptophan residue for binding as predicted from the crystal structure 
(see Figure 16). On the other hand, the Abl N32L HAL protein showed a greatly reduced FP 
signal in comparison to the wild-type protein with the p41 probe. This result is consistent with 
enhanced cis-interaction of the linker with SH3 domain in this protein as a result of the higher 
linker proline content (see Figure 16A for HAL sequence). Results with these control proteins 
demonstrate that the p41 probe peptide interacts with the Abl N32L target protein through its 
SH3 domain. FP experiments with the recombinant purified Abl SH3 domain alone also 
produced a very similar FP response, supporting this conclusion. Findings with these Abl N32L 
mutants support the idea that small molecules that disrupt or stabilize intramolecular interaction 
between the SH3 domain and linker will also reduce probe peptide binding and loss of the FP 
signal.   
We next tested the stability of the FP signal as a function of time (Figure 18B). For this 
experiment, the p41 probe peptide (50 nM) and Abl N32L protein (12.8 μg/well) concentrations 
were held constant. Under these conditions, no significant variation in the FP signal was
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Figure 18. Abl N32L FP assay development and optimization. 
A) The p41 FP probe binds the Abl N32L protein through the SH3 domain.  The p41 probe peptide (50 nM) was 
combined with wild-type, HAL, and W118A Abl N32L proteins over the range of concentrations shown. The 
resulting FP signals were measured and plotted as a function of N32L protein concentration.  B) FP assay stability. 
The p41 probe peptide (50 nM) was combined with the three Abl N32L proteins (12.8 μg/well) and FP signals were 
recorded over the time course shown.  C) DMSO tolerance.  FP assays consisting of the p41 probe peptide (50 nM) 
and each Abl N32L protein (25 μg/well) were incubated with the DMSO concentrations shown, and FP signals were 
recorded 1 h later.  D) Unlabeled peptide competition.  For the competition assay, the p41 probe peptide (50 nM) 
was mixed with unlabeled p41 peptide or a negative control peptide (Con) of similar length over the range of 
concentrations shown. The Abl N32L protein (20 μg/well) was then added, and FP signals were recorded.  FP 
signals were corrected for the background p41 peptide FP signal and plotted as a function of the unlabeled peptide 
concentration. In all experiments (A through D), FP signal was measured at ambient temperature and average FP 
values are shown ± SE from four measurements per condition. 
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observed up to 10 hours. We also found that DMSO, the carrier solvent for the screening library 
compounds, did not influence the FP signal or the negative controls even at the highest 
concentration tested (1%; Figure 18C). 
In a final validation experiment, we tested the effect of unlabeled p41 peptide on the FP 
signal (Figure 18D).  For this study, we fixed the p41 probe peptide concentration at 50 nM and 
the wild-type Abl N32L protein concentration at 20 μg/well.  Unlabeled p41 peptide was added 
to the assay over the concentration range of 2.5 to 100 μM. The FP signal decreased as a function 
of unlabeled p41 peptide concentration, demonstrating competition for the labeled probe peptide 
binding to the N32L protein.  As a negative control, the peptide competition experiment was 
repeated with a non-specific peptide of similar length. This peptide had no effect on the FP 
signal, even at a concentration of 100 µM, demonstrating the specificity of p41 peptide 
recognition by the SH3 domain in the N32L target protein. 
3.4.6 Identification of inhibitors of p41 interaction with Abl N32L 
To test the performance of the Abl N32L FP assay under screening conditions, we performed 
pilot screens with two small molecule libraries – a collection of 1200 FDA-approved 
compounds, and a diversity set consisting of 1600 chemical scaffolds. The wild-type Abl N32L 
protein (25 μg) was added to each well together with the p41 probe peptide (50 nM).  The 
compounds were then added to a final concentration of 10 μM in 1% DMSO.  Each plate 
contained twenty-eight wells with the wild-type N32L target protein plus DMSO as positive 
controls, and twenty-eight wells with the non-binding W118A mutant protein plus DMSO as 
negative controls. The overall Z factors were 0.57 and 0.36 for the FDA-approved library and the 
diversity set, respectively, indicative of a reliable screening assay [203]. The average FP signals  
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Figure 19. Pilot screens identify inhibitors of p41 interaction with the Abl N32L protein. 
Two small molecule libraries were screened using the Abl N32L protein (25 μg/well) and the p41 probe peptide (50 
nM) in the FP assay. Screening data from a library of 1200 FDA-approved compounds (A) and a diversity set of 
1600 compounds from NCI (B) are shown. For both (A) and (B), the solid lines correspond to the mean FP signals 
for the wild-type (WT) and negative control (W118A) control N32L proteins across all assay plates, with the dotted 
lines indicating three standard deviations from the means (± 3σ). Each compound was tested at 10 μM, and each of 
the resulting 2800 FP signals is represented as an individual circle. Twenty-three putative hit compounds were 
identified (green circles), five from the FDA-approved compounds library (A) and eighteen from the NCI Diversity 
Set III (B). 
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observed with the controls as well as the readings observed with each of the test compounds are 
presented in Figure 19. 
The FP signals for each compound were ranked by three different methods: increasing 
raw FP signal, decreasing normalized percent inhibition, and increasing Z score (described in 
section 3.3.4). For each library screen, we then compared the top 1% of compounds present 
ineach of these three rankings. In the FDA-approved compounds library, five compounds were 
present in at least two of these rankings, and were selected for follow-up assays (compound 
numbers 3, 42, 142, 787, and 1415; Figure 19A). From the diversity set, eighteen compounds 
were identified from at least two of the rankings and selected for follow-up assays (compounds 
1A3, 1A5, 1C11, 1E14, 1G12, 2A19, 3A3, 3A7, 3A11, 3A13, 3A15, 3E3, 4A7, 4A11, 4B7, 5A7, 
5A13, and 5E8; Figure 19B). These hit compounds are represented as green circles in Figure 19. 
Each of the raw hit compounds was then retested in multiple wells under screening assay 
conditions (Figure 20). Out of the five compounds identified from the FDA-approved 
compounds library, four compounds produced a significant inhibition of the FP signal relative to 
the DMSO controls (compounds 42, 142, 787, and 1415; Figure 20A). From the diversity set, 
thirteen out of eighteen compounds significantly inhibited the FP signal in comparison to the 
DMSO controls (compounds 1A3, 1C11, 1E14, 1G12, 3A3, 3A7, 3A11, 3A15, 4A11, 4B7, 5A7, 
5A13, and 5E8; Figure 20B). We then performed control FP experiments with each of these 
compounds under the same conditions but in the absence of the N32L target protein (Figure 21).  
This counter-screen showed that compounds 787, 1C11, 1E14, and 1G12 reduced the baseline 
FP signal produced by the p41 probe peptide by at least three standard deviations from the 
DMSO control, thus indicating non-specific quenching of the FP signal (Figure 21).  These  
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Figure 20. Confirmation of reproducible inhibition of p41 interaction with the Abl N32L protein. 
Five potential hit compounds from the FDA-approved compounds library (A), and eighteen hit compounds from the 
NCI Diversity Set III (B) were re-tested in quadruplicate at 10 μM vs. the DMSO control under FP screening assay 
conditions, and the mean FP values are shown ± SE. Seventeen of these compounds significantly inhibited the FP 
signal relative to the DMSO control as indicated by the asterisk (p < 0.05; 2-tailed t-test). The dotted line (-3σ) 
shows FP value three standard deviations below the DMSO control FP signal. 
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Figure 21. Identification of non-specific inhibitors of p41 FP signal. 
Five potential hit compounds from the FDA-approved compounds library (A), and eighteen hit compounds from the 
NCI Diversity Set III (B) were tested with the p41 peptide in the absence of Abl N32L proteins. These compounds 
were tested in quadruplicate at 10 μM vs. the DMSO control, and the mean FP values are shown ± SE. The dotted 
line (-3σ) shows FP value three standard deviations below the DMSO control FP signal. Four of these compounds 
caused a decrease in FP signal greater than 3σ relative to the DMSO control. 
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compounds were not considered further. None of the other compounds affected the baseline p41 
probe peptide fluorescence, and were therefore moved forward into secondary assays. 
3.4.7 Compounds identified in the Abl N32L FP screen interact directly with the Abl 
N32L protein in orthogonal assays 
As an independent measure of hit compound interaction with the Abl N32L target protein, we 
performed differential scanning fluorimetry assays [182]. For these experiments, the Abl N32L 
protein was heated with a molar excess of each compound in the presence of the reporter dye, 
SYPRO orange. As the temperature rises and the N32L protein unfolds, the reporter dye accesses 
the hydrophobic interior of the protein, resulting in an increase in dye fluorescence. The resulting 
protein ‘melt curve’ is then fit by regression analysis to obtain a Tm value, the temperature at 
which half-maximal thermal denaturation is observed. Small molecule binding to a target protein 
can either increase or decrease the Tm value, depending upon the effect of the compound on 
protein stability. Differential scanning fluorimetry was performed with the wild-type N32L 
protein in the presence of each of the hit compounds from the FP assay, and the change in Tm 
value (ΔTm) was determined compared to DMSO as the reference control.  As shown in Figure 
22A, the three hit compounds from the FDA-approved drugs library resulted in a decrease in the 
Tm value. Compound 142 had the largest impact on N32L thermal stability, producing a decrease 
of more than 2 °C in the Tm, consistent with its effect in the FP assay (Figure 20A). Ten 
compounds from the diversity set were tested in this assay, and three of these led to a decrease of 
at least 1 °C in the Tm value (3A7, 3A11, and 4B7; Figure 22B). One compound, 3A3, was found 
to interfere with this assay and the Tm value could not be determined. Since compounds 142 and 
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Figure 22. Six hit compounds directly interact with the Abl N32L protein. 
Differential scanning fluorimetry assays were performed on the Abl N32L protein in the presence of the thirteen 
confirmed hit compounds, three from the FDA-approved compounds library (A) and ten from the NCI Diversity Set 
III (B), as described under Materials and Methods. The average change in the mid-point of the thermal melt profile 
(ΔTm) is plotted on the Y-axis ± S.E. (n = 2). One compound from the diversity set, 3A3, interfered with the assay 
and is not shown here. 
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4B7 had a robust effect in the FP assay (Figure 20) and exhibited direct interaction with the Abl 
N32L protein in the DSF assay (Figure 22), we tested the effect of these compounds in the 
secondary assays discussed below.  
Compounds that inhibit the FP signal in the Abl N32L assay may either interfere directly 
with probe peptide binding to the SH3 domain or allosterically tighten the cis-interaction of the 
SH3 with the linker, indirectly reducing probe peptide interaction.  To distinguish between these 
two possibilities with compounds, we performed FP experiments with the isolated Abl SH3 
domain as well. We performed FP assays with the Abl N32L protein as well as the isolated Abl 
SH3 domain over a range of compound concentrations. As shown in Figure 23, compounds 142 
and 4B7 resulted in a concentration-dependent decrease in the FP signal with both the Abl N32L 
and SH3 proteins, suggesting that both compounds bind directly to the Abl SH3 domain. 
To confirm direct interaction of hit compounds with the Abl N32L protein and explore 
the binding kinetics, we next performed surface plasmon resonance (SPR) assays. For these 
experiments, the Abl N32L protein was immobilized on the biosensor surface while compounds 
were flowed past the immobilized protein over a range of concentrations. As shown in Figure 
24A, concentration-dependent interaction of compound 142 with Abl N32L was readily detected 
by this approach, yielding an association rate constant of 3.87 + 0.59 x 103 M-1s-1 and a 
dissociation rate constant of 2.70 + 0.72 x 10-2 s-1. The equilibrium dissociation constant (KD) for 
this interaction, calculated as the ratio of kd/ka, is 6.90 + 0.78 x 10-6 M.  
We observed that compounds 142 and 4B7 inhibit p41 interaction with the Abl SH3 
domain, indicating that they directly interact with the Abl SH3 domain. To confirm this direct 
interaction, we performed SPR experiments with the isolated Abl SH3 domain as well. In these  
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Figure 23. Hit compounds 142 and 4B7 inhibit  interaction of p41 peptide with the Abl N32L and Abl SH3 
proteins. 
Compounds 142 (A) and 4B7 (B) inhibit p41 peptide binding to the Abl N32L and SH3 proteins in the FP assay.  
Compounds were added to N32L and SH3 FP assays over the range of concentrations shown, and the resulting FP 
signals are presented as the mean ± S.E.  Significant inhibition for both N32L and SH3 was observed at 3 and 10 μM 
(p < 0.05 by 2-tailed t-test; columns marked with an asterisk). C) Chemical structure of compound 142 
(dipyridamole). D) Chemical structure of compound 4B7 (10-(2-methoxyethyl)-3-phenyl-Benzo[g]pteridine-
2,4(3H,10H)-dione). 
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Figure 24. Hit compound 142 interacts directly with the Abl N32L and Abl SH3 proteins. 
Surface plasmon resonance (SPR) was performed with the Abl N32L (A) or Abl SH3 (B) proteins 
immobilized on the biosensor chip and compound 142 as analyte. Responses were recorded for the 
indicated compound concentrations, and the flow path was switched back to buffer after 180 s to induce 
dissociation (arrow). The resulting sensorgrams (black lines) were fit by a 1:1 Langmuir binding model 
(red lines) to generate kinetic constants.  
SPR experiments were performed and analyzed by Haibin Shi, Smithgall lab, Department of 
Microbiology and Molecular Genetics, University of Pittsburgh. 
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experiments, the Abl SH3 protein was immobilized on the biosensor surface while a range of 
compound concentrations were flowed past the immobilized protein. As shown in Figure 24B, 
compound 142 interacts with the Abl SH3 protein, albeit only at higher concentrations and the 
response is weaker in comparison to the Abl N32L protein. The association rate constant for this 
interaction is 3.83 + 0.37 x 103 M-1s-1 while the dissociation rate constant is 1.15 + 0.18 x 10-1 s-
1. The equilibrium dissociation constant (KD) for this interaction is 2.99 + 0.40 x 10-5 M, which is 
nearly 5-fold higher than the KD with the Abl N32L protein. This suggests that the presence of 
the N-cap, SH2 domain, and the SH2-kinase linker in addition to the SH3 domain enhance the 
binding of the compound 142. 
We also tested binding of compound 4B7 to the Abl N32L and Abl SH3 in SPR assays.  
Unlike compound 142, we were unable to detect a binding response, suggesting that the change 
in FP produced by this compound in the screening assay may be due to non-specific adsorption 
to the Abl N32L protein. 
3.4.8 Allosteric activation of Abl kinase by compound 142 
Compound 142 reproducibly scored as a hit in the Abl N32L FP assay and demonstrated direct 
interaction with the Abl N32L protein by both differential scanning fluorimetry and SPR.  This 
compound, a symmetrically substituted pyrimido-pyrimidine known as dipyridamole (Figure 
23C), is a selective inhibitor of phosphodiesterase V and also an adenosine transport inhibitor 
used clinically for its antithrombotic activity [204]. However its potential impact on protein 
kinase function has not been reported.  Because compound 142 interacts with the regulatory 
region of Abl, we investigated its effects on Abl kinase activity using three purified recombinant 
forms of Abl in a kinetic kinase assay. The first of these included the wild-type Abl core region, 
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consisting of the Ncap, the SH3 and SH2 domains, the SH2-kinase linker, and the kinase 
domain. This Abl protein was produced in Sf9 insect cells, which results in myristoylation of the 
N-cap and interaction with the C-lobe of the kinase domain, thereby assembling the 
downregulated state (Figure 14A). In addition to the wild-type core, we also tested a high-
affinity linker (HAL) mutant version of the Abl protein, which has a modified proline-rich linker 
that packs more tightly against the SH3 domain [30]. Additionally, we tested the Abl kinase 
domain protein, which lacks all the regulatory features present in the Abl core proteins. The 
structure of each Abl kinase protein is illustrated in Figure 25. 
Baseline kinase activities and kinetic parameters of each recombinant Abl kinase protein 
were determined first using ADP Quest assay, a fluorimetric assay that measures the kinase 
reaction rate as the generation of ADP [176].  For wild-type Abl, we obtained Km values of 9.8 ± 
0.1 µM and 144.6 ± 1.6 µM for ATP and peptide substrate, respectively.  The Abl HAL core 
yielded a similar Km value for substrate (150.2 ± 5.4 µM), with a higher value for ATP (21.2 ± 
1.6 µM).  For the Abl kinase domain, the Km value for the substrate (20.9 + 0.4 µM) is much 
lower than the wild-type Abl core, while the Km value for ATP is higher (36.0 + 3.5 µM). These 
observations are consistent with the allosteric effects of the regulatory domains on the 
conformation of the active site in the kinase domain. In subsequent experiments with 
compounds, the ATP and peptide substrate concentrations were set to their respective Km values, 
and input kinase concentrations were adjusted to yield similar basal reaction rates (7 pmol ADP 
produced per minute for Abl core proteins, and 2.5 pmol ADP produced per minute for Abl 
kinase domain).   
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Figure 25. Compound 142 activates the Abl kinase core in vitro. 
A) The recombinant Abl core protein, consisting of the Ncap, SH3, SH2 and kinase domains, was assayed in the 
presence of compound 142 (10 µM), the known Abl activator DPH (10 µM), and imatinib (1 µM) or with DMSO as 
control (Con) using the ADP Quest kinetic kinase assay (see Materials and Methods). Data are plotted as pmol ADP 
produced per ng kinase as a function of time. The cartoon (right) depicts the domain organization of the wild-type 
Abl core, and indicates the binding site for DPH (myristic acid binding pocket) as well as the predicted binding site 
for compound 142 (SH3 domain). B) and C) Kinase assays were performed using a Abl core protein with a high-
affinity linker (HAL) (B) or the Abl kinase domain (C)  in the presence of the same three compounds; the cartoons 
indicate the position of the modified linker (HAL) in (B) and the kinase domain in (C). 
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We first examined the effect of compound 142 on the activity of the wild-type Abl kinase core 
protein.  As shown in Figure 25A, compound 142 stimulated wild-type Abl kinase activity by 
about 40% at a concentration of 10 µM relative to the DMSO control in this assay. As a positive 
control, we also assayed Abl core activity in the presence of the same concentration of a 
previously described Abl activator, DPH, and observed a similar degree of activation.  DPH, 
unlike compound 142, stimulates Abl through the kinase domain via the myristic acid binding 
pocket in the C-lobe [185]. 
The mechanism of Abl activation by compound 142 may involve binding to the SH3 
domain and subsequent displacement of its regulatory interaction with the SH2-kinase linker.  
Indeed, mutations that disrupt SH3:linker interaction also have a stimulatory effect on Abl kinase 
activity (discussed earlier in sections 1.2.1.2 and 1.2.1.4). To test this idea, we next examined the 
effect of this compound on the Abl core mutant with enhanced SH3:linker interaction. Unlike 
wild-type Abl, compound 142 did not affect the kinase activity of the Abl core with the HAL 
substitution (Figure 25B), consistent with the idea that enhanced SH3:linker interaction prevents 
compound 142 access to the Abl SH3 domain.  Interestingly, DPH did not activate the Abl HAL 
core protein either, consistent with previous results showing that enhanced SH3:linker interaction 
overcomes Abl core activation by mutations in the myristic-acid binding pocket [30]. 
Additionally, we examined the effect of compound 142 and DPH on the Abl kinase 
domain that lacks all of the regulatory domains (Figure 25C). Unlike the wild-type Abl core 
protein, the reaction velocity of the kinase domain protein was not significantly affected by 
compound 142. This observation is consistent with the proposed allosteric mechanism of 
compound 142 acting through the SH3 and linker interface, which is lacking in this construct. 
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Interestingly, DPH also failed to activate the kinase domain in the absence of the regulatory 
domains, even though its binding pocket is present in the C-lobe of the kinase domain.  This 
observation suggests that this kinase domain construct is maximally active and therefore no 
longer susceptible to regulation by compounds that bind through the myristic acid binding 
pocket. 
To further characterize Abl activation by compound 142, we repeated kinetic kinase 
assays with the wild-type Abl core over a range of compound concentrations.  As shown in 
Figure 26A, compound 142 activates the Abl core in a concentration-dependent manner, with an 
EC50 value of 0.63 ± 0.07 μM. This value compares favorably to that obtained with DPH, the 
myristic acid binding pocket agonist (EC50 = 1.11 ± 0.5 μM).  We also calculated the activation 
constant (Kact) for each compound from these data (Figure 26B), which is defined as the 
concentration at which the reaction rate reaches half-maximum velocity (Vact). For compound 
142, the Kact was calculated as 0.4 ± 0.02 μM, while DPH yielded a value of 1.02 ± 0.07 μM. 
The extent of Abl activation (Vmax) by compound 142 was also higher than that for DPH. 
Having established the activating effect of compound 142 in in vitro kinase assays, we 
proceeded to test its effect on Abl core kinase activity in cells. For this, we used an experimental 
system optimized in our lab where the phosphotyrosine content in HEK 293T cells transiently 
expressing Abl core proteins correlates with the catalytic activity of the Abl proteins [30]. Earlier 
studies from our lab as well as results shown in section 2.4.1 have shown that expression of the 
down-regulated wild-type or HAL Abl core proteins results in negligible phosphotyrosine levels 
(as observed by immunoblotting), while expression of the active Abl mutants (A356N, T315I, or 
ΔNcap-2PE) results in an increase in phosphotyrosine levels. On treatment with compound 142 
at three different concentrations (1, 3, and 10 µM), we did not observe any significant increase in 
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the total phosphotyrosine levels of cells expressing wild-type or A356N Abl core proteins. In 
addition to the total phosphotyrosine levels, we also examined the phosphorylation levels of 
specific tyrosine residues involved in kinase regulation in the immunoprecipitated Abl protein 
fraction and did not observe any significant changes. While we observed a reproducible 
enhancement of kinase activity in the in vitro kinase assays in the presence of compound 142, we 
did not observe any effect on the total phosphotyrosine content in this cellular system. This 
discrepancy could be explained by a multitude of reasons. For example, compound 142 could 
potentially be binding to other proteins in cells with a higher affinity and getting sequestered, 
thus resulting in an insufficient concentration of the compound to activate Abl kinase. On the 
other hand, compound 142 could potentially be activating a small pool of Abl kinase and that 
effect may not be observable in the total phosphotyrosine blots. Future experiments to evaluate 
the effect of compound 142 on Abl activation in a different experimental setup could be helpful 
to confirm its effect in cellular assays.  
Compound 4B7 reproducibly inhibited p41 interaction with the Abl N32L and SH3 
proteins and demonstrated a direct interaction with Abl N32L protein in the differential scanning 
fluorimetry assay. The chemical name of this compound is 10-(2-Methoxyethyl)-3-
phenylbenzo[g]pteridine-2,4-(3H,10H)-dione, and its structure is presented in Figure 23D. 
However, this compound failed to bind to the N32L or SH3 proteins by SPR, raising questions 
about the specificity of binding.  To resolve this issue, we tested the effect of compound 4B7 on 
the wild-type Abl core protein as well as the Abl kinase domain in the kinetic kinase assay. At a 
concentration of 10 µM, compound 4B7 was found to inhibit wild-type Abl core kinase activity 
by about 15%. However, the compound had a similar inhibitory effect on the isolated Abl kinase  
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Figure 26. Concentration-dependent activation of the Abl kinase core protein by compound 142. 
The wild-type Abl kinase core was assayed in the presence of compound 142 and DPH at the indicated 
concentrations using the ADP Quest kinetic kinase assay (see Materials and Methods). A) Reaction velocities are 
plotted as a function of compound concentrations. The resulting data were curve-fit to determine the EC50 for each 
activator as described under Materials and Methods. B) Compound dependent reaction rates, calculated by 
subtracting the basal rate of reaction in the absence of the compounds, are plotted as a function of concentration. 
These were curve-fit to determine the activation constant Kact and Vmax for each activator as described under 
Materials and Methods. For both (A) and (B), each of the parameters was determined in triplicate, and the mean 
values ± SE are presented in the Table. 
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domain that lacks the presumptive binding site for this compound. This indicates that compound 
4B7 has a weak, non-specific effect on Abl kinase activity that persists in the absence of the 
regulatory domains and thus, is not a consequence of the modulation of the SH3:linker 
interaction. 
3.4.9 Molecular dynamics simulations and docking studies predict binding of compound 
142 to the SH3:linker interface in the Abl kinase core  
Data presented in the previous sections demonstrate that compound 142 interacts with the 
regulatory N32L region of Abl, resulting in a decrease in thermal stability and a concomitant 
increase in kinase activity. We used molecular dynamics (MD) simulations to explore the 
dynamics of the N32L region used in the assays. To model the effect of the linker being 
displaced from the SH3 domain, we manually pulled the linker a short distance away from the 
SH3 domain prior to the simulation (as described in section 3.3.8). After approximately 20 ns, 
the linker reconnected with the SH3 domain through the interaction of linker Pro249 and SH3 
Trp118. To explore possible binding sites for this compound on the N32L region of the Abl 
kinase core, we used the computational docking tool smina [201] to dock 142 to snapshots of the 
simulation prior to the reconnection of the SH3:linker interface. As shown in Figure 27 (top 
panel), compound 142 fits into a surface pocket defined by the SH3:linker interface in the N32L 
protein. This predicted binding site involves an aromatic interaction between the pyrimido-
pyrimidine moiety of 142 and the indole side chain of SH3 Trp118, as well as polar contacts 
involving all four hydroxyl groups on the ligand. This aromatic interaction is consistent with 
probe peptide displacement as well as the observed decrease in the FP signal produced by the 
W118A mutation (Figure 18C). Two of the hydroxyl groups of 142 make potential hydrogen  
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Figure 27. Computational docking predicts binding of hit compound 142 (dipyridimole) to the Abl SH3:linker 
interface. 
Top: The lowest energy pose of the ligand (compound 142; carbon atoms rendered in green) is shown docked to a 
snapshot of an MD simulation of the Abl N32L structure.  SH3 domain residues predicted to contribute to ligand 
binding include Asn97, Thr98, Asn115, Trp118, and Trp129 (carbons in red).  The backbone of the linker is shown 
as an orange ribbon, with Gly246, Val247, Pro249 and Trp254 predicted to contribute to the binding pocket. One of 
the piperidine groups of compound 142 makes hydrophobic contacts with linker Pro249 and Trp254, while the 
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pyrimido-pyrimidine scaffold of compound 142 is π-stacking with Trp118.  Middle panel:  Model of the SH3:linker 
interface in the N32L region based on the crystal structure of the downregulated Abl core (PDB:2FO0), highlighting 
the interaction of linker Pro249 with SH3 Trp118 and Trp129.  Ligand binding (top panel) is predicted to displace 
this regulatory interaction, leading to kinase activation.  Lower panel:  The lowest energy pose of compound 142 is 
shown docked to a snapshot of an MD simulation of the SH3 domain in the absence of the linker.  The position of 
the 142 ligand is similar (within 1.5 Å RMSD) to that in the SH3 domain of N32L (top), except that the ligand 
contacts Glu117 rather than linker residues Gly246 and Val247.  Without the linker, the potential hydrophobic 
stabilization of the 142 piperidine group is also lost. 
Molecular dynamic simulations and docking were performed by Matthew Baumgartner and Carlos Camacho, 
Department of Computational Biology, University of Pittsburgh. 
  
 
 
bonds with the side and main chains of SH3 Asn97 as well as the side chain of Thr98. The other 
two hydroxyl groups of 142 form hydrogen bonds with the main chain carbonyls of linker 
Gly246 and Val247 as well as the side chain of SH3 Asn115.  In addition, one of the piperidine 
groups of compound 142 makes hydrophobic contacts with SH3 Trp129, while the other 
approaches the side chains of linker residues Pro249 and Trp254. Note that in the crystal 
structure of the fully assembled, downregulated conformation of the Abl core, linker Pro249 
inserts between SH3 Trp118 and Trp129 (Figure 27, middle panel); displacement of this 
regulatory contact by compound 142 binding may contribute to kinase activation. 
For comparison, we also ran unconstrained MD simulations of the SH3 domain in the 
absence of the linker.  Our docked model to a snapshot from this simulation is shown in Figure 
27 (bottom panel).  The overall position of the ligand in this model is quite similar to that 
observed with the N32L snapshot (within 1.5 Å RMSD), and includes the potential stacking 
interaction with SH3 Trp118 and hydrogen bonding to SH3 Asn97, Thr98 and Asn115.  Polar 
contacts of compound 142 with linker Gly246 and Val247 as well as hydrophobic interactions 
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with linker Trp254 and Pro249 are not possible. However, additional hydrogen bonds are 
observed with SH3 Glu117. Loss of these hydrophobic interactions in the SH3-only model helps 
to explain the lower binding affinity of compound 142 for the isolated SH3 domain (KD = 2.99 ± 
0.40 x 10-5 M) relative to the N32L protein (KD = 6.90 ± 0.78 x 10-6 M) as determined by SPR 
(Figure 24). 
3.5 SUMMARY AND CONCLUSIONS 
In this study, we developed a screening strategy to identify allosteric small molecule modulators 
of Abl kinase activity that work outside of the kinase domain. Our FP-based assay targets the 
regulatory domains of Abl that control its kinase activity through intramolecular interactions. 
Specifically, this assay is based on a recombinant Abl protein comprising the complete 
regulatory apparatus (Ncap-SH3-SH2-linker) and a synthetic polyproline probe peptide (p41) 
that selectively binds the Abl SH3 domain.  Interaction of the probe peptide with the Abl N32L 
protein results in a robust and reproducible FP signal.  Mutation of the SH3 binding site 
(W118A) or introduction of a high-affinity linker both resulted in loss of the FP signal, 
demonstrating that probe access requires an intact and accessible SH3 domain.  Small-scale pilot 
screens of two small molecule libraries (2800 total compounds) identified dipyridamole 
(compound 142) as an inhibitor of the FP signal observed with the N32L:p41 complex, and 
direct interaction of this compound with the Abl N32L protein was confirmed by SPR and DSF 
assays. Dipyridamole was observed to stimulate the kinase activity of downregulated Abl kinase 
in vitro, and was more potent than the previously described Abl agonist DPH which targets the 
myristic acid binding pocket in the kinase domain. In contrast to wild-type Abl, dipyridamole 
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had no effect on a modified Abl core protein with a high-affinity linker, suggesting that it works 
by binding to the SH3 domain and disrupting the SH3:linker interface. Molecular dynamics 
simulations in combination with molecular docking support this proposed mechanism of action: 
dipyridamole was predicted to interact with the Abl core through a pocket defined by the 
SH3:linker interface.  This interaction involved the Trp residue 118 the SH3 domain binding 
surface, potentially disrupting a key regulatory interaction with Pro249 in the linker. The 
identification and characterization of dipyridamole as an allosteric modulator of Abl kinase 
activity required multiple secondary assays, and the hit validation and characterization strategy is 
summarized in Figure 28. 
Discovery of dipyridamole as an Abl agonist provides an important proof of concept that 
small molecules altering SH3:linker interaction represent allosteric modulators of Abl kinase 
activity. Selective agonists of Abl function have potential as chemical probes to better 
understand the role of Abl kinase activity in solid tumors and in response to genotoxic stress. 
Conversely, allosteric antagonists may also be discovered by this approach and have the potential 
to complement current ATP-competitive inhibitors of Bcr-Abl in the context of CML and other 
cancers.  The allosteric inhibitor discovery concept may also be extended to the discovery of 
allosteric modulators of other kinases systems with multidomain regulatory interactions, 
including members of the Src and Tec kinase families. 
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Figure 28. A summary of the hit selection and validation strategy. 
Hit compounds identified from the pilot screens were first confirmed for reproducible FP inhibition of p41 
interaction with Abl N32L protein. Compounds that quenched FP signal in a non-specific manner were then 
eliminated by testing for FP inhibition in the absence of the Abl N32L protein. The remaining 13 hit compounds 
were then tested for direct binding to the Abl N32L and SH3 proteins using a combination of DSF, FP, and SPR 
assays. Finally, the hit compounds were tested in functional assays where their effect on Abl kinase activity was 
examined in an in vitro kinetic kinase assay. This led to the identification of compound 142 (dipyridamole) that 
allosterically activates wild-type Abl core through the SH3:linker interface. 
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4.0  OVERALL DISCUSSION 
The role of intramolecular interactions in maintaining the down-regulated conformation of the 
Abl core has been well established, though their status in the context of kinase activation is less 
clear. In this study, we have shown that Abl core kinase activation does not require complete 
disruption of intramolecular interactions or total rearrangement of regulatory domains. 
Moreover, we show that enhancing the interaction between the SH3 domain and the SH2-kinase 
linker has a dominant effect on the conformation and stability of active Abl core mutants. In the 
second part of this study, we have developed a novel biochemical assay, which is amenable to 
high throughput screening, to identify small molecules targeting the regulatory interaction 
between the SH3 domain and the SH2-kinase linker in the Abl protein. Using this screening 
assay, we have identified a small molecule that activates Abl kinase through a remarkably subtle 
disruption of the SH3:linker interaction. The data presented in this study provide important 
insights into Abl kinase conformation on activation, and alteration of intramolecular interactions 
to identify allosteric modulators of kinase activity.  
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4.1 EFFECT OF ACTIVATING AND STABILIZING MUTATIONS ON ABL 
KINASE ACTIVITY, STABILITY, AND CONFORMATION 
In chapter 2, we investigated the effect of activating and stabilizing conformations on the kinase 
activity, enzyme kinetics, thermal stability, and conformation of Abl core proteins. The relative 
orientation of the regulatory SH3 and SH2 domains has been previously established for both the 
down-regulated conformation and a maximally activated conformation of the Abl core by X-ray 
crystallography [9,12]. We hypothesized that Abl kinase activation does not require complete 
disruption of all intra-molecular interactions and reorientation of regulatory domains. To test this 
hypothesis, we created the following four recombinant proteins modeling a graded range of 
active states: 1) the wild-type Abl core; 2) Abl core A356N that has a mutation in the myristic 
acid binding pocket leading to kinase activation; 3) Abl core T315I that has a mutation in the 
gatekeeper residue and exhibits enhanced kinase activity and resistance to imatinib; 4) Abl 
ΔNcap-2PE that lacks the N-cap region and includes mutations in two proline residues in the 
linker that disrupt the SH3:linker interaction. We observed that the kinase activity of these 
proteins spans a broad range of intrinsic catalytic activities both in vitro and in cells, with the 
following rank order:  wild-type < A356N < T315I < ΔNcap-2PE. We next investigated the 
effect of these mutations on the Abl core protein stability in the DSF assay. We found that the 
ΔNcap-2PE exhibits a significantly lower melt temperature (Tm) in comparison to the wild-type 
Abl core protein. Interestingly, while the A356N Abl core mutant showed a moderate decrease in 
Tm (5 °C), the T315I mutant showed only a 2 °C decrease in Tm indicating that this protein 
adopts a relatively stable conformation despite its relatively high kinase activity. Data from X-
ray scattering experiments demonstrated that the A356N mutant adopts a similar conformation as 
the wild-type Abl core protein. On the other hand, the T315I mutant adopted a unique ‘squashed 
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pear’ conformation with an increased radius of gyration. Shape reconstructions based on the X-
ray scattering indicated a rearrangement of the overall core structure in the T315I mutant, with 
the SH2 domain reoriented to the top of the kinase domain and the SH3 domain next to the 
kinase domain. It is remarkable that a single point mutation in the kinase domain causes such a 
dramatic rearrangement of regulatory domains in the Abl core protein. This rearranged 
conformation could explain the enhanced kinase activity and altered substrate selectivity of the 
Abl T315I protein in the context of Bcr-Abl [45,138]. The ΔNcap-2PE mutant of Abl exhibited 
an elongated conformation with a linear rearrangement of the kinase domain followed by the 
SH2 and SH3 domains, which is consistent with the lack of all regulatory interactions in this 
protein. 
A recent study from our lab has shown that a high affinity linker (HAL) that results in 
enhanced SH3:linker interaction is able to overcome the effect of activating mutations A356N 
and T315I on Abl kinase activity [30]. To examine the effect of enhanced SH3:linker interaction 
on Abl core protein stability and conformation, we introduced the HAL mutations into the three 
Abl core proteins described above. We observed that the HAL mutation has a stabilizing effect 
on the Abl core protein, and results in an increased Tm for the wild-type Abl core as well as the 
A356N and T315I mutant Abl core proteins. Molecular reconstruction from the X-ray scattering 
data shows that the conformation of the Abl core HAL is similar to the wild-type Abl core, thus 
indicating that the addition of proline residues to the linker does not distort the downregulated 
Abl core conformation. Remarkably, the introduction of HAL into the T315I Abl core mutant 
resulted in a restoration of the regulatory domains to their observed positions in the 
downregulated core conformation. These observations indicate that enhanced SH3:linker 
interaction has a dominant effect on the conformation and thermal stability of Abl core mutants. 
 133 
These results are in agreement with the earlier study from our lab that reported a dominant effect 
of enhanced SH3:linker interaction on kinase activity and conformational dynamics of Abl core 
mutants [30]. Based on these observations, a small molecule that strengthens the SH3:linker 
interaction is predicted to overcome the effect of activating mutations in the Abl core protein. 
These observations contributed to the rationale for assay development and small molecule 
discovery discussed in Chapter 3. 
Ponatinib is the only current ATP-competitive inhibitor that can bind the Bcr-Abl T315I 
mutant and inhibit its kinase activity [159]. To examine its effect on the conformation of the Abl 
core proteins, we examined the effect of ponatinib and imatinib on Abl core thermal stability in 
the DSF assay. Ponatinib has a robust stabilizing effect on all three Abl core proteins (WT, 
A356N, and T315), while imatinib only stabilizes the WT and A356N Abl core proteins as 
expected. Future studies will determine the X-ray scattering patterns of Abl core proteins in the 
presence of these small molecules to further understand the effect of these inhibitors on the Abl 
core conformation. Specifically, X-ray scattering analysis of a complex of Abl core T315I and 
ponatinib could provide valuable insight into the relative orientation of the regulatory domains. 
Additionally, HXMS analysis of Abl core T315I in complex with ponatinib can be used to 
elucidate the effect of ponatinib on Abl core conformational dynamics. In particular, it would be 
very interesting to determine whether the addition of ponatinib is sufficient to restore the 
positions of the N-cap, SH3 and SH2 domains to those observed in the assembled, 
downregulated state, similar to what we observed with HAL substitution. 
Though molecular reconstruction of the X-ray scattering patterns was used to indicate the 
positions of the SH2 and SH3 domains in the Abl core T315I protein, the position of the SH2-
kinase linker or the status of the SH3:linker interaction could not be established. The SH2-kinase 
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linker may still be bound to the SH3 domain, or this interaction could have been allosterically 
disrupted by the T315I mutation and reorientation of the SH2 and SH3 domains. One way to test 
for the presence of the SH3:linker interaction in the Abl core T315I mutant is by introducing the 
2PE mutation into this protein. A comparison of the two Abl core T315I proteins (with or 
without 2PE) in terms of their kinase activity, thermal stability, and X-ray scattering patterns 
could be useful in this context. If the SH3:linker interaction persists in the Abl core T315I 
mutant, disruption of this interaction by the 2PE mutation could result in a potential change in 
kinase activity, thermal stability, and overall protein conformation. As discussed in section 
1.2.2.2, HXMS has been utilized to examine the effects of mutations (including A356N and 
T315I) on the conformational dynamics of Abl core proteins in solution [30,46]. An increase in 
protein dynamics manifests as a specific increase in deuterium uptake that can be measured by 
mass spectrometry. A change in deuterium uptake in the SH3 domain on introduction of the 2PE 
mutation in the Abl core T315I protein would indicate that the SH3:linker interaction persists in 
the Abl T315I protein. Moreover, it would be interesting to see if the 2PE mutation results in 
deuterium uptake changes in other parts of the protein, as these changes would indicate allosteric 
effects of the SH3:linker interaction in the Abl T315I protein. 
DSF (thermal melt) data suggest that the Abl core T315I protein is relatively stable in 
solution, in comparison to the active A356N and ΔNcap-2PE mutants, and therefore maybe 
amenable to crystallization. An X-ray crystal structure of the Abl core T315I protein would 
unequivocally identify the locations of the regulatory SH2 and SH3 domains as well as the SH2-
kinase linker in the most stable state of this protein. Moreover, SAXS analysis of the Abl T315I 
protein in complex with ponatinib (proposed above) could present useful information on the 
utility of ponatinib as a stabilizing ligand for these crystallization studies. 
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The intensive investigation of the conformation and dynamics of the Abl core T315I 
protein can provide valuable information to therapeutically target the clinically relevant Bcr-Abl 
T315I protein. The reorientation of the SH2 domain in the Abl core T315I protein could be 
partially responsible for its enhanced kinase activity and altered substrate specificity [45,138]. 
Moreover, the diversity observed in the mechanisms of Abl kinase activation may also be present 
in other multi-domains kinase families such as Src and Tec family kinases. This diversity can be 
used to identify small molecules that act through allosteric mechanisms and selectively modulate 
kinase activity. 
4.2 IDENTIFICATION OF ALLOSTERIC MODULATORS OF ABL KINASE 
FUNCTION 
The interaction between the SH3 domain and the SH2-kinase linker of Abl has been shown to be 
critical for regulation of the Abl kinase. We hypothesized that a small molecule that influences 
the SH3:linker interaction may be a potential agonist or antagonist of Abl kinase activity. In 
chapter 3, we focused on discovering small molecule allosteric modulators of Abl kinase activity 
that act through the regulatory domains. Specifically, we developed a novel fluorescence 
polarization (FP) screening assay to identify small molecules that target the SH3:linker 
regulatory interaction in Abl. This assay is based on a recombinant Abl protein that includes the 
complete regulatory apparatus (Ncap-SH3-SH2-linker, N32L) and a synthetic polyproline probe 
peptide (p41) that selectively binds the Abl SH3 domain. Interaction of the probe peptide with 
the Abl N32L protein results in a robust and reproducible FP signal.  Mutation of the SH3 
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binding site (W118A) or introduction of a high-affinity linker both resulted in loss of the FP 
signal, demonstrating that probe access requires an intact and accessible SH3 domain. 
We performed pilot screens with two small molecules libraries (2800 compounds total) 
and identified dipyridamole (‘compound 142’, an antithrombotic drug) as a hit compound. The 
interaction of dipyridamole to the Abl N32L protein was validated by SPR and DSF assays. In 
subsequent experiments with the wild-type Abl core, we observed that dipyridamole stimulates 
Abl kinase activity in vitro through an allosteric mechanism. Interestingly, dipyridamole had no 
effect on a modified Abl core protein with a high-affinity linker, suggesting that it acts through 
the SH3:linker interface. Moreover, molecular dynamics simulations in combination with 
molecular docking predicted that the compound interacts with the Abl core through a pocket 
defined by the SH3:linker interface. This predicted interaction involved a highly conserved 
residue on the binding surface of the SH3 domain (Trp118), in addition to other residues in the 
SH3 domain and the SH2-kinase linker, potentially disrupting a key regulatory interaction with 
Pro249 in the linker. 
The discovery of dipyridamole as an Abl agonist shows that screening assays based on 
the non-catalytic domains of Abl can identify allosteric small molecule regulators of kinase 
function. Moreover, this compound provides an important proof of concept that small molecules 
that alter the SH3:linker interaction represent allosteric modulators of Abl kinase activity. Robust 
assay performance in our pilot screens predicts that this FP assay should be readily scalable to 
screen larger chemical libraries. In collaboration with Dr. Paul Johnston and David Close at the 
School of Pharmacy, University of Pittsburgh, we are in the process of screening two larger 
chemical libraries using the FP assay described in this study (60,000 diverse compounds in total). 
These fully automated library screens will potentially identify additional chemical scaffolds that 
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modulate the SH3:linker interaction and allosterically influence Abl kinase activity. Putative hit 
compounds identified from these screens will need to be first validated for binding and activity 
as described in Chapter 3 of this study. Lead selection must also consider drug-like properties of 
the hit compounds.  Lipinski and colleagues analyzed over 2000 clinically available drugs and 
identified important properties that signify ‘drug-likeness’ in chemical compounds, and these 
include criteria for molecular weight, lipophilicity, and the number of hydrogen bond donor and 
acceptor groups [205]. Hit compounds identified from the FP screens that exhibit these 
properties, in addition to an optimum number of rotatable bonds and the possibility of chemical 
modifications, will be considered as strong lead compounds. Additional structure activity 
relationship studies can be utilized to improve the pharmacokinetic properties as well as 
specificity of these putative hit compounds. 
Future studies can explore the effect of allosteric lead compounds on Abl as well as Bcr-
Abl kinase activity in cells. Our lab has optimized experimental conditions where the 
phosphotyrosine content in HEK 293T cells transiently expressing Abl core proteins correlates 
with their intrinsic catalytic activity [30]. While expression of the down-regulated wild-type or 
HAL Abl core proteins results in negligible phosphotyrosine levels (as observed by 
immunoblotting), expression of the active Abl mutants (A356N, T315I, or ΔNcap-2PE) results in 
an increase in phosphotyrosine levels. Treatment with putative allosteric lead compounds that 
specifically affect the Abl core conformation and lead to a consequent increase or decrease in 
kinase activity could be assessed using this system. While the effect of agonists can be assessed 
on the wild-type and HAL Abl core proteins, the effect of antagonists can be assessed on the 
active Abl core mutants. In addition to the total phosphotyrosine levels, we can also examine the 
phosphorylation levels of specific tyrosine residues involved in kinase regulation.  These include 
 138 
pTyr89 (SH3 domain), pTyr245 (SH2-kinase linker) and pTyr412 (activation loop) [30]. In 
addition to the experimental system described above, we could also examine the effect of 
putative allosteric modulators on Bcr-Abl kinase activity in TF-1 cells. TF-1 cells are human 
myeloid cells that require granulocyte-macrophage colony stimulating factor (GM-CSF) for 
proliferation, and Bcr-Abl expression transforms these cells to GM-CSF-independent growth 
[206,207]. The effect of putative lead compounds on Bcr-Abl’s transforming potential as well as 
kinase activity can be assessed by soft agar colony assays and immunoblotting for 
phosphotyrosine levels, respectively. 
Data presented in this study as well as an earlier study from our lab has shown that 
enhancement of SH3:linker interaction overcomes the effects of  activating mutations in Abl 
kinase [30]. Moreover, incorporation of the engineered HAL into Bcr-Abl proteins sensitizes 
Bcr-Abl to both ATP-competitive and allosteric inhibitors. Thus, a small molecule that 
strengthens the SH3:linker interaction in Abl may be a potential allosteric inhibitor of Bcr-Abl. 
Such allosteric antagonists may be discovered by the FP assay discussed in Chapter 3 and have 
the potential to complement current ATP-competitive and allosteric inhibitors of the Bcr-Abl 
kinase domain in the context of CML. Initial studies could focus on the effect of putative 
allosteric inhibitors on sensitization of Bcr-Abl transformed cells to imatinib or GNF-2 induced 
apoptosis. It will also be interesting to examine the effect of such inhibitors on imatinib-resistant 
Bcr-Abl mutants such as T315I. Furthermore, it would be crucial to identify any potential 
resistance mutations that develop following treatment with allosteric inhibitors acting through 
the SH3:linker interface, both alone and in combination with ATP-competitive inhibitors. While 
mutations in the regulatory domains including the SH3:linker interface could give rise to 
resistance against the putative allosteric inhibitor alone, we predict a decreased incidence of 
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resistance mutations against a combination of allosteric and ATP-competitive inhibitors that 
target multiple structural regions in the Abl kinase. This prediction is consistent with earlier 
studies where a combination of allosteric and ATP-competitive inhibitors was found to result in a 
decrease in the incidence of resistance mutations [55]. 
Several biophysical approaches can be utilized to characterize the effect of allosteric 
modulators on Abl protein dynamics and kinase conformation. As discussed in section 1.2.2.2, 
HXMS studies have been utilized to examine the effect of small molecule inhibitors of Abl (e.g. 
GNF-5, dasatinib) on the conformational dynamics of Abl core proteins [54]. The effect of lead 
allosteric compounds on SH3:linker interaction in the Abl N32L protein, and the deuterium 
uptake in different regions of the Abl core protein could provide useful information about the 
mechanism of action of these allosteric modulators. Additionally, SAXS analysis can provide 
useful information about the overall conformation of the Abl core proteins in complex with a 
lead compound that disrupts or enhances the SH3:linker interaction. It would be especially 
interesting to examine the effect of an allosteric antagonist on the conformation of the Abl core 
T315I mutant, to see if it mimics the ‘HAL effect’ and restores the regulatory domains to the 
positions observed in the downregulated Abl core conformation. 
Small molecules that selectively activate Abl kinase can potentially be used as chemical 
probes to better understand the role of Abl kinase activity in response to genotoxic stresses. As 
discussed in section 1.3, Abl is activated in response to several genotoxic agents and has been 
shown to interact with proteins involved in both DNA damage repair as well as apoptotic 
induction pathways. While Abl has been clearly shown to induce apoptotic death in response to 
genotoxic agents, its effect on the outcome of DNA damage repair processes is less clear. Small 
molecules that selectively activate the Abl kinase may help to clarify the effect of Abl activation 
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on the DNA-damage repair pathways. Moreover, inhibition of Abl kinase activity has been 
shown to induce resistance to apoptosis in cells treated with ionizing radiation [93]. Selective Abl 
agonists may therefore cause the opposite effect, and represent useful therapeutic agents to 
sensitize radio-resistant tumor cells to ionizing radiation-induced apoptosis.  
As discussed in section 1.5, the role of Abl kinases in solid tumors is not well defined, 
with conflicting reports in terms of its contribution to tumor growth and spread. Abl has been 
shown to promote anchorage-independent growth in breast, gastric, and hepatocellular carcinoma 
cells [169,170]. In contrast, a few studies found that Abl activation suppresses the growth of 
certain breast cancer xenografts [172,173]. Clinical studies investigating the treatment of solid 
tumors with imatinib, nilotinib, and dasatinib have yielded mixed results, which can partially be 
explained by the limited selectivity of these inhibitors [165,208,209]. An added complexity is the 
discrepancy in the effect of Abl in promoting vs. suppressing growth or invasiveness of solid 
tumors due to their heterogeneity. Selective allosteric modulators of Abl may be useful to 
delineate the effect of Abl kinase activity in diverse cancer cell types and tumor 
microenvironments. These small molecules may represent useful probes to identify tumor 
microenvironment and cellular biomarkers in which Abl kinase acts as a tumor promoter vs. 
suppressor. 
In addition to Abl, the Src and Tec kinase families have a similar multidomain 
organization and mechanisms of intramolecular interactions that are important for regulation of 
kinase activity [210,211]. On one hand, since some of the residues in the SH3:linker interaction 
are conserved (e.g. SH3 domain Trp118), it will be important to evaluate the selectivity of 
putative allosteric modulators by testing them against related kinases for both binding as well as 
effects on kinase activity. On the other hand, there is enough sequence and structural diversity 
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between these kinase families that it may be possible to identify allosteric compounds that are 
selective for specific kinases. Moreover, chemical modifications of putative lead allosteric hits in 
combination with structure activity relationship studies can be utilized to further enhance 
specificity for Abl over related kinase families. Furthermore, this allosteric inhibitor discovery 
concept developed using the Abl kinase can be extended to the discovery of allosteric modulators 
of other similar kinases systems. 
4.3 CLOSING REMARKS 
Results presented in this study provide valuable insight into the importance of allosteric 
interactions on Abl kinase activity. The first part of the study demonstrates that Abl kinases can 
adopt diverse active conformations, while the second part of the study presents a platform to 
discover small molecules that specifically modulate allosteric interactions in Abl. These studies 
thus present a new approach to selective drug discovery for this important kinase system. 
Allosteric modulators may help us better understand the function of Abl kinase in response to 
DNA damage agents and potentially overcome radioresistance observed in certain tumors in the 
future. Additionally, such compounds may identify cellular contexts in solid tumors where Abl 
activity can be exploited for therapeutic gain. Finally, selective allosteric antagonists of Abl can 
complement the existing ATP-competitive inhibitors and present important therapeutic agents to 
counter the high incidence of resistance mutations observed in Bcr-Abl positive CML patients. 
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APPENDIX A 
LIST OF ABBREVIATIONS 
Abl Abelson tyrosine kinase 
Arg Abl related gene 
Bcr Breakpoint cluster region 
CML Chronic myelogenous leukemia 
DDR DNA damage repair 
DSF Differential scanning fluorimetry 
EC50 Half-maximal effective concentration 
EGFR Epidermal growth factor receptor 
FP Fluorescence polarization 
GM-CSF Granulocyte monocyte colony stimulating factor 
HAL High affinity linker 
HXMS Hydrogen exchange mass spectrometry 
Kact Activation constant 
KD Equilibrium dissociation constant 
MD Molecular dynamics 
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N32L Ncap-SH3-SH2-Linker 
N-cap N terminal cap 
NMR Nuclear magnetic resonance 
PDGFR Platelet derived growth factor receptor 
PP II Poly-proline type II 
Rg Radius of gyration 
SAXS Small angle X-ray scattering 
SH Src homology 
SPR 
TKI 
Surface plasmon resonance 
Tyrosine kinase inhibitor 
Tm Thermal melt temperature 
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